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ABSTRACT 
 
Approximately 2.8 million Americans seek medical care for traumatic brain 
injury (TBI) each year. Of this population, the majority are sufferers of diffuse TBI, or 
concussion. It is unknown how many more individuals decline to seek medical care 
following mild TBI. This likely sizeable population of un- or self-treated individuals 
combined with a lack of definitive biomarkers or objective post-injury diagnostics creates 
a unique need for practical therapies among diffuse TBI sufferers. Practical therapies 
stand to decrease the burden of TBI among those who would otherwise not seek 
treatment or do not meet clinical diagnostic criteria upon examination. For this unique 
treatment niche, practical therapies for TBI are defined as having one or more of the 
following qualities:  common availability, easy administration, excellent safety profile, 
and cost-effectiveness. This dissertation identifies and critically examines the efficacy of 
four classes of practical treatments in improving rodent outcome from experimental 
diffuse traumatic brain injury.  
Over-the-counter (OTC) analgesics, omega-3 fatty acids, specialized pro-
resolving mediators (SPMs), and remote ischemic conditioning (RIC) were administered 
before or following midline fluid percussion injury. Behavioral, histological, and 
molecular analyses were used to assess treatment effects on functional outcome and 
secondary injury progression. Acute administration of common OTC analgesics had little 
effect on post-injury outcome in mice. Dietary supplementation with omega-3 fatty acid 
docosahexaenoic acid (DHA) prior to or following diffuse TBI significantly reduced 
injury-induced sensory sensitivity and markers of neuroinflammation with no effect on 
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spatial learning. Intraperitoneal administration of omega-3 fatty acid-derived SPM 
resolvin E1 significantly increased post-injury sleep and suppressed microglial activation. 
Aspirin-triggered (AT) resolvin D1 administration improved both motor and cognitive 
outcome following diffuse TBI. RIC treatment in mice demonstrated little effect on 
functional outcome from diffuse TBI. Untargeted proteomic analysis of plasma samples 
from RIC-treated mice was used to identify candidate molecular correlates of RIC. 
Identification of these candidates represents a vital first step in elucidating the 
neuroprotective mechanisms underlying RIC. The overall findings suggest that omega-3 
fatty acid supplementation, SPM administration, and RIC may serve as effective practical 
therapies to reduce the somatic, cognitive, and neurological burden of diffuse TBI felt by 
millions of Americans. 
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CHAPTER 1 
1 INTRODUCTION 
TREATING THE UNTREATED: DEFINING PRACTICAL THERAPIES FOR 
DIFFUSE TRAUMATIC BRAIN INJURY 
Approximately 2.8 million Americans seek medical care for traumatic brain 
injury (TBI) each year (Taylor, Bell et al. 2017). The most common cause of TBI varies 
by age group with falls most prominent among the very young and elderly. Other 
common mechanisms of injury include strikes against the head, motor vehicle accidents, 
and assault (Faul and Coronado 2015). The wide array of long term consequences of TBI 
can include impaired cognitive or emotional function (Arciniegas, Topkoff et al. 2000; 
Albensi and Janigro 2003; Masel and DeWitt 2010), sensory sensitivity or dysfunction 
(Goodrich, Flyg et al. 2013; Goodrich, Martinsen et al. 2014), and loss of neurological 
function (Arciniegas, Topkoff et al. 2000). These symptoms of TBI, paired with pain 
from post-concussive headache, can profoundly degrade quality of life from months to 
years following injury. 
Of patients seeking care for TBI, approximately 60-90% are sufferers of mild TBI 
(Holm, Cassidy et al. 2005). It is unknown how many more individuals decline to seek 
medical care following mild TBI, but in one survey over 40% of respondents having 
suffered a TBI reported not seeking medical attention (Setnik and Bazarian 2007). This 
large population of un- or self-treated individuals combined with a lack of definitive 
biomarkers or objective post-injury diagnostics creates a unique need for practical 
therapies among diffuse TBI sufferers. Practical therapies could stand to decrease the 
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burden of TBI among those who would otherwise not seek treatment for minor symptoms 
such as headache or do not meet clinical diagnostic criteria upon examination. For this 
unique treatment niche, we define practical therapies for TBI as having one or more of 
the following qualities: without risk of harm, readily available, easily administered, and 
cost-effective. Practical therapies may vary with regard to the window of treatment and 
could be applied continuously as a prophylactic, immediately after TBI, or in an extended 
time course following TBI. 
In this dissertation, practical therapies were chosen in part for their potential to 
decrease inflammation following TBI. Following the primary mechanical injury force, 
secondary injury cascades are activated in the brain which can persist for up to years 
following injury (Johnson, Stewart et al. 2013). Thus, TBI can be thought of not only as 
an event but the initiation of a disease process which can be treated. These secondary 
injury mechanisms include but are not limited to inflammation, oxidative stress, 
glutamate excitotoxicity, and programmed cell death. Inflammation was chosen as a 
tractable therapeutic target because of its early activation and potential for chronic 
persistence. While inflammation is a normal host response to injury which includes 
necessary repair processes such as clearing of cellular debris, prolonged inflammation in 
the context of TBI is thought to exacerbate the primary injury and coincide with a 
worsening of symptoms or impairments (Morganti-Kossmann, Rancan et al. 2002). The 
goal of this dissertation is to test the efficacy of applying an early practical therapy to 
prevent an excessive inflammatory state from manifesting along with worsened motor, 
cognitive, or affective function. 
   
 
3 
 
A key element to the translational goal of this dissertation is to evaluate practical 
therapies using a rodent model of TBI and tests which reflect quality of life in humans. 
For example, after TBI deficits in balance and dizziness are often reported and 
investigated with questionnaires and physical exams (Chandrasekhar 2013). In mice, 
behavioral tests can be used to objectively assess sensorimotor function prior to and 
following experimental brain injury. One such test, the neurological severity score (NSS), 
tests mice on eight criteria for ability to balance on and traverse beams of different sizes 
along with the presence of normal neurological reflexes (Chen, Constantini et al. 1996). 
Tests such as the NSS allow experimenters to draw conclusions on efficacy that relate to 
human symptoms. The subsequent chapters of this dissertation use this and similar 
behavior tests to infer efficacy in domains of sensorimotor, cognitive, and affective 
function with the long-term translational goal of reducing these burdens among human 
sufferers of TBI. 
Current clinical treatment of diffuse TBI includes a graded return to play or 
activity approach (May, Marshall et al. 2014). This approach advocates a period of 
physical and mental rest immediately following TBI that is followed by incremental 
addition of activity. If new symptoms arise or current symptoms worsen, it is advised to 
revert back to the previous state of activity until symptoms subside. Practical therapies 
would ideally be implemented with similar recommendations:  if a practical therapy is 
administered and symptoms worsen, the treatment regimen should be discontinued and 
additional professional medical care may be warranted. Safety is a paramount 
consideration in the advancement of practical therapies, but it is not expected that all 
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individuals will respond uniformly to treatment, especially in the case of a very 
heterogeneous patient population such as TBI. The current chapter is an overview of 
promising areas from which practical therapies for mild TBI may arise with particular 
focus on translational outcome measures—or tests that mirror outcome in the human 
condition. 
1.1 DIET/NUTRITION 
 Nutritional supplementation and diet modification represent a potential branch of 
practical therapies for mild TBI. From omega-3 fatty acids, to caloric restriction, to plant-
based compounds, nutritional approaches have shown promise of neuroprotection in 
experimental studies of TBI. This section will provide an overview of research on each of 
these approaches.  
Omega-3 fatty acids are polyunsaturated fatty acids primarily found in cold water 
fish which chiefly include docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA). Omega-3 fatty acid have widely studied anti-inflammatory properties (Calder 
2017). In the brain, fatty acids are incorporated into cell membranes and subsequently 
released in response to cellular stress or injury. Western diets are typically high in 
omega-6 fatty acids, including arachidonic acid (ARA), which displace omega-3 fatty 
acids, including DHA and EPA, in cell membranes (Bradbury 2011). Omega-6 derived 
lipid mediators include pro-inflammatory prostaglandin E2 and leukotriene B4 which 
may prolong inflammation and secondary injury in the absence of omega-3 fatty acids. 
With omega-3 fatty acid supplementation, the balance of lipid mediator metabolic 
precursors can be restored (Harrison, Rowe et al. 2016). DHA has demonstrated potent 
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anti-inflammatory effects in animal models of ischemic stroke (Belayev, Khoutorova et 
al. 2009) and TBI (Wu, Ying et al. 2011). While the mechanisms of action of DHA in the 
wake of neurological injury remain widely unknown, its therapeutic potential is 
compelling (Hasadsri, Wang et al. 2013). Special considerations for use of omega-3 fatty 
acid as a practical therapy include the relatively long time needed for incorporation into 
cell membranes. This limits the effective time window to long-term pre-treatment or 
post-treatment with little effect of acute treatment at time of injury. 
A broad category of nutritional supplementation using natural, plant-based 
compounds has emerged with applications as practical therapies for TBI (for full review, 
see (Scheff and Ansari 2017)). Among the most studied of these diverse natural 
compounds are caffeine, curcumin, and resveratrol. Chronic pre-treatment of mice with 
caffeine before controlled cortical impact TBI was shown to significantly decrease 
markers of inflammation. This finding was in contrast to that from an acutely-caffeine-
treated group in the same study which showed no neuroprotective effects (Li, Dai et al. 
2008). Chronic, dietary pre-treatment with curcumin-supplemented food decreased 
markers of oxidative stress and spatial learning impairment following lateral fluid 
percussion TBI in rats (Wu, Ying et al. 2006). Acute treatment of rats with resveratrol, a 
naturally occurring compound found in grapes, for three days following controlled 
cortical impact injury reduced markers in an array of outcomes including edema, motor 
impairment, and inflammatory markers (Feng, Cui et al. 2016). Together, these studies 
demonstrate the breadth of natural compound efficacy with varying beneficial effects in 
edema, inflammation, and oxidative stress. Unlike omega-3 fatty acid supplementation, 
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some natural compounds, including resveratrol, showed promise of acute and post-injury 
treatment instead of relying solely on chronic pre-treatment. 
In nearly perfect contrast with nutritional supplementation, caloric restriction is 
another prophylactic practical therapy which has demonstrated neuroprotection following 
experimental models of TBI (Rich, Van Landingham et al. 2010; Loncarevic-Vasiljkovic, 
Pesic et al. 2012). Three months of relatively extreme caloric restriction (50% reduced 
daily intake) preceding cortical stab injury in rats resulted in significant decreases in 
secondary injury—particularly neuroinflammatory cascades and microglial activation 
(Loncarevic-Vasiljkovic, Pesic et al. 2012). Similarly, four months of more modest 
restriction (30% reduced daily intake) improved spatial memory performance following 
weight-drop cortical contusion in rats (Rich, Van Landingham et al. 2010). In a more 
practical approach due to its post-injury application, fasting has been demonstrated to be 
neuroprotective after controlled cortical impact TBI in mice (Davis, Pauly et al. 2008). 
This study found that 24 hours of post-injury fasting, but not 48 hours of post-injury 
fasting, significantly increased tissue sparing following injury. In humans, chronic caloric 
restriction (25% reduced daily intake) has been demonstrated to be safe and well 
tolerated (Romashkan, Das et al. 2016). The demonstrated neuroprotective effects and 
safety of prophylactic caloric restriction and post-injury acute fasting make them ideal 
candidate practical therapies. 
The low cost of supplementation (or negative cost associated with caloric 
restriction), over-the-counter availability of many fatty acid and plant-based supplements, 
and often well-studied safety profiles make diet modification a prime avenue from which 
   
 
7 
 
to draw practical therapies. The primary limitation to these approaches is in timing: many 
require chronic pre-treatment prior to an injury which cannot be predicted. While this 
uncertainty is partially countered by the aforementioned strengths in convenience and 
availability, chronic diet modification appears particularly appropriate for demographics 
at high-risk for sustaining TBI such as contact sports participants, the military, and the 
elderly. Nutritional supplements are regulated by the Food and Drug Administration, but 
the Dietary Supplement Health and Education Act of 1994 restricted the authority of the 
FDA concerning supplements. Supplement manufacturers are not required to prove to the 
FDA that labeling claims are accurate. Because of this often products with similar 
labeling can contain ingredients of vastly different quality, origin, or processing (Swann 
2016). An important part of making dietary modification an effective practical therapy, 
after basic and clinical research on efficacy, is the establishment of middle ground 
classification between food and drug for the regulation and assurance of quality among 
supplements. A dedicated regulatory body for this does not yet exist in the U.S.A. 
1.2 EXERCISE 
 Exercise and self-rehabilitation are examples of practical therapies that are 
generally health-improving in and out of the context of TBI. Voluntary cardiovascular 
exercise has been well documented to improve outcome from experimental models of 
TBI, but timing of exercise in relation to TBI appears to be vital. Consistent 
cardiovascular exercise pre-treatment has been demonstrated to improve outcome from 
TBI in mice (Taylor, Montgomery et al. 2015; Zhao, Sabirzhanov et al. 2015). A study in 
rats, however, demonstrated that post-injury exercise within one week of fluid percussion 
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brain injury significantly decreased a wide array of potentially beneficial plasticity-
related proteins compared to un-exercised controls (Griesbach, Gomez-Pinilla et al. 
2004). This finding was supported in mice where late (5 weeks following TBI), but not 
early (1 week following TBI), exercise improved functional outcome (Piao, Stoica et al. 
2013). These studies suggest there may be a critical period acutely following TBI in 
which exercise is not beneficial or could even worsen long term cognitive and motor 
symptoms. This potential for harm detracts from the promise of acute post-injury exercise 
as a practical therapy, but pre-injury exercise and closely regimented post-injury exercise 
remain viable self-treatment options, particularly when used in a graded approach which 
can be decreased if symptoms worsen. 
 Alternatives to cardiovascular exercise which focus on mental and holistic 
wellbeing have been preliminarily assessed. These approaches understandably rely upon 
clinical studies due to limitations in adapting treatments to animal models. Both 
mindfulness-based stress reduction (MBSR) and yoga have shown indications of 
improvement among TBI patients in domains relevant to their practice. Eight weeks of 
MBSR for stroke and TBI patients reporting mental fatigue improved self-reported 
outcome in mental fatigue and tests of neuropsychological function compared to non-
treated controls (Johansson, Bjuhr et al. 2012). Two preliminary clinical studies of yoga 
among TBI patients showed promising results for yoga-related outcomes including breath 
control, balance, and self-reported psychological wellbeing (Silverthorne, Khalsa et al. 
2012; Schmid, Miller et al. 2016). Further research is needed to understand mechanisms 
behind these alternative exercise regimens, but current research indicates they are very 
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low-risk practical therapeutic opportunities. Additional consideration of timing of these 
interventions, similar to those given to cardiovascular exercise, may be warranted as all 
current clinical studies include patients beyond the acute treatment window. 
1.3 PHYSIOLOGICAL 
 Physiological interventions are an emerging field in practical therapies for TBI. 
Among these, interventions in sleep hygiene have been demonstrated to improve sleep-
related symptoms in TBI patients (for review, see (Bogdanov, Naismith et al. 2017)). 
Sleep disturbances including insomnia, hypersomnia, fatigue and sleep apnea are 
common among TBI patients (Barshikar and Bell 2017). A promising practical therapy 
for sleep disturbances after TBI is blue light therapy. Blue light therapy is a self-
administered, in-home practical therapy that consists of exposure to high-intensity blue 
light in the morning.  A randomized clinical study demonstrated that four weeks of 45 
minute daily light therapy sessions was sufficient to decrease measures of fatigue and 
daytime sleepiness among TBI patients (Sinclair, Ponsford et al. 2014).  With the goal of 
improving individual sleep quality after TBI, sleep hygiene interventions pose very little 
risk of harm. Further research is warranted to identify additional sleep routine 
modifications which improve outcome. 
 Remote ischemic conditioning (RIC), the process of transiently impeding blood 
flow to an organ to impart protection to a distant target organ, has demonstrated pre-
clinical neuroprotective effects in stroke and now recently in TBI. To date, the majority 
of clinical and laboratory studies have employed several short cycles (3-5 minutes each) 
of RIC using a blood pressure cuff (clinically) or femoral artery clamp (pre-clinically) 
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with equally spaced periods of cuff deflation and limb reperfusion. This non-invasive 
procedure can provide cellular protection from subsequent or prior injury to the brain and 
other organs. Though many mechanistic pathways have been proposed including nitric 
oxide synthase, inflammatory cytokines, opioid receptors, and potassium ATP channels, 
none have been definitively accepted (for review, see (Tapuria, Kumar et al. 2008)). A 
study of RIC induced two hours following controlled cortical impact in mice 
demonstrated significant reduction of TBI-induced motor and cognitive impairments 
(Sandweiss, Azim et al. 2017). Clinically, TBI patients treated in the emergency 
department with RIC showed significantly decreased biomarkers of TBI, potentially 
indicating a less severe injury response (Joseph, Pandit et al. 2015). RIC qualifies as a 
practical therapy for its ease and speed of administration, cost-effectiveness, and lack of 
indication of harmful effects. Further studies are needed to identify the most effective 
RIC administration paradigm with regard to timing relative to TBI and cycle duration. 
1.4 OVERVIEW OF DISSERTATION RESEARCH 
 Practical therapies are a diverse category of approaches as outlined above. The 
current dissertation is a multi-pronged pre-clinical examination of practical therapies for 
diffuse TBI with consideration of translationally relevant outcome measures. For this, 
each study incorporates tests which mirror the long term consequences of TBI in humans 
including motor, cognitive, and/or affective impairments. A key secondary injury 
mechanism, inflammation, is identified as a specific therapeutic target of the practical 
therapies investigated herein for its early activation and potential to perpetuate for years 
following TBI (Johnson, Stewart et al. 2013). Applying an early therapeutic intervention 
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such as the currently examined practical therapies has the potential to prevent secondary 
injury processes from persisting and accordingly improve quality of life after diffuse TBI. 
The chapters that follow critically assess four practical therapies for efficacy in a 
single model of diffuse brain injury. The effects of over-the-counter analgesics, 
docosahexaenoic acid (DHA), resolvins, and remote ischemic conditioning on outcome 
from diffuse TBI are measured with numerous overlapping approaches including 
behavioral analysis, molecular profiling of inflammatory markers, and histological 
analysis. The order of presentation of these four approaches is not congruent with their 
chronological progression due to the nature of this multi-pronged assessment in which 
many of the studies overlapped in their execution or analysis. 
In Chapter 2, we hypothesized that common over-the-counter analgesic 
medications acetaminophen and ibuprofen would improve functional outcome from 
diffuse TBI by attenuating the injury-induced inflammatory response. Ibuprofen is a non-
steroidal anti-inflammatory drug and was hypothesized to have a greater impact on 
injury-induced inflammation than acetaminophen. Results indicated that acetaminophen-
treated mice trended toward better outcome as measured by the rotarod test and 
neurological severity score, but no robustly significant differences were detected among 
brain-injured treatment groups. In conclusion, these over-the-counter medications were 
found to be practical but not efficacious therapies in this application. The finding that 
these medications did not adversely affect outcome indicated, however, that they may be 
safe for treating post-concussive symptoms including headache. 
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In Chapter 3, a dietary supplementation paradigm was tested as a potential 
practical therapy. We hypothesized that rats fed a DHA-enriched diet either prior to or 
following diffuse TBI would perform better on tests cognitive and sensory function due 
to attenuation of injury-induced inflammation. DHA-treated rats were found to behave 
more similarly to their sham-injured counterparts in a test of sensory sensitivity. As 
hypothesized, DHA treatment did significantly decrease TBI-induced microglial 
activation and cytokine production in the brain with greater effects seen from post-injury 
rather than pre-injury supplementation. These findings suggest that steady-state 
prophylactic and also post-injury dietary DHA supplementation may serve as effective 
practical therapies. The primary limitation of DHA as a practical therapy is the relatively 
long supplementation period required for effective DHA incorporation into cell 
membranes. 
In Chapter 4, a follow-up approach to DHA supplementation was examined in an 
effort to provide the therapeutic efficacy of DHA without the long supplementation 
period. Resolvins are lipid mediators of inflammation derived from omega-3 fatty acids. 
We hypothesized that treatment with resolvins would improve functional outcome from 
TBI in mice due to the timely resolution of inflammation without the protracted 
supplementation period required by their omega-3 fatty acid precursors. Results indicated 
that aspirin-triggered resolving D1 (AT-RvD1), but not resolvin E1 (RvE1) improved 
both motor and cognitive outcome from TBI. This finding complemented findings from 
Chapter 3 as AT-RvD1, but not RvE1, is derived specifically from DHA and shared its 
indications of neuroprotection. While resolvins were demonstrated to be efficacious, 
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ultimately they are not presently a very practical therapy due to their lack of availability 
and high cost to the general public. Future studies (of biology, chemistry, and economics) 
are warranted to determine the plausibility of their development into more practical 
therapies. 
Finally, Chapter 5 examines a physiological approach to practical therapies—
RIC. RIC has shown pre-clinical efficacy in improving outcome from neurological injury 
(see Appendix C for summary table of previous studies). As a pilot study we 
hypothesized that RIC would similarly improve outcome from diffuse TBI in mice. 
Simultaneously, a hypothesis-generating approach was undertaken to identify plasma 
protein correlates of RIC in the context of TBI for further elucidation of the presently 
unknown mechanistic underpinnings of RIC. While RIC did not improve motor outcome 
from TBI, cognitive and affective outcome measures were inconclusive due to lack of 
TBI-induced impairments at the selected time points. Plasma protein correlates of RIC 
were identified in both the brain-injured condition and sham mice. Proteins selectively 
responsive to RIC regardless of TBI, including selenium-binding protein 1 and fatty acid 
binding protein 4 were identified as candidates for future RIC mechanism investigation. 
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CHAPTER 2 
2 ACUTE OVER-THE-COUNTER PHARMACOLOGICAL INTERVENTION DOES 
NOT ADVERSELY AFFECT BEHAVIORAL OUTCOME FOLLOWING DIFFUSE 
TRAUMATIC BRAIN INJURY IN THE MOUSE 
Published in Experimental Brain Research (Harrison et al. 2014) 
2.1 ABSTRACT 
 
 Following mild TBI, patients may self-treat symptoms of concussion, including 
post-traumatic headache, taking over-the-counter (OTC) analgesics. Administering one 
dose of OTC analgesics immediately following experimental brain injury mimics the at-
home treated population of concussed patients and may accelerate the understanding of 
the relationship between brain injury and OTC pharmacological intervention. In the 
current study, we investigate the effect of acute administration of OTC analgesics on 
neurological function and cortical cytokine levels after experimental diffuse TBI in the 
mouse. 
 Adult, male C57BL/6 mice were injured using a midline fluid percussion (mFPI) 
injury model of concussion (6-10 min righting reflex time for brain-injured mice). 
Experimental groups included mFPI paired with either ibuprofen (60mg/kg, i.p.; n=16), 
acetaminophen (40mg/kg, i.p.; n=9), or vehicle (15% ethanol (v/v) in 0.9% saline; n=13) 
and sham injury paired OTC medicine or vehicle (n=7-10 per group). At 24 hours after 
injury, functional outcome was assessed using the rotarod task and a modified 
neurological severity score (NSS). Following behavior assessment, cortical cytokine 
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levels were measured by multiplex ELISA at 24 hours post-injury. To evaluate efficacy 
on acute inflammation, cortical cytokine levels were measured also at 6 hours post-injury. 
 In the diffuse brain-injured mouse, immediate pharmacological intervention did 
not attenuate or exacerbate TBI-induced functional deficits. Cortical cytokine levels were 
affected by injury, time, or their interaction. However, levels were not affected by 
treatment at 6 hours or 24 hours post-injury. These data indicate that acute administration 
of OTC analgesics did not exacerbate or attenuate brain-injury deficits which may inform 
clinical recommendations for the at-home treated mildly concussed patient. 
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2.2 INTRODUCTION 
 
Traumatic brain injury (TBI) is a major cause of death and disability throughout 
the world (Langlois, Rutland-Brown et al. 2006; Reilly 2007; Roozenbeek, Maas et al. 
2013). In the United States between 2002 and 2006, the Centers for Disease Control and 
Prevention estimated 52,000 deaths, 275,000 hospitalizations, and 1,365,000 emergency 
department visits resulting from TBI each year (Faul, Xu et al. 2010). It is also estimated 
that as high as 42% of TBIs are not included in these statistics because 1.2-4.3 million 
survivors of mild TBI annually do not seek medical attention (Setnik and Bazarian 2007) 
and likely self-medicate.  
The mechanical forces of TBI initiate a cascade of secondary injury processes, 
including inflammation, which continue for days to weeks following injury (Werner and 
Engelhard 2007). In conflicting studies, cerebral inflammation has been shown to 
contribute to either beneficial or deleterious effects after traumatic insult (for review, see 
(Morganti-Kossmann, Rancan et al. 2002)). TBI triggers a cascade of inflammation-
mediating cytokines (Morganti-Kossmann, Rancan et al. 2001; Frugier, Morganti-
Kossmann et al. 2010; Semple, Bye et al. 2010; Ziebell and Morganti-Kossmann 2010), 
which can elicit a range of responses including cell differentiation, immune activation, 
and cell death (Allan and Rothwell 2001). For the present study, the midline fluid 
percussion injury (mFPI) experimental model in the mouse induces multifocal 
neuropathology with translational application to mild diffuse TBI, or concussion. 
Principally in the first day after mFPI in mice, we have reported significantly increased 
levels of pro-inflammatory cytokine IL-1β in the cortex (Rowe, Striz et al. 2014) along 
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with acute neurological impairments manifested within one hour of injury (Rowe, 
Harrison et al. 2014). In diffuse TBI, the effects of clinically relevant acute 
pharmacological inhibition of inflammation on functional outcome are not yet 
understood. 
Secondary injury processes initiated by TBI, including inflammation, are tractable 
therapeutic targets. Inflammation in the wake of TBI is, in part, mediated by the 
conversion of membrane-released arachidonic acid into pro-inflammatory prostaglandins 
by cyclooxygenase-2 (COX-2) (Dash, Mach et al. 2000). NSAIDs are widely available 
over-the-counter drugs used to treat acute pain and inflammation, with mechanisms of 
action to block COX-1 and/or COX-2, thereby slowing the production of prostaglandins 
(Vane 1971). Acetaminophen, on the other hand, is presented as an analgesic with actions 
on cannabinoid receptors (Ottani, Leone et al. 2006; Dani, Guindon et al. 2007), with 
weaker inflammatory properties. Previous studies suggest anti-inflammatory drugs 
improve outcome following brain injury as early as 72 hours post-injury (Gopez, Yue et 
al. 2005; Ng, Semple et al. 2012; Thau-Zuchman, Shohami et al. 2012; Chio, Chang et al. 
2013; Gatson, Liu et al. 2013). Treatment with the highly specific COX-2 inhibitor DFU 
[5,5-dimethyl-3(3-fluorophenyl)-4(4-methylsulfonyl)phenyl-2(
5
H)-furanone], 
administered daily for three days following lateral cortical impact in rats attenuated 
injury-induced prostaglandin production in the brain and improved functional recovery 
measured by the Morris water maze and neuroscore at 72 hours post-injury (Gopez, Yue 
et al. 2005). Carprofen, a COX-2 inhibitor, administered daily for seven days following 
experimental TBI using a closed head injury (CHI) model in mice, also improved 
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functional recovery (Thau-Zuchman, Shohami et al. 2012). Recovery of function 
measured by the NSS, however, was not present until 72 hours post-injury (Thau-
Zuchman, Shohami et al. 2012). Treatment with anti-inflammatory minocycline for 
fourteen days following CHI in mice resulted in improved NSS scores starting at 72 
hours post-injury, with improvements lasting through day 7 (Ng, Semple et al. 2012). 
These studies suggest that inhibiting inflammation after mild to severe TBI can improve 
functional recovery; however, there is evidence to suggest that treatment with ibuprofen 
over an extended timeframe may worsen cognitive outcome. Rats which were 
continuously treated with ibuprofen for four months following lateral fluid percussion 
injury performed significantly worse in the Morris Water Maze than non-treated brain-
injured rats (Browne, Iwata et al. 2006). Taken together, previous reports indicate that 
repeated doses of OTC analgesics, depending on the timeframe, may be beneficial or 
detrimental to recovery from TBI. The acute nature of neurological impairments induced 
by the mFPI model necessitates acute behavioral analysis to assess the effects of 
pharmacological intervention (Rowe, Harrison et al. 2013). The current study delivers 
ibuprofen and acetaminophen to determine if a single treatment with common over-the-
counter (OTC) analgesics after diffuse TBI promotes recovery or worsens behavioral 
outcome. 
The current study investigated the effects of acetaminophen and ibuprofen—two 
common analgesic drugs with different anti-inflammatory mechanisms—on neurological 
function and cortical cytokine levels after diffuse TBI in the mouse. We hypothesized 
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that acute pharmacological inhibition of injury-induced inflammation will lead to a 
decrease in inflammatory cytokines, possibly altering functional outcome. 
2.3 METHODS 
 
2.3.1 Animals 
 Male C57BL/6 mice (Harlan Laboratories, Inc., Indianapolis, IN) were used for 
all experiments (n=57). Mice were housed in a 12 h light/12h dark cycle at a constant 
temperature (23°C ± 2° C) with food and water available ad libitum according to the 
Association for Assessment and Accreditation of Laboratory Animal Care International. 
All mice used in this study were singly housed. Mice were acclimated to their 
environment following shipment for at least three days prior to any experiments. After 
surgery, mice were evaluated daily for post-operative care by a physical examination and 
documentation of each animal‘s condition. Animal care was approved by the Institutional 
Animal Care and Use Committees at St. Joseph‘s Hospital and Medical Center (Phoenix, 
AZ). 
2.3.2 Midline Fluid Percussion Injury (mFPI) 
Mice (20-24g) were subjected to midline fluid percussion injury (mFPI) 
consistent with methods previously described (Lifshitz 2008). Group sizes are indicated 
in the results section and figure legends for individual studies. Mice were anesthetized 
using 5% isoflurane in 100% oxygen for five minutes and the head of the mouse was 
placed in a stereotaxic frame with continuously delivered isoflurane at 2.5% via 
nosecone. While anesthetized, body temperature was maintained using a Deltaphase
®
 
isothermal heating pad (Braintree Scientific Inc., Braintree, MA). A midline incision was 
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made exposing bregma and lambda, and fascia was removed from the surface of the 
skull. A trephine (3 mm outer diameter) was used for the craniotomy, centered on the 
sagittal suture between bregma and lambda without disruption of the dura. An injury cap 
prepared from the female portion of a Luer-Loc needle hub was fixed over the 
craniotomy using cyanoacrylate gel and methyl-methacrylate (Hygenic Corp., Akron, 
OH). The incision was sutured at the anterior and posterior edges and topical Lidocaine 
ointment was applied. The injury cap was closed using a Luer-Loc cap and mice were 
placed in a heated recovery cage and monitored until ambulatory before being returned to 
their home cage. 
For injury induction 24 hours post-surgery, mice were re-anesthetized with 5% 
isoflurane delivered for five minutes. The cap was removed from the injury-hub assembly 
and the dura was visually inspected through the hub to make sure it was intact with no 
debris. The hub was then filled with normal saline and attached to a tube connected to the 
male end of the fluid percussion device (Custom Design and Fabrication, Virginia 
Commonwealth University, Richmond, VA). An injury of moderate severity for our 
injury model (1.4 atm) was administered by releasing the pendulum onto the fluid-filled 
cylinder. Sham-injured mice underwent the same procedure except the pendulum was not 
released. Mice were monitored for the presence of a forearm fencing response and 
righting reflex times were recorded for the injured mice as indicators of injury severity 
(Hosseini and Lifshitz 2009). The righting reflex time is the total time from the initial 
impact until the mouse spontaneously rights itself from a supine position. The fencing 
response is a tonic posturing characterized by extension and flexion of opposite arms that 
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has been validated as an overt indicator of injury severity (Hosseini and Lifshitz 2009). 
The injury hub was removed and the brain was inspected for uniform herniation and 
integrity of the dura. The dura was intact in all mice; none were excluded as technical 
failures. The incision was cleaned using saline and closed using sutures. Moderate brain-
injured mice had righting reflex recovery times greater than six minutes and a positive 
fencing response. Sham injured mice recovered a righting reflex within 20 seconds. After 
spontaneously righting, mice were placed in a heated recovery cage and monitored until 
ambulatory (approximately 5 to 15 minutes) before being returned to their cage. 
Adequate measures were taken to minimize pain or discomfort.  
2.3.3 Pharmacological Intervention 
 All mice received either vehicle or drug treatment immediately following 
induction of injury or sham. Drugs were administered intraperitoneally in 100µl of sterile 
vehicle solution of normal saline and 15% (v/v) ethanol. Drug-treated mice received 
either ibuprofen (60 mg/kg; Sigma-Aldrich, St. Louis, MO) or acetaminophen (40 mg/kg; 
Sigma-Aldrich, St. Louis, MO). These doses were chosen with respect to clinically 
relevant doses. Dose translations from human to mice were based on body surface area 
(Reagan-Shaw, Nihal et al. 2008) and were maintained within the maximum daily dose 
recommended by the United States Federal Drug Administration (www.fda.gov). Both 
drugs were compared to the same vehicle-treated control group treated with normal saline 
and 15% (v/v) ethanol. 
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2.3.4 Behavioral Testing 
Rotarod: Sensorimotor function was assessed using the Economex Rotarod 
system from Columbus Instruments (Columbus, OH). Mice were pre-trained for three 
consecutive days. The first two days were acclimation (60 sec at 4 RPM for 3 trials) and 
on day three baseline scores were collected using the test day procedures (see below). For 
the test at 24 hours post-injury, mice were placed on the rod with a starting speed of 4 
RPM, and rod rotation speed was continuously increased over 5 minutes up to a max 
speed of 28 RPM, as previously published (Bachstetter, Rowe et al. 2013). The trial 
ended when the mouse fell from the rod or 5 minutes elapsed. Two trials were performed 
at each time point. Data are presented (average of two trials) as latency to fall in seconds 
and total distance traveled in centimeters. Improvement in performance is presented as 
the difference in each mouse‘s baseline score and test day score, where positive numbers 
indicate improvement in the task. 
Neurological Severity Score (NSS): Post-traumatic neurological impairments 
were assessed at 24 hours post-injury using an 8-point NSS paradigm adapted from those 
previously used in experimental models of TBI (Chen, Constantini et al. 1996; Semple, 
Bye et al. 2010; Pleasant, Carlson et al. 2011; Ziebell, Bye et al. 2011). One point was 
given for failure on an individual task, and no points were given if a mouse completed a 
task successfully. Mice were observed for hind limb flexion, startle reflex, and seeking 
behavior (presence of these behaviors was considered successful task completion). Mice 
traversed in sequence, 3, 2, and 1 centimeter beams. The beams were elevated and mice 
were given 1 minute to travel 30 centimeters on the beams. The task was scored as a 
   
 
23 
 
success if the mouse traveled 30 centimeters with normal forelimb and hindlimb position 
(forelimb/hindlimb did not hang from the beam). Mice were also required to balance on a 
0.5 centimeter beam and a 0.5 centimeter round rod for 3 seconds in a stationary position 
with front paws between hind paws. Non-parametric data are presented as a composite 
score ranging from 0 to 8 representing performance on all tasks combined. High final 
NSS scores were indicative of task failure and interpreted as neurological impairment.   
2.3.5 Tissue preparation and cytokine quantification 
At 6 or 24 hours post-injury mice were given an overdose of sodium pentobarbital 
and transcardially perfused with ice cold phosphate buffered saline (PBS). Mice were 
decapitated and the brains were dissected on ice. Cortical biopsies (2mm diameter x 2mm 
thickness) were taken and snap frozen in methanol cooled over dry ice then stored at -
80°C. The protein levels of a panel of inflammation-related cytokines were measured by 
Quansys Biosciences Mouse Cytokine IR Q-Plex assay (Quansys Biosciences, Logan, 
UT), according to manufacturer protocol. Cortical biopsies were bead-homogenized 
using a Precellys 24 in 200 µl of ice-cold Tris-buffered lysis solution supplemented with 
protease inhibitor cocktail (Complete Protease Inhibitor Cocktail Mini Tablet, Roche 
Diagnostics, Mannheim, Germany). The cortical homogenate was centrifuged at 3000 
RCF for 20 minutes at 4°C in a microcentrifuge. The resulting supernatant (25µl) was 
loaded per well of the Q-Plex plate, and cytokine levels were determined by Q-Plex 
assay. Cytokine levels in the cortex were normalized to the total amount of protein in the 
sample, as determined by BCA Protein Assay (Thermo Scientific, Rockford, IL). 
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2.3.6 Statistical Analysis 
Data are shown as mean ± SEM and analyzed using statistical software 
(GraphPad-Prism 6). For analysis of behavior, uninjured shams from all drug treatment 
groups were combined and used as a single control (see results). Differences in rotarod 
performance following TBI were determined by one-way analysis of variance (ANOVA) 
followed by Sidak‘s multiple comparisons test. Non-parametric NSS data were analyzed 
by Kruskal-Wallis ANOVA, followed by Dunn‘s comparison post-hoc test (see results). 
Differences in cytokine concentrations were analyzed by two-way ANOVA. Statistical 
significance was assigned when p<0.05. 
2.4 RESULTS 
 
It was not anticipated that drug treatment would change functional outcome in the 
uninjured sham mice. Statistical analyses confirmed no significant change in rotatrod 
performance or neurological severity score between any sham treatment groups. Vehicle-
treated, ibuprofen-treated, and acetaminophen-treated shams were combined into a single 
control. As anticipated, anti-inflammatory treatment altered cytokine levels in sham 
treatment groups; cytokine data were analyzed without combining shams.  
2.4.1 Diffuse TBI reduced motor performance on the rotarod task regardless of 
pharmacological intervention. 
To assess motor function we used the rotarod task as previously published (Bachstetter, 
Rowe et al. 2013).  Across groups, there was a significant effect on latency to stay on the 
rotarod (F(3, 53)=3.688, p=0.0174; Figure 1A; sham n=27, vehicle-treated injury n=10, 
ibuprofen-treated injury n=12, acetaminophen-treated injury n=8). Rotarod latency was 
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significantly reduced in vehicle-treated and ibuprofen-treated brain-injured mice 
compared to sham mice at 24 hours post-injury (Figure 1A). There was no significant 
latency reduction in acetaminophen-treated brain-injured mice compared to shams 
(Figure 1A). Further analysis of rotarod performance confirmed the latency data with 
distance traveled, showing similar significant effects on distance traveled (F(3, 
53)=3.909, p=0.0135; Figure 1B). Distance traveled was significantly reduced in both 
vehicle and ibuprofen-treated brain-injured mice compared to uninjured sham. There was 
no difference in distance traveled by acetaminophen-treated brain-injured mice compared 
to shams. To compensate for trial-based learning, improvement in motor performance 
was analyzed. Latencies (Figure 1C) and distances (Figure 1D) of each mouse at 24 hours 
post-injury were compared to their individual baseline scores at training. Brain-injured 
mice treated with vehicle and ibuprofen showed significantly less improvement in latency 
to stay on the rod compared to the improvement of uninjured shams (F(3, 53)=4.553, 
p=0.0065; Figure 1C). Acetaminophen-treated brain-injured mice did not show a 
difference in improvement compared to uninjured shams (Figure 1C). All brain-injured 
mice, regardless of treatment, showed significantly less improvement in distance traveled 
compared to shams (F(3, 53)=6.017, p=0.0013; Figure 1D). 
Overall, diffuse brain injury reduced motor performance measured on the rotarod 
task. Acetaminophen-treated brain-injured mice did not show injury-induced impairments 
measured by latency (Figure 1A, 1C) or distance (Figure 1B), but did have a significantly 
worse improvement in distance from baseline compared to uninjured shams (Figure 1D). 
However, the acetaminophen-treated brain-injured mice did not show significant 
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improvements in motor impairments compared to all other brain-injured groups 
(F(2,27)=0.5684, p=0.5730; Figure 1A; (F(2,27)=1.063, p=0.03594; Figure 1B; 
(F(2,27)=0.06751, p=0.9349; Figure 1C). Acute pharmacological intervention, regardless 
of drug, did not exacerbate or attenuate brain-injury induced motor deficits. 
2.4.2 Diffuse TBI resulted in neurological impairments regardless of pharmacological 
intervention. 
All brain-injured mice showed significant neurological impairments measured by 
the neurological severity score (NSS) compared to uninjured shams, regardless of 
pharmacological intervention (KW(4, 57)=27.37, p<0.001; Figure 2; sham n=27, vehicle- 
treated injury n=10, ibuprofen-treated injury n=12, acetaminophen-treated injury n=8). At 
24 hours post-injury all brain-injured groups had significantly higher NSS scores 
compared to uninjured shams. There was no significant effect of post-injury 
pharmacological treatment. 
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Figure 2.1. No adverse effects of pharmacological intervention on injury-induced 
motor deficits on the rotarod task. 
(A) Injury significantly impaired motor performance as indicated by reduced latency to 
stay on the rotarod (mean ±SEM; F(3, 53)=3.688, p=0.0174), with significant differences 
between vehicle-treated and ibuprofen-treated brain-injured mice compared to uninjured 
shams at 24 hours post-injury. There was no significant difference between 
acetaminophen-treated brain-injured mice compared to uninjured shams. (B)  Reduced 
distance traveled on the rotarod also indicated a significant injury-induced impairment in 
motor function (mean ±SEM; F(3, 53)=3.909, p=0.0135). There was a significant 
difference between vehicle-treated and ibuprofen-treated brain-injured mice compared to 
uninjured shams at 24 hours post-injury. There was no difference in distance traveled by 
acetaminophen-treated brain-injured mice compared to uninjured shams. (C) Brain injury 
significantly impaired the improvement in latency to stay on the rotarod from baseline 
(mean ±SEM; F(3, 53)=4.553, p=0.0065) indicated by a difference between vehicle-
treated and ibuprofen-treated brain-injured mice compared to uninjured shams at 24 
hours post-injury. (D) Brain injury also significantly impaired improvement in distance 
traveled (mean ±SEM; F(3, 53)=6.017, p=0.0013) between vehicle-treated, ibuprofen-
treated, and acetaminophen-treated brain-injured mice compared to uninjured shams at 24 
hours post-injury. (sham n=27, vehicle-treated injury n=10, ibuprofen-treated injury 
n=12, acetaminophen-treated injury n=8; *, p<0.05; **, p<0.01).   
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2.4.3 Diffuse TBI resulted in increased cytokine levels at 6 or 24 hours post-injury 
regardless of pharmacological intervention.  
 Upon brain dissection, no differences in hemorrhage or gross pathology were 
noted among treatment groups. To determine the changes in the inflammatory response 
following diffuse brain injury, we measured inflammatory cytokines in whole cortex at 
select time points following injury (6 hours, 24 hours). Data from both time points and all 
measured analytes are presented as measured concentration from cortical homogenate 
(pg/ml/mg) ± SEM (Table 1). Pro-inflammatory cytokines were found to increase by 6 
hours post-injury but did not remain increased at 24 hours post-injury (Figure 3). Anti-
inflammatory cytokines were not altered at 6 hours post-injury but increased by 24 hours 
post-injury (Figure 4). For all analytes, effect of pharmacological treatment was 
evaluated across brain-injured groups via one-way ANOVA revealing no significant 
differences in OTC analgesic-treated vs vehicle-treated groups. 
Diffuse brain injury resulted in increased cortical levels of pro-inflammatory 
cytokines IL-6 and TNF-α when compared to uninjured shams at 6 hours post-injury 
(F(1, 30)=4.468, p=0.0430, Figure 3B; F(1, 30)=6.853, p=0.0137, Figure 3C). Another 
pro-inflammatory cytokine, IL-1α exhibited a modest increase in response to injury 
which failed to reach statistical significance (F(1, 30)=1.192, p=0.2837; Figure 3A). 
Significant injury effects are denoted in Figure 3 by asterisks. No significant injury 
effects were noted in pro-inflammatory cytokine levels at 24 hours post-injury. By 24 
hours post-injury, IL-6 (F(1, 58)=14.76, p=0.0003, Figure 3B), IL-12 (F(1,59)=35.61, 
p<0.001, Table 1), and TNF-α (F(1, 59)=11.38, p=0.0013; Figure 3C), were each  
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Figure 2.2. No adverse effects of pharmacological intervention on injury-induced 
neurological impairments. 
Significant neurological impairments were detected between groups, as measured by 
modified neurological severity score (mean ±SEM; KW(4, 57)=27.37, p<0.001). Dunn‘s 
multiple comparisons test indicated vehicle-treated, ibuprofen-treated, and 
acetaminophen-treated brain-injured mice showed significantly higher NSS scores 
compared to uninjured shams 24 hours post-injury. There were no significant changes in 
function between any brain-injured groups regardless of treatment. (sham n=27, vehicle-
treated injury n=10, ibuprofen-treated injury n=12, acetaminophen-treated injury n=8; *, 
p<0.05; ***, p<0.001).   
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decreased compared to their respective 6 hour measurements. Additionally, pro-
inflammatory cytokines IL-1α, IL-1β, and IFNγ were reduced to undetectable levels at 24 
hours, precluding statistical comparisons. Significant effects of time between 6 hour and 
24 hour measurements are denoted in Figure 3 by crosses. 
Diffuse brain injury did not alter cortical levels of anti-inflammatory cytokines 
IL-4 or IL-10 when compared to uninjured shams at 6 hours post-injury (F(1, 23)=1.047, 
p=0.3169; F(1, 30)=0.2279, p=0.6366, Figure 4A,B) or 24 hours post-injury (F(1, 
23)=0.6964, p=0.4126, Figure 4B). IL-4 levels were increased at 24 hours post-injury 
compared to 6 hours post-injury; however, 6 hour IL-4 levels were undetectable, 
precluding statistical comparisons (Figure 4A). Levels of IL-2 and IL-10 were 
significantly increased at 24 hours post-injury compared to 6 hours post-injury (F(1, 
59)=0.1672, p<0.0001, Figure 4B; (F(1,59)=25.87, p<0.0001, Table 1). Significant 
effects of time between 6 hour and 24 hour measurements are denoted in Figure 3 by 
crosses. 
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Figure 2.3. Diffuse brain injury increased pro-inflammatory cytokines in the cortex 
at 6 hours post-injury regardless of pharmacological treatment. 
For all analytes, effect of pharmacological treatment was evaluated across brain-injured 
groups via one-way ANOVA revealing no significant differences in OTC analgesic-
treated vs vehicle-treated groups. (A) IL-1α was increased in the cortex following brain 
injury at 6 hours post-injury compared to uninjured shams but failed to reach significance 
(mean ±SEM; F(1, 30)=1.192, p=0.2837). Overall, IL-1α decreased 24 hours post-injury 
to levels that were undetectable (UD) preventing statistical analysis. (B) IL-6 was 
significantly increased in the cortex following brain injury at 6 hours post-injury 
compared to uninjured shams (mean ±SEM; F(1, 30)=4.468, *; p=0.0430). Though there 
was an evident trend of both ibuprofen and acetaminophen toward reduction of injury-
induced IL-6 compared to vehicle, these differences did not reach statistical significance 
(F(2,18)=1.818, p=0.1909). There were no significant injury-induced changes in IL-6 at 
24 hours post-injury (mean ±SEM; F(1, 22)=0.02819, p=0.8682), however, levels were 
significantly lower compared to levels at 6 hours post-injury (mean ±SEM; F(1, 
58)=14.76, †; p=0.0003). (C) TNF-α was significantly increased in the cortex following 
brain injury at 6 hours post-injury compared to uninjured shams (mean ±SEM; F(1, 
30)=6.853, *; p=0.0137). There were no significant injury-induced changes in IL-6 at 24 
hours post-injury (mean ±SEM; F(1, 23)=1.756, p=0.1981), however, levels were 
significantly lower compared to levels at 6 hours post-injury (mean ±SEM; F(1, 
59)=11.38, †; p=0.0013). (6 hrs: sham n=5 per treatment, injury n=7 per treatment; 24 
hrs: sham n=5 per treatment, injury n=4-5 per treatment). 
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Figure 2.4. Neither brain injury nor pharmacological treatment altered anti-
inflammatory cytokine levels in the cortex at 6 hours or 24 hours post-injury. 
For all analytes, effect of pharmacological treatment was evaluated across brain-injured 
groups via one-way ANOVA revealing no significant differences in OTC analgesic-
treated vs vehicle-treated groups. (A) IL-4 was undetectable in the cortex at 6 hours post-
injury, and levels were not statistically analyzed. IL-4 was present in the cortex 24 hours 
post-injury and there were no significant injury-induced changes compared to uninjured 
shams (mean ±SEM; F(1, 23)=1.047, p=0.3169). Overall, IL-4 increased 24 hours post-
injury compared to 6 hours post-injury; however, levels were undetectable (UD) 
preventing statistical analysis. (B) There were no injured-induced changes in IL-10 in the 
cortex at 6 hours (mean ±SEM; F(1, 30)=0.2279, p=0.6366) or 24 hours (mean ±SEM; 
F(1, 23)=0.6964, p=0.4126) post-injury compared to uninjured shams. Levels of IL-10 
were significantly higher at 24 hours post-injury compared to levels at 6 hours post-injury 
(mean ±SEM; F(1, 59)=0.1672, †; p<0.0001). (6 hrs: sham n=5 per treatment, injury n=7 
per treatment; 24 hrs: sham n=5 per treatment, injury n=4-5 per treatment). 
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Table 2.1. Inflammation-related cytokines in the cortex at 6 and 24 hours following 
diffuse brain injury. 
 
Data are presented as concentration levels (mean pg/ml/mg ± SEM). IL-6 and TNF-α 
were both significantly increased in the brain-injured cortex at 6 hours post-injury 
compared to uninjured shams (F(1, 30)=4.468, *; p=0.0430; F(1, 30)=6.853, *; 
p=0.0137). There were also time dependent decreases in IL-6 and TNF-α at 24 hours 
post-injury compared to 6 hours post-injury ((F(1, 58)=14.76, †; p=0.0003; F(1, 
59)=11.38,†; p=0.0013). There were time dependent increases in IL-2, IL-10, and IL-12 
at 24 hours post-injury compared to 6 hours post-injury (F(1,59)=25.87,†; p<0.0001; F(1, 
59)=0.1672, †; p<0.0001; F(1,59)=35.61, †; p<0.001). (UD=undetectable) (6 hrs: sham 
n=5 per treatment, injury n=7 per treatment; 24 hrs: sham n=5 per treatment, injury n=4-5 
per treatment). 
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2.5 DISCUSSION 
 
In the diffuse brain-injured mouse, immediate pharmacological intervention with 
over-the-counter analgesics did not adversely affect sensorimotor or neurological 
outcome. A single, clinically relevant dose of ibuprofen or acetaminophen was 
hypothesized to reduce early inflammation leading to a worsened functional outcome. In 
the current study, we show immediate treatment with ibuprofen or acetaminophen did not 
impact TBI-induced functional deficits measured by the rotarod and neurological severity 
score (NSS). We also show drug treatment did not alter expression of cortical cytokines 
at 24 hour post-injury. 
 There is no approved pharmacological treatment for TBI and current medical care 
focuses primarily on controlling physiological parameters including intracranial pressure 
and blood pressure (Wang, Larner et al. 2006), as well as pain. Severity of TBI is 
categorized based on the Glasgow Coma Scale (GCS) which reliably classifies the 
severity of TBI based on clinical symptoms with a total GCS score classifying their 
injury as mild (score: 13-15), moderate (score: 9-12) or severe (score: <9) (Prins, Greco 
et al. 2013). Given the majority of human TBI encompasses mild to moderate diffuse 
brain injury for which self-medication may be the primary treatment, the current study 
sought to replicate the real-life situation in which a survivor of mild TBI self-medicates 
with a single dose of an OTC analgesic. For this study, we used a moderate severity 
diffuse brain injury which in our injury model (mFPI) reflects a mild clinical TBI (GCS 
13-15). The most frequent symptom after TBI is post-traumatic headache TBI (Theeler, 
Lucas et al. 2013), making ibuprofen and acetaminophen principal choices for self-
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medication. Administering one dose of over-the-counter (OTC) analgesics immediately 
following brain injury mimics the at-home treated population of concussed patients and 
may accelerate the understanding of the relationship between brain injury and OTC 
pharmacological intervention. Administering ibuprofen, an NSAID and COX inhibitor, in 
opposition to administering acetaminophen, an analgesic with weak anti-inflammatory 
properties, allowed for the investigation of inflammation inhibition on brain injury-
induced deficits. 
While clinical and experimental data suggest the chronic over-production of pro-
inflammatory cytokines contributes to the progression of pathology in TBI (Schmidt, 
Heyde et al. 2005; Lloyd, Somera-Molina et al. 2008; Cao, Thomas et al. 2012), the role 
of immediate inflammation is less clear. Inflammation is critical to the repair process and 
health of the organism, however, inflammation that is excessive or prolonged can 
exacerbate damage after the primary injury (Bachstetter, Rowe et al. 2013). Previous 
reports have shown that multiple doses of analgesics can alter not only functional 
outcome but also cellular mechanisms following experimental TBI, see review (Rowe, 
Harrison et al. 2013). In this study, a single dose of ibuprofen or acetaminophen given at 
the time of injury did not attenuate or exacerbate injury-induced sensorimotor or 
neurological deficits measured 24 hours post-injury. Previous studies suggest anti-
inflammatory drugs can improve outcome following brain injury as early as 72 hours 
post-injury (Gopez, Yue et al. 2005; Ng, Semple et al. 2012; Thau-Zuchman, Shohami et 
al. 2012; Chio, Chang et al. 2013; Gatson, Liu et al. 2013). Treatment with the highly 
specific COX-2 inhibitor DFU [5,5-dimethyl-3(3-fluorophenyl)-4(4-
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methylsulfonyl)phenyl-2(
5
H)-furanone], following lateral cortical impact in rats 
attenuated injury-induced prostaglandin production in the brain and improved functional 
recovery measured by the Morris water maze and neuroscore at 72 hours post-injury 
(Gopez, Yue et al. 2005). Carprofen, a COX-2 inhibitor, administered following closed 
head injury (CHI) in mice, also improved functional recovery (Thau-Zuchman, Shohami 
et al. 2012). Recovery of function measured by the NSS, however, was not present until 
72 hours post-injury (Thau-Zuchman, Shohami et al. 2012). Treatment with anti-
inflammatory minocycline following CHI in mice resulted in improved NSS scores 
starting at 72 hours post-injury, with improvements lasting through day 7 (Ng, Semple et 
al. 2012). These studies suggest that inhibiting inflammation can improve functional 
recovery. While the administration of analgesics has been primarily shown to positively 
influence functional outcome, these studies have incorporated multiple dosing strategies 
either before or after TBI. While the results are experimentally valid, they do not address 
the situation faced by a mildly concussed individual not seeking medical attention. In this 
scenario, an individual would likely self-treat prominent symptoms, including headache, 
with OTC analgesics immediately post-injury. Experimentally, it would be expected that 
a single dose of OTC analgesics would have less profound effects upon outcome than a 
more aggressive dosing strategy. 
In the current study, we found that a single dose of OTC analgesics did not 
attenuate or exacerbate TBI induced functional deficits. Sensorimotor deficits measured 
by the Rotarod task were present in brain-injured groups compared to uninjured shams 
regardless of drug treatment at the time of injury. Similarly, brain-injured groups had 
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neurological deficits measured by a modified NSS compared to uninjured shams 
regardless of drug treatment. Multiple studies have shown analgesics to provide 
neuroprotection from TBI when administered continually, such that a single clinically 
relevant dose of OTC analgesics does not affect the pathophysiological and molecular 
cascades induced by diffuse brain injury. In this way, any initial inhibition of 
inflammation provided by a single analgesic dose may not prevent the development of 
neurological deficits by 24 hours post-injury. It is also possible that the route of drug 
administration used in this study reduced the bioavailability of the compounds. Alternate 
administration routes could increase the bioavailability of the drugs, and should be 
considered for future studies, recognizing the reduced clinical applicability. Overall, this 
study shows one dose of OTC analgesics given immediately following injury does not 
alter functional outcome. Given that the OTC analgesics administered in the current study 
did not worsen behavioral outcome, they may be safe for the clinical treatment of post-
traumatic symptoms. It is of note, though, that some anti-inflammatory drugs, including 
ibuprofen, are not indicated for clinical use after TBI due to their anti-coagulant effects 
increasing the possibility of intracranial bleeding (Maiese 2008).   
Our experimental model of concussion has shown elevated levels of pro-
inflammatory cytokines peaking between three and nine hours post-injury (Bachstetter, 
Rowe et al. 2013; Rowe, Striz et al. 2014). In the current study, we measured a panel of 
inflammation related interleukins at 6 and 24 hours post-injury to investigate the presence 
or absence of inflammation following injury and at the time behavioral testing was 
completed. Interestingly, the pattern of cytokine levels over time reflected their 
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functionality and immune properties. Immune mediators that are secreted following brain 
injury can be divided into subgroups: archetypal pro-inflammatory cytokines (IL-1, TNF, 
IL-6), anti-inflammatory cytokines (IL-2, IL-4, IL-10, transforming growth factor-beta), 
and the chemotactic cytokines or chemokines (Banchereau, Pascual et al. 2012; 
Woodcock and Morganti-Kossmann 2013). Our data showed, regardless of 
pharmacological treatment, pro-inflammatory cytokines were increased in the cortex at 6 
hours but not 24 hours post-injury. In contrast, we found anti-inflammatory cytokines 
were increased in the cortex at 24 hours post-injury compared to 6 hours post-injury. Our 
experimental model of injury has shown injury-induced elevations in cortical chemokines 
with a similar timecourse as the pro-inflammatory cytokines measured in this study, 
reaching significant increases at 6 hours post-injury (Bachstetter, Rowe et al. 2013). 
While chemokines were not measured in the current study, based on previously reported 
data, we predict similar elevations occurred. 
IL-1α and IL-1β are key mediators of the inflammatory response both peripherally 
and centrally (Woodcock and Morganti-Kossmann 2013). The IL-1 family of cytokines 
are regulators of inflammation in relation to acute TBI (Woodcock and Morganti-
Kossmann 2013) and  previous temporal associations of injury-induced cytokine levels in 
our injury model have shown increased IL-1β peaking between 3 and 9 hours post-injury 
(Bachstetter, Rowe et al. 2013; Rowe, Striz et al. 2014). In this study, there were 
increases in production of IL-1 but the injury effect did not reach significance. By 24 
hours post-injury, the IL-1 cytokines had become undetectable supporting the role of IL-1 
in acute inflammation following TBI. IL-6 and TNF-α are also associated with the acute 
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immune response following TBI. Our study measured cytokines identified as key 
regulators of the acute phase response including , IL-6, and TNFα (Gabay and Kushner 
1999). We found both IL-6 and TNF-α were significantly increased in brain-injured 
cortex compared to uninjured sham at 6 hours supporting their role as key regulators of 
the acute phase response. When measured at 24 hours post-injury there was a time 
dependent reduction in pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-12, IFNγ) 
suggesting that acute inflammation following experimental diffuse brain injury has 
resolved, which may or may not emerge at later time points. 
In contrast, we found a time dependent increase in anti-inflammatory cytokines 
(IL-2, IL-4, and IL-10) at 24 hours post-injury compared to 6 hours post-injury. IL-10 has 
been shown to have inhibitory effects on the production of pro-inflammatory cytokines 
(IL-1, IL-6, TNF-α) which supports different patterns of anti-inflammatory versus pro-
inflammatory cytokines after diffuse brain injury. IL-10 is significantly increased at 24 
hours post-injury which could have inhibitory effects on the pro-inflammatory cytokines, 
which further validates IL-10 inhibition of IL-1β and TNF to dampen the inflammatory 
response (Woodcock and Morganti-Kossmann 2013). Overall, there were both injury-
induced and time dependent changes in cortical cytokine levels at both 6 and 24 hours 
post-injury, however there were no alterations dependent upon pharmacological 
intervention.  
Regardless of treatment there were no significant reductions in cytokine levels 
following the administration of OTC analgesics with varying anti-inflammatory 
properties. Overall, immediate pharmacological intervention following brain injury did 
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not adversely impact functional outcome as indicated by performance on the rotarod and 
NSS task. Further investigation is needed to determine if multiple doses of over-the-
counter analgesics attenuate injury-induced deficits. It is possible that chronic treatment 
may impact the course of recovery following TBI. Ibuprofen administered chronically 
over a four month period to rats subjected to FPI led to a decline in cognitive function, as 
measured by the Morris water maze (Browne, Iwata et al. 2006). Future studies should 
extend the functional evaluation beyond 24 hours post-injury. It is possible that the single 
dose given in this study may have improved or worsened functional outcome at later 
post-injury time points. 
2.6 CONCLUSIONS 
 
In the diffuse brain-injured mouse, immediate pharmacological intervention did 
not attenuate or exacerbate TBI-induced functional deficits. Pro-inflammatory cortical 
cytokine levels were elevated at 6 hours post-injury and anti-inflammatory cytokines 
were elevated at 24 hours post-injury. We conclude that while a single dose of OTC 
analgesics does not significantly inhibit the immediate injury-induced inflammation, it 
does not adversely affect functional outcome. Further investigation is needed to examine 
time of drug treatment and multiple dosing. 
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CHAPTER 3 
3 DIETARY DOCOSAHEXAENOIC ACID (DHA) ALLEVIATES LONG-TERM 
SENSORY HYPERSENSITIVITY AND INFLAMMATION INDUCED BY 
EXPERIMENTAL DIFFUSE BRAIN INJURY IN RATS 
Published in Current Research: Concussion (In Press) 
3.1 ABSTRACT 
 
Docosahexaenoic acid (DHA) is an omega-3 fatty acid that has importance for 
brain development and function. In the current study, we investigated the effect of dietary 
supplementation with DHA either before or after experimental brain injury. After 28 days 
on predetermined diets, rats were subjected to moderate midline fluid percussion injury 
or sham surgery and the effects of DHA-enriched diets and traumatic brain injury (TBI) 
on spatial learning, sensory hypersensitivity, neuroinflammation and fatty acid profiles 
were evaluated. The results provide novel evidence that sufficient dietary intake of DHA, 
fed either before or after TBI, decreased injury-induced sensory sensitivity and that post-
injury DHA supplementation most effectively attenuated injury-induced 
neuroinflammation. This divergence suggests that the pre-injury protective mechanisms 
of DHA may differ from post-injury mechanisms. Overall, the results indicate sufficient 
DHA intake may be an effective nutritional approach to minimizing pathology and 
maximizing recovery after TBI. 
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3.2 INTRODUCTION 
 
In the United States alone, over 1.7 million people per year sustain traumatic 
brain injuries (TBI) (Faul, Xu et al. 2010), which may grossly underestimate the true 
incidence due to underreporting, particularly of diffuse TBI. The long term symptoms of 
TBI can include impaired cognitive or emotional ability (Arciniegas, Topkoff et al. 2000; 
Albensi and Janigro 2003; Masel and DeWitt 2010), sensory sensitivity or dysfunction 
(Goodrich, Flyg et al. 2013; Goodrich, Martinsen et al. 2014), and loss of neurological 
function (Arciniegas, Topkoff et al. 2000). TBI is induced by mechanical forces which 
initiate a protracted cascade of secondary injury processes, including inflammation and 
oxidative stress (Werner and Engelhard 2007). To date, many pharmacological therapies 
have been selected to target specific cellular and molecular cascades which contribute to 
secondary injury in the hours to days following TBI. In attenuating secondary signaling, 
the approach is to alleviate long term symptoms of TBI. 
The shortcomings of recent clinical trials for TBI therapeutics (Margulies and 
Hicks 2009) suggest that a drug that targets a single secondary injury process may not be 
sufficient to alleviate the multifaceted pathophysiology of TBI. Pleiotropic agents that 
target multiple components of the secondary injury cascade may prove more effective. 
One potential such approach, investigated in the current study, may be the maintenance 
of sufficient levels of docosahexaenoic acid (DHA). DHA is the most concentrated 
omega-3 polyunsaturated fatty acid (PUFA) in the nervous system, and dietary sources of 
this nutrient include mothers‘ milk, cold water fish, marine algae, and supplements 
containing DHA. Randomized, controlled trials in humans indicate that DHA has an 
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excellent safety profile (Hughbanks-Wheaton, Birch et al. 2014) and that elevation of its 
tissue concentration throughout the body allows for better cognitive function in healthy, 
aging populations (Yurko-Mauro, McCarthy et al. 2010; Salem, Vandal et al. 2014) and 
improved neurodevelopment (Mulder, King et al. 2014). The positive findings in these 
clinical trials are likely due to the multiple actions of DHA, which include regulation of 
apoptotic signaling (Sinha, Khare et al. 2009), decreased inflammatory signaling (Chang, 
Kuan et al. 2013) and reduced oxidative stress (Chaung, Chang et al. 2013). 
 While DHA administration has already shown favorable effects in animal models 
of TBI (Bailes and Mills 2010; Wu, Ying et al. 2011; Wu, Ying et al. 2013; Begum, Yan 
et al. 2014), the present study was designed with the novel goal of assessing DHA 
administration before and after diffuse TBI within the same study using a defined DHA-
enriched diet, rather than direct administration of DHA-containing oil. Dietary 
administrations of DHA before or after TBI represent two equally valid scenarios of 
prophylaxis and therapy, respectively, which may differ in efficacy and mechanism. 
Behavioral outcome measures were chosen to model the clinical conditions of cognitive 
impairment and sensory sensitivity. We evaluated each administration schedule by testing 
post-injury learning with the Morris water maze (MWM), sensory hypersensitivity with 
the whisker nuisance task (WNT), and neuroinflammation with [
3
H]PK11195 binding 
density—a ligand of the translocator protein (TSPO). TSPO has previously been shown 
to predominantly label activated microglia and exhibited regional co-localization with 
microglial activation following CNS injury, along with some macrophages and to a lesser 
extent astrocytes (Weissman and Raveh 2003; Cao, Thomas et al. 2012). To further 
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understand the effect of DHA supplementation and TBI on central and peripheral fatty 
acid profiles, fatty acid analysis was conducted on brain, plasma, and red blood cells. We 
hypothesized that both pre- and post-injury DHA supplementation would increase brain 
DHA content, improve functional outcome from TBI and reduce post-traumatic 
neuroinflammation. 
3.3 METHODS 
 
3.3.1 Animals 
Adult male Sprague-Dawley rats were obtained from Harlan, Inc. (Indianapolis, 
IN), housed in pairs on a 12h:12h light schedule with ad libitum access to rat chow and 
water. The ordering, receipt and dietary supplementation of the animals were timed to 
accommodate the study design calling for 28 days of supplementation and a standard 
injury weight of 350 grams. All animals were between 84-96 days of age at the time of 
injury.  All animal procedures were approved by the University of Kentucky Institutional 
Animal Care and Use Committee. 
3.3.2 Diets 
The animal diets were designed to provide either 0% (control) or ~1 wt% DHA, 
expressed as a percentage of the total fatty acids. The diets were based on the AIN-93G 
standard, but their fat contents consisted of controlled blends of coconut oil, high-oleic 
safflower oil, TBHQ-free soy oil (Dyets, Inc.), and DHASCO
®
 oil (DSM Nutritional 
Products).  The oils were analyzed as fatty acid methyl esters (FAME) prior to diet 
formulation by Dyets, Inc., and the diets were similarly analyzed prior to their use in the 
study.  Thus, the oil blends allowed for a balancing of all fatty acids between diets except  
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Figure 3.1. Experimental Design 
All rats received a base diet containing No DHA (gray) or an equivalent diet containing 
DHA as ~1% of the total fatty acids (green). One group received a base diet for the entire 
study. The second group was given a DHA diet for 28 days prior to surgery/injury, 
followed by a base diet. The third group was given a base diet prior to surgery/injury 
followed by a post-injury treatment of the DHA diet for 23-24 days post-injury. Each 
experimental arm included both traumatic brain injury (TBI) and uninjured control 
(Sham) animals. For analysis of Morris Water Maze (MWM), Whisker Nuisance Task 
(WNT), and fatty acid profiles, a combined sham group was formed from random 
selection among diet groups. Following injury, rats were evaluated for spatial learning in 
the MWM task (15-18 days post-injury; dpi). Sensory sensitivity was assessed using the 
WNT at 22 days post-injury. Following behavior tasks, tissue was collected for 
autoradiography and lipid profiling (23-24 dpi). 
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Table 3.1. Diet Compositions 
Ingredient 
No 
DHA 
Diet 
DHA Diet 
Casein 20.00 20.00 
L-cystine 0.30 0.30 
Sucrose 10.00 10.00 
Cornstarch 39.75 39.75 
Dyetrose
a
 13.20 13.20 
Cellulose 5.00 5.00 
Mineral Mix 210025
b
 3.50 3.50 
Vitamin Mix 310025
c
 1.00 1.00 
Choline 0.25 0.25 
Fat 
Composition:  
7.00 7.00 
 
Coconut Oil 2.34 2.30 
 
Safflower Oil 3.82 3.68 
 
Soybean Oil
d
 0.84 0.84 
 
DHASCO Oil
e
 0.00 0.18 
 
Fatty Acid Composition: 
(wt% Total Fatty 
Acids) 
 
Sat 41.06 41.14 
 
Mono 41.71 41.14 
 
18:2n6 15.88 15.45 
 
18:3n3 1.29 1.28 
 20:4n6 0.02 0.01 
 22:6n3 0.00 0.92 
 
PUFA 17.30 17.78 
 
n3 1.37 2.29 
 
n6 15.92 15.49 
 
n6:n3 11.59 6.76 
a
Carbohydrate composition (%): monosaccharides, 1; 
disaccharides, 4; trisaccharides, 5; tetrasaccharides and higher, 
90. 
b
AIN-93G mineral mix (mg/100g diet): calcium, 500; phosphorus, 
156.1; potassium, 360; sodium, 101.9; chloride, 157.1; sulphur, 30; 
magnesium, 50.7; iron, 3.5; copper, 0.6; manganese, 1; chromium, 
0.1; iodine, 0.02; selenium, 0.02; fluoride, 0.1; boron, 0.05; 
molybdenum, 0.02; silicon, 0.5; nickel, 0.05; lithium, 0.01; 
vanadium, 0.01 
c
AIN-93VX vitamin mix (units/100g diet): thiamin, 0.6 mg; 
riboflavin, 0.6 mg; pyridoxine, 0.7 mg; niacin, 3 mg; pantothenate, 
1.6 mg; folate, 0.2 mg; biotin, 0.02 mg; cyanocobalamin, 2.5 mg; 
vitamin A, 400 IU; Vitamin E, 7.5 IU; Vitamin D3, 100 IU; Vitamin 
K1, 0.08 mg. 
d
TBHQ-free 
e
Provided by DSM Nutritional Products 
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for DHA content and total omega-3 content (see Table 1 for details). The diets were fed 
for 28 days prior to sham or brain injury.  Directly after injury or sham surgeries, the 
animals were either maintained on a DHA-deficient diet (controls), switched to DHA-
deficient diets (pre-injury DHA), or switched to DHA-sufficient diets (post-injury DHA; 
see Figure 1). The animals were randomized to the diets, and the researchers were 
blinded from the treatments throughout all experimental procedures. 
3.3.3 Midline Fluid Percussion Injury 
A total of 100 rats were subjected to midline fluid percussion injury (mFPI) 
consistent with methods previously described (Lifshitz 2007; Lifshitz 2008; McNamara, 
Lisembee et al. 2010; Cao, Thomas et al. 2012; Ziebell, Taylor et al. 2012). Rats were 
anesthetized using 5% isoflurane in 100% oxygen for five min and the head of the rat was 
placed in a stereotaxic frame with continuously delivered isoflurane at 2.5% via 
nosecone. While anesthetized, body temperature was maintained using a Deltaphase
®
 
isothermal heating pad (Braintree Scientific Inc., Braintree, MA). A midline incision was 
made exposing bregma and lambda, and fascia was removed from the surface of the 
skull. A trephine (4.8 mm outer diameter) was used for the craniotomy, centered on the 
sagittal suture between bregma and lambda without disruption of the dura. An injury cap 
prepared from the female portion of a Luer-Loc needle hub was fixed over the 
craniotomy using cyanoacrylate gel and methyl-methacrylate (Hygenic Corp., Akron, 
OH). The incision was sutured at the anterior and posterior edges and topical Lidocaine 
ointment was applied. Rats were placed in a heated recovery cage and monitored until 
ambulatory. 
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For injury induction, rats were re-anesthetized (60-90 min after surgery) with 5% 
isoflurane delivered for five min. The dura was visually inspected through the hub to 
make sure it was intact with no debris. The hub was then filled with normal saline and 
attached to the male end of the fluid percussion device (Custom Design and Fabrication, 
Virginia Commonwealth University, Richmond, VA). An injury of moderate severity for 
our injury model (2.0 atm) was administered by releasing the pendulum onto the fluid-
filled cylinder. Sham-injured rats underwent the same procedure except the pendulum 
was not released. Rats were monitored for the presence of a forearm fencing response and 
righting reflex times were recorded for the injured rats as indicators of injury severity 
(Hosseini and Lifshitz 2009). The injury hub was removed and the brain was inspected 
for uniform herniation and integrity of the dura through the craniotomy. The incision was 
cleaned using saline and closed using sutures. Moderate brain-injured rats had righting 
reflex recovery times greater than five min and a positive fencing response; injury 
severities were comparable between brain-injured diet groups. Sham-injured rats 
recovered a righting reflex within 20 sec. After spontaneously righting, rats were placed 
in a heated recovery cage and monitored until ambulatory (approximately 5 to 15 min) 
before being returned to their cage. Adequate measures were taken to minimize pain or 
discomfort. Mortality was not encountered as a result of surgery or TBI. 
3.3.4 Morris Water Maze (MWM) 
Spatial learning ability was assessed in 100 rats  using a MWM testing paradigm 
similar to those used in other experimental models of TBI (Smith, Soares et al. 1995; 
Murai, Pierce et al. 1998; Smith, Nakamura et al. 1998; Prins and Hovda 2001; Guseva, 
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Hopkins et al. 2008; Pleasant, Carlson et al. 2011; Rowe, Harrison et al. 2014). Briefly, 
animals were tested in a 127 cm diameter × 56 cm tall circular pool with a 13.5 cm 
diameter circular platform submerged 1 cm below the waterline. Black, non-toxic 
powdered paint was added to obscure the platform. The lighting of the room and various 
spatial cues were constant throughout the acquisition period. At selected time points post-
injury (15, 16, 17, 18 days), rats were tested in sets of four trials per day. Rats started 
from one of four starting points (North, South, East, West). If the animal did not find the 
platform in 60 sec, it was placed there by the handler and allowed to rest for 15 sec. The 
animals were allowed a 5 min rest between each trial. During all phases of the MWM, the 
animals' performance was recorded and analyzed with Accuscan Instruments EzVideoDV 
Automated Tracking System (Columbus, OH) that allowed quantification of escape 
latency and swim speed for the tests. Data are presented as average daily latency to find 
the hidden platform in seconds and average swim speed (cm/sec) for all trials. 
3.3.5 Whisker Nuisance Task (WNT) 
Protocols were conducted as described previously to evaluate sensory sensitivity 
(McNamara, Lisembee et al. 2010; Learoyd and Lifshitz 2012). A darkened plastic test 
cage (16.5 × 38.1 × 55.9 cm) lined with an absorbent pad was used. Rats were acclimated 
to the test cage for 5 min prior to testing. Testing involved manually stimulating the 
whiskers of both mystacial pads with a wooden applicator stick for three periods of 5 min 
with periods (≤1 min) of non-stimulation between periods. Animals were tested 
individually and the absorbent pad and wooden applicator stick were replaced for each 
animal after cleaning the test cage. For each five min period, observations were made 
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regarding the predominant observed behavior. These observations were recorded as 
discontinuous, categorical data for (1) movement, (2) stance and body position, (3) 
breathing quality, (4) whisker position, (5) whisking response, (6) evading stimulation, 
(7) response to stick presentation, and (8) grooming response. Normal behavior for each 
category consisted of those typically seen in uninjured animals during stimulation and 
was recorded as a score of zero. For example, an animal that was relaxed and looking 
upward during stimulation was given a score of 0 for stance and body position. 
Meaningful abnormal behaviors expressed in response to whisker stimulation were 
assigned scores of 1–2, depending on degree of expression. For example, an animal that 
cowered and showed a guarded position was given a score of 2 for stance and body 
position. The maximum whisker nuisance score was 16 (two points for each of eight 
categories), where each two point increase indicated the meaningful expression of 1-2 
behaviors. Higher scores indicate abnormal responses to the stimulation overall, in which 
the rat freezes, becomes agitated or is aggressive. Lower scores indicate normal 
responses, in which the rat is either soothed or indifferent to the stimulation. A five min 
period of non-stimulation was scored immediately following the final stimulatory trial as 
a control for spontaneously occurring behaviors (McNamara, Lisembee et al. 2010; 
Learoyd and Lifshitz 2012). 
3.3.6 Tissue Extraction 
Following rapid decapitation on day 23 or 24 post-TBI approximately 3 ml of whole, 
trunk blood was collected from all animals. Each whole blood sample was split equally 
and centrifuged at 100g for 15 min at 4ºC.  Plasma was transferred to a fresh tube. Prior 
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to closure, the tube‘s headspace was purged with nitrogen gas. The remaining red blood 
cell pellet was resuspended in 2 volumes of isotonic saline solution and centrifuged 
again. The supernatant was removed, and the pellet was resuspended again in 2 volumes 
of isotonic saline. The pelleted red blood cells and the isotonic saline supernatant were 
then stored together at -80ºC. After blood collection, the brain was extracted and flash 
frozen in isopentane chilled on dry ice. Brains were then stored at -80ºC until use. 
3.3.7 [
3
H]PK11195 autoradiography 
Radioligand binding was carried out using protocols previously described (Cao, Thomas 
et al. 2012; van Bregt, Thomas et al. 2012). Briefly, rats were euthanized by decapitation 
and brains were removed and flash frozen in an isopentane-dry ice slurry. Brains were 
cryosectioned at 16 µm. Translocator protein 18 kDa (TSPO) receptor densities were 
measured using [
3
H]PK-11195 autoradiography, as previously described (Little, 
McLaughlin et al. 1998; van Bregt, Thomas et al. 2012). A ligand concentration of 1 nM 
([
3
H]PK-11195 specific activity 85.5 Ci/mmol; Perkin-Elmer Life Sciences, Boston, MA, 
USA) was used for incubation. RayMax Beta High Performance Autoradiography Film 
was used to visualize ligand binding. All films were processed using Kodak GBX 
developer. Binding data were analyzed using NIH image v1.59 with a Sony XC-77 CCD 
camera via a Scion LG-3 frame-grabber. Areas of interest were outlined manually to 
include cortex (18-24 sections per rat), hippocampus (18-24 sections per rat), thalamus 
(9-13 sections per rat), and substantia nigra (6 sections per rat). For each brain region, 
sham rat sections were measured to acquire a background intensity level. A threshold 
intensity value was set at the highest gray scale value measured for any sham operated 
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rat. Regions of interest were drawn by their anatomical boundaries (Paxinos and Watson 
2007) and the percentage of pixels over threshold was calculated for each region. 
3.3.8 Fatty Acid Profiling 
All brain, plasma and red blood cell samples were freeze-dried prior to homogenization 
and Folch extraction (Folch, Lees et al. 1957). Lipids from red blood cell samples were 
extracted using the methods of Bligh and Dyer (Bligh and Dyer 1959). Briefly, 
tricosanoic free fatty acid was added to each sample as an internal standard. Butylated 
hydroxytoluene was added to all samples before saponification with 0.5 N methanolic 
NaOH, and all samples were purged with N2 throughout the process to minimize 
oxidation. Fatty acids were converted to methyl esters with 14% BF3/methanol at 100ºC 
for 30 min (Morrison and Smith 1964). Fatty acid methyl esters were analyzed by GLC 
using a Hewlett Packard 6890 equipped with a flame ionization detector. The fatty acid 
methyl esters were separated on a 30-meter FAMEWAX capillary column (Restek; 0.25 
mm diameter, 0.25 µm coating thickness) using hydrogen at a flow rate of 40 mL/min 
with a split ratio of 48:1. Chromatographic run parameters included an oven starting 
temperature of 130ºC that was increased at 6ºC/min to 225ºC, where it was held for 20 
min before increasing to 250ºC at 15ºC/min, with a final hold of 5 min. The injector and 
detector temperatures were constant at 220ºC and 230ºC, respectively. Peaks were 
identified by comparison of retention times with external fatty acid methyl ester standard 
mixtures from NuCheck Prep. The fatty acid profiles were expressed as weight percent of 
the total fatty acids in each sample. 
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3.3.9 Statistical Analysis 
Data are shown as mean ± SEM and analyzed using statistical software (GraphPad-Prism 
6). Differences in escape latencies for the MWM were analyzed using a repeated measure 
two-way ANOVA across injury group and testing day. Differences in overall swim speed 
for the MWM between groups were analyzed using a one-way ANOVA. Non-parametric 
whisker nuisance task data were analyzed using a Kruskal-Wallis test with a Dunn‘s 
multiple comparison test since the data obtained from the WNT were not continuous. 
Differences in autoradiography data were analyzed by one-way ANOVA with a Tukey‘s 
post-hoc comparison. Fatty acid profiles were compared using a two-way ANOVA 
between brain injury and diet groups with a Tukey‘s post-hoc comparison. Statistical 
significance was assigned when p<0.05. Initial group sizes were determined for each 
outcome measure by power analysis (GPower; Dusseldorf University) and final group 
sizes are indicated in the figure legends. 
3.4 RESULTS 
 
It was not anticipated that dietary supplementation with DHA would change functional 
outcome or inflammation in uninjured sham rats. Statistical analyses confirmed no 
significant differences in Morris water maze performance (F(3,34)=1.2, p=0.3) or 
whisker nuisance task scores (KW(3,34)=4.7, p=0.1) between any sham groups. There 
were no statistical differences in ligand binding density between sham groups (Cortex, 
F(2,19)=0.9673, p=0.4). Uninjured shams treated with No DHA supplementation, pre-
DHA supplementation, and post-DHA supplementation were combined into a single 
sham control group with a group size comparable to injured groups. Sham animals were 
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selected using a random number generator (Microsoft Excel). In contrast to the above, it 
was anticipated that DHA administration would affect DHA tissue content regardless of 
injury status.  Therefore, sham animals were not combined for lipid profiling analyses 
that investigated the potential effect of brain injury on the fatty acid profiles. 
3.4.1 Spatial Learning 
To test spatial learning following TBI, 12-14 rats per experimental arm were tested in the 
MWM for four consecutive days starting at day 15 post-injury. Latency to find the 
submerged platform was measured to assess learning and swim speed was evaluated as a 
control for gross motor dysfunction. A two-way ANOVA indicated all groups had a 
significant time-dependent improvement in latency to find the hidden platform 
(F(3,147)=62.35, p<0.0001; Figure 2A). There was no significant treatment effect on 
performance measured by latency to find the platform at the selected post-injury time 
points (F(3,49)=0.9860, p=0.4071; Figure 2A). A probe trial for recall was not pursued as 
all groups improved over time. Further analysis indicated no significant difference in 
average swim speed across groups (F(3,49)=0.4616, p=0.6553; Figure 2B).  
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Figure 3.2. Spatial learning in the Morris Water Maze was not affected by brain 
injury or dietary administration of DHA. 
(A) A repeated measure two-way ANOVA showed a significant time-dependent 
improvement in latency to the platform, indicating that animals in all groups learned the 
task. There was no significant treatment effect. (B) A one-way ANOVA showed no 
significant treatment effect on average swim speed. Data presented as mean ± SEM 
(Non-matching letters indicate Tukey‘s post-hoc specific effects p<0.05; combined sham 
n=14, TBI No DHA n=14, TBI DHA-Pre n=13, TBI DHA-Post n=12). 
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3.4.2 Sensory Sensitivity 
We have previously reported increased sensory sensitivity in rats following 
diffuse TBI, as a late-onset injury-induced morbidity using the whisker nuisance task 
(McNamara, Lisembee et al. 2010). All animals that underwent MWM testing were also 
subjected to the WNT (N=12-14 per experimental arm).  A Kruskal-Wallis test indicated 
an overall significant effect on sensory sensitivity (KW(4,53)=16.02, p=0.0011; Figure 
3A). Further analysis using Dunn‘s multiple comparison test indicated brain-injured rats 
receiving No DHA dietary supplementation had significantly higher whisker nuisance 
task scores compared to the uninjured sham control group. However, brain-injured rats 
receiving DHA-supplemented diets either before or after injury were not significantly 
different from uninjured shams. There was no significant difference in sensory sensitivity 
when animals were scored on the WNT with no whisker stimulation (KW(4,53)=4.38, 
p=0.2232; Figure 3B).  
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Figure 3.3. Injury-induced increase in sensory sensitivity observed during the 
Whisker Nuisance Task was mitigated by dietary administration of DHA. 
(A) Sensory sensitivity assessed by the whisker nuisance task (WNT) at 22 days post-
injury was significantly increased compared to uninjured sham without dietary 
supplementation. There was no difference in sensory sensitivity in brain-injured rats 
receiving dietary DHA supplementation compared to the combined uninjured sham 
group. (B) There was no significant difference in sensory sensitivity between groups 
when animals were scored on the WNT after cessation of whisker stimulation. Data 
presented as mean ± SEM (Non-matching letters indicate Dunn‘s post-hoc specific 
effects p<0.05; combined sham n=14, TBI No DHA n=14, TBI DHA-Pre n=13, TBI 
DHA-Post n=12). 
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3.4.3 Inflammation 
The effect of DHA on brain injury-induced inflammation has not been previously 
evaluated after mFPI. Here, [H
3
]PK11195 was used to label activated glia as an index of 
neuroinflammation at 23-24 days post-injury.  Approximately 75% of the available brain 
tissue was used for this analysis (N=8-9 for each experimental group).  Uninjured sham 
rats displayed minimal glial activation, with [H
3
]PK11195 binding limited to areas 
normally without an intact blood-brain barrier (Figure 4A), while all brain-injured groups 
indicated at least some regions of increased microglial activation (Figure 4B-D). Binding 
density quantification was conducted in four regions of interest: cortex, hippocampus, 
thalamus and substantia nigra (Figure 4E-H). A one-way ANOVA indicated an overall 
main treatment effect in the cortex (F(3,33)=13.40, p<0.0001; Figure 4E) and 
hippocampus (F(3,33)=13.93, p<0.0001; Figure 4F). Tukey‘s multiple comparison test 
indicated brain-injured rats treated with No DHA or DHA-Pre had significantly greater 
binding density in the cortex and hippocampus compared to uninjured sham rats. DHA-
Post treated rats showed binding density in the cortex and hippocampus equivalent to 
sham rats and significantly lower than both other injured groups. A one-way ANOVA 
indicated an overall main treatment effect in the thalamus (F(3,33)=4.157, p=0.0133; 
Figure 4G) and the substantia nigra (F(3,33)=7.147), p=0.0008; Figure 4H). Tukey‘s 
multiple comparison test indicated brain-injured rats treated with No DHA had 
significantly higher binding density in the hippocampus and substantia nigra compared to 
uninjured sham rats. In the substantia nigra, the binding density of brain-injured rats 
treated with No DHA was also significantly higher compared to brain-injured rats treated 
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with DHA-Post. Overall, TBI resulted in increased [H
3
]PK11195 binding density, 
indicative of microglial activation. 
Following the behavioral studies and autoradiography, the remaining brains from 
each group (N=5-6) were used for lipid profile analysis by GC/FID. A two-way ANOVA 
indicated diffuse brain injury significantly reduced DHA fatty acid levels in brain 
(F(1,27)=4.860, p=0.0362; Figure 5A) but not plasma (F(1, 19)=0.7678, p=0.3918; 
Figure 5C) or red blood cells (F(1,19)=0.1805, p=0.6757; Figure 5E). A two-way 
ANOVA indicated a significant overall effect of diet in the brain (F(2,27)=6.073, 
p=0.0066; Figure 5A). Tukey‘s multiple comparison test indicated significantly increased 
brain levels of DHA fatty acid in rats receiving DHA supplementation (pre or post) 
compared to rats receiving No DHA. Similarly, diet exerted a significant effect in the 
plasma (F(2,19)=62.80, p<0.0001; Figure 5C). Tukey‘s multiple comparison test 
indicated significantly increased DHA fatty acid levels in the plasma of rats receiving 
Pre-DHA compared to rats receiving No DHA, and significantly increased levels in the 
rats receiving Post-DHA compared to rats receiving Pre-DHA or No DHA. Lastly, a two-
way ANOVA indicated a significant dietary effect in red blood cells (F(2,19)=8.928, 
p=0.0018; Figure 5E). Tukey‘s multiple comparison test indicated significantly increased 
DHA fatty acid levels in the brain of rats receiving Post-DHA supplementation compared 
to rats receiving Pre-DHA or No DHA. To distinguish between DHA and EPA mediated 
effects, comparisons of EPA levels were made. Post-DHA increased levels of EPA in the  
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Figure 3.4. Dietary DHA reduced microglial activation following diffuse brain 
injury. 
[H
3
]PK11195 autoradiography was used to label activated microglia 23-24 days post-
injury. (A-D) Representative coronal sections from each treatment group are labeled by 
[H
3
]PK11195 ligand-binding, with binding densities ranging from maximal to minimal 
indicated by colors red, yellow, green, blue. Uninjured sham rats displayed minimal 
microglial activation, with [H
3
]PK11195 binding limited to areas normally without an 
intact blood-brain barrier, while all brain-injured groups indicated focal regions of 
increased microglial activation. Binding density quantification was conducted in four 
regions of interest. (E) In the cortex, brain-injured rats treated with No DHA or DHA-Pre 
had significantly higher binding densities than sham rats. Binging density in DHA-Post 
treated rats were equivalent to sham rats and significantly lower than both other injured 
groups. (F) The same pattern of activation among groups was observed in the 
hippocampus. (G) In the thalamus, No DHA treated rats had significantly higher binding 
density than sham rats. (H) In the substantia nigra, No DHA treated rats had significantly 
higher binding density than sham and DHA-Post treated rats. Overall, TBI resulted in 
increased [H
3
]PK11195 binding density, indicative of greater microglial activation. DHA 
administration before or after TBI reduced microglial activation, but this effect was most 
evident in DHA-Post treated rats (Non-matching letters indicate Tukey‘s post-hoc 
specific effects p<0.05; combined sham n=12, TBI No DHA n=8, TBI DHA-Pre n=9, 
TBI DHA-Post n=8). DHA administration before or after TBI reduced microglial 
activation, but this effect was most evident among DHA-post treated rats. 
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Figure 3.5. Dietary DHA supplementation and diffuse TBI altered brain levels of 
DHA but not EPA. 
Diffuse brain injury significantly reduced DHA fatty acid levels (main effect of TBI) in 
the brain (A), but not in plasma (C) or red blood cells (E; RBC). DHA supplementation 
significantly increased the level of DHA fatty acids (main effect of diet) in the brain, 
plasma, and red blood cells. DHA dietary supplementation increased EPA levels in 
plasma (D) and RBC (F), but not the brain (B). Data presented as mean percentage DHA 
of total fatty acids ± SEM (Non-matching letters indicate Tukey‘s post-hoc specific 
effects p<0.05; Brain: sham n=5 per treatment, TBI n=6 per treatment; Plasma and RBC: 
sham n=3 per treatment, TBI n=4-6 per treatment). 
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plasma (Figure 5D; F(2,19)=16.63, p<0.0001) and red blood cells (Figure 5F; 
F(2,19)=6.785, p=0.006), but did not affect brain levels of EPA (Figure 5B; 
F(2,26)=0.2810, p=0.281). 
In addition to TBI-induced decreases in DHA, fatty acid profiling indicated a significant 
injury-induced increase in brain arachidonic acid (20:4ω6), a precursor of pro-
inflammatory prostaglandins (Table 2). Overall, two-way ANOVAs indicated dietary 
DHA supplementation resulted in significantly altered fatty acid profiles in brain, plasma 
and red blood cells. See Table 3.2 for full statistical results. 
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Table 3.2. Dietary DHA and TBI affected levels fatty acids in brain, plasma, and red 
blood cells. 
Brain 
No DHA 
Sham 
No DHA  
TBI 
DHA-Pre 
Sham 
DHA-Pre 
TBI 
DHA-
Post 
Sham 
DHA-Post  
TBI 
Effect F p 
18:2 
0.57 ± 
0.02 
0.57 ± 
0.02 
0.62 ± 
0.01 
0.63 ± 
0.03 
0.64 ± 
0.02 
0.63 ± 0.02 Diet 
F(2,27)= 
5.481 
0.0100 
20:4ω6 
11.04 ± 
0.07 
11.25 ± 
0.07 
10.90 ± 
0.10 
11.09 ± 
0.07 
11.02 ± 
0.12 
11.00 ± 0.09 Injury 
F(2,27)= 
2.584 
0.0386 
22:0 
0.32 ± 
0.01 
0.32 ± 
0.01 
0.28 ± 
0.02 
0.28 ± 
0.01 
0.30 ± 
0.01 
0.31 ± 0.01 Diet 
F(2,27)= 
4.159 
0.0266 
22:2 
0.03 ± 
0.00 
0.03 ± 
0.00 
0.03 ± 
0.00 
0.02 ± 
0.00 
0.03 ± 
0.00 
0.02 ± 0.01 Diet 
F(2,27)= 
16.02 
<0.000
1 
22:6ω3 
(DHA) 
13.81 ± 
0.09 
13.66 ± 
0.17 
14.06 ± 
0.13 
14.15 ± 
0.08 
14.23 ± 
0.09 
13.95 ± 0.12 
Diet 
Injury 
F(2,27)= 
6.073 
F(1,27)= 
4.860 
0.0066 
0.0362 
24:0 
0.38 ± 
0.02 
0.41 ± 
0.02 
0.33 ± 
0.02 
0.34 ± 
0.01 
0.38 ± 
0.02 
0.39 ± 0.01 Diet 
F(2,27)= 
6.770 
0.0041 
24:1 
0.44 ± 
0.04 
0.49 ± 
0.02 
0.37 ± 
0.05 
0.40 ± 
0.02 
0.48 ± 
0.04 
0.43 ± 0.04 Diet 
F(2,27)= 
4.642 
0.0185 
Plasm
a 
No DHA 
Sham 
No DHA  
TBI 
DHA-Pre 
Sham 
DHA-Pre 
TBI 
DHA-
Post 
Sham 
DHA-Post  
TBI 
Effect F p 
16:1 
3.45 ± 
0.35 
3.68 ± 
0.24 
2.80 ± 
0.51 
2.62 ± 
0.46 
2.80 ± 
0.53 
3.54 ± 0.33 Injury 
F(1,19)= 
5.541 
0.0295 
18:0 
7.42 ± 
0.30 
6.97 ± 
0.21 
8.29 ± 
0.33 
8.24 ± 
0.32 
8.01 ± 
0.37 
7.49 ± 0.28 
Intera
ction 
F(2,19)= 
7.470 
0.0040 
22:6ω3 
(DHA) 
2.05 ± 
0.10 
1.88 ± 
0.07 
2.71 ± 
0.54 
2.53 ± 
0.53 
2.00 ± 
0.15 
1.99 ± 0.15 Diet 
F(2,19)= 
62.80 
<0.000
1 
RBC 
No DHA 
Sham 
No DHA  
TBI 
DHA-Pre 
Sham 
DHA-Pre 
TBI 
DHA-
Post 
Sham 
DHA-Post  
TBI 
Effect F p 
16:1 
1.08 ± 
0.14 
1.06 ± 
0.24 
1.50 ± 
0.21 
1.34 ± 
0.02 
0.85 ± 
0.00 
1.03 ± 0.12 Diet 
F(2,19)= 
5.675 
0.0117 
18:0 
11.14 ± 
0.46 
11.88 ± 
0.54 
9.93 ± 
0.88 
10.55 ± 
0.18 
11.72 ± 
0.21 
11.08 ± 0.41 Diet 
F(2,19)= 
4.661 
0.0225 
18:1ω7 
3.82 ± 
0.11 
3.87 ± 
0.30 
4.16 ± 
0.12 
4.30 ± 
0.09 
3.90 ± 
0.07 
3.94 ± 0.09 Diet 
F(2,19)= 
3.862 
0.0391 
22:4ω6 
1.83 ± 
0.14 
2.00 ± 
0.10 
1.41 ± 
0.07 
1.52 ± 
0.08 
1.73 ± 
0.07 
1.61 ± 0.15 Diet 
F(2,19)= 
8.207 
0.0027 
22:5ω6 
0.51 ± 
0.05 
0.57 ± 
0.01 
0.35 ± 
0.03 
0.45 ± 
0.04 
0.39 ± 
0.05 
0.34 ± 0.03 Diet 
F(2,19)= 
10.77 
0.0007 
22:6ω3  
(DHA) 
2.13 ± 
0.27 
2.09 ± 
0.10 
2.28 ± 
0.11 
2.46 ± 
0.08 
2.90 ± 
0.07 
2.82 ± 0.24 Diet 
F(2,19)= 
10.22 
0.0010 
 
Fatty acid methyl ester (FAME) analysis was conducted on brain, plasma, and red blood 
cells (RBC) from each group. All fatty acids significantly altered by diet or TBI in 
comparison to untreated, sham animals are shown. Data are presented as mean percentage 
of fatty acid content ± SEM. 16:1-palmitoleic acid; 18:1ω7-vaccenic acid; 18:2-linoleic 
acid; 20:4-arichidonic acid; 22:0-behenic acid; 22:2-docosadienoic acid; 22:4ω6-
docosatetraenoic acid; 22:5ω3-docosapentaenoic acid; 22:5ω6-docosapentaenoic acid; 
22:6ω3-docosahexaenoic acid; 24:0-nervonic acid; 24:0-lignoceric acid; 24:1-nervonic 
acid. (Brain: sham n=5 per treatment, TBI n=6 per treatment. Plasma and RBC: sham n=3 
per treatment, TBI n=4-6 per treatment) 
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3.5 DISCUSSION 
 
 The current study was designed with the goals of: (1) directly comparing the 
therapeutic efficacy of dietary DHA supplementation before vs after diffuse brain injury 
on translational outcomes; (2) contributing to the understanding of the role of DHA 
supplementation in trauma-induced neuroinflammation; and (3) establishing a 
comprehensive fatty acid profile detailing the influences and interactions of TBI and 
DHA supplementation. Dietary DHA supplementation both before and after diffuse brain 
injury attenuated late-onset sensory hypersensitivity as detected by the whisker nuisance 
task. DHA supplementation also reduced [
3
H]PK-11195 binding density, an index of 
neuroinflammation, at 28 days post-injury. This effect, however, was somewhat 
asymmetrical with regard to timing, as post-TBI DHA supplementation showed greater 
efficacy than pre-TBI supplementation. TBI resulted in a significant loss of brain DHA 
content and a significant increase in brain arachidonic acid, a precursor of pro-
inflammatory prostaglandins. These data add to the body of evidence supporting the 
beneficial effects of omega-3 fatty acid supplementation on outcome from brain injury. 
 Several studies have shown that DHA (Bailes and Mills 2010) and fish oil 
(containing both EPA and DHA) supplementation can attenuate TBI-induced functional 
deficits (Wu, Ying et al. 2013; Desai, Kevala et al. 2014; Russell, Berman et al. 2014). 
Based on these findings, it was expected that brain-injured rats require more time to 
locate the submerged platform compared to uninjured animals; DHA supplementation 
was hypothesized to shorten the search durations. During days 15 to 17 post-injury, all 
groups had equivalent latencies to locate the submerged platform, indicating no learning 
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impairment, which precluded an evaluation of recall. No motor impairment was indicated 
by the equivalence of swim speeds. In two previous reports, supplementation with DHA 
following lateral fluid percussion brain injury in rats served to preserve cognitive 
function as measured in the Morris water maze (Wu, Ying et al. 2011; Wu, Ying et al. 
2013). Literature in the currently used midline fluid percussion injury model has 
indicated a spatial learning deficit using the MWM at earlier post-injury time points 
(Hamm, Lyeth et al. 1993), but rats in the current study did not exhibit a significant 
injury-induced cognitive deficit when tested in the MWM at later post-injury time points 
(15-18 days).  Thus, the effect of DHA supplementation on spatial learning was 
inconclusive. It is possible that these impairments could have resolved by the time of 
testing.  Alternatively, lateral FPI, CCI, and the impact-acceleration weight-drop models 
are known to cause lesions and swelling of the brain parenchyma not typically resulting 
from midline FPI (Zhang, Cai et al. 2014). It may be that greater injury forces are 
required to elicit a sustained cognitive impairment.  Such circumstances would provide 
some explanation for the differences in this study from earlier studies (Mills, Hadley et 
al. 2011; Wu, Ying et al. 2011) for the effects of DHA on spatial learning after TBI. 
We have previously reported increased sensory sensitivity in rats following 
diffuse TBI as a late-onset morbidity (McNamara, Lisembee et al. 2010; Learoyd and 
Lifshitz 2012) that reflects clinical symptomology of agitation (Goodrich, Flyg et al. 
2013; Goodrich, Martinsen et al. 2014). The whisker nuisance task was used to test for 
sensory hypersensitivity 22 days post-injury. Brain-injured rats not supplemented with 
DHA exhibited significantly increased nuisance scores compared to uninjured shams; 
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both DHA supplemented groups exhibited sensory sensitivity levels comparable to sham. 
DHA supplementation before or after TBI attenuated whisker nuisance scores by 
approximately two points from non-supplemented injured rats; the magnitude of this 
effect is meaningful as it indicates that treatment completely ameliorated one adverse 
reaction to sensory stimulation or a reduced the intensity of two different reactions to 
sensory stimulation. The timing of DHA supplementation cannot delineate the critical 
period to affect sensory sensitivity, however histopathology and inflammation data 
suggest a window of 7-10 days post-injury may be optimal (Cao, Thomas et al. 2012; 
Lifshitz and Lisembee 2012; Ziebell, Taylor et al. 2012) 
Following TBI, the role of inflammation remains somewhat unclear, with 
evidence for its contribution to both beneficial and detrimental outcomes (for review, see 
Morganti-Kossmann et al. 2002(Morganti-Kossmann, Rancan et al. 2002)). TBI results in 
the acute expression of inflammation-mediating cytokines (Morganti-Kossmann, Rancan 
et al. 2001; Frugier, Morganti-Kossmann et al. 2010; Semple, Bye et al. 2010), which 
elicit a range of responses including immune activation and programmed cell death 
(Allan and Rothwell 2001). Some cytokine signaling can persist into sub-acute and 
chronic stages of injury. Omega-3 fatty acids can inhibit the production of pro-
inflammatory cytokines in response to insults both in vitro (De Caterina, Cybulsky et al. 
1994; Khalfoun, Thibault et al. 1997) and in vivo (Yaqoob and Calder 1995). In the 
current study, [
3
H]PK11195 autoradiography was used to measure the efficacy of DHA 
supplementation on suppressing the microglial response to TBI. Two regions of interest, 
the cortex (Cao, Thomas et al. 2012) and substantia nigra (van Bregt, Thomas et al. 
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2012), were chosen for their vulnerability to mFPI. The remaining two areas of interest, 
the thalamus (Lifshitz, Kelley et al. 2007; McNamara, Lisembee et al. 2010) and 
hippocampus (Hamm, Lyeth et al. 1993), were chosen for their roles in the whisker 
nuisance task and MWM, respectively. Although [
3
H]PK11195 binding has some 
limitations in that it can partially label macrophages and astroglia, it predominately labels 
activated microglia (Venneti, Lopresti et al. 2009).  Despite these limitations, post-injury 
DHA supplementation significantly reduced injury-induced inflammation as measured by 
[
3
H]PK11195 autoradiography in three of four regions of interest. Furthermore, pre-
injury DHA supplementation resulted in binding densities not significantly higher than 
that of uninjured shams nor significantly lower than that of non-supplemented rats; a 
result interpreted as a modest reduction in this index of inflammation. 
The discrepancy in efficacy between the two supplementation regimens may 
indicate that while both pre- and post-injury DHA impart functional benefit in the WNT, 
they may act through separate mechanisms.  One set of possibilities is that pre-injury 
DHA may attenuate the initiation of the beneficial immune response acutely post-injury, 
while post-injury DHA may help resolve the ongoing immune response.  While this 
supposition has not been tested directly in the context of TBI in vivo,  in vitro 
pretreatment with DHA increases the phagocytic activity of microglia and promotes the 
M2, alternatively activated microglial phenotype (Chen, Zhang et al. 2014) that is more 
closely associated with tissue repair than with the inflammatory cascades of the M1 
phenotype (Cherry, Olschowka et al. 2014).  It therefore seems plausible that the 
intermediate [
3
H]PK11195  findings we observed for the DHA pretreatment group could 
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have been due to increased phagocytosis being part of an activated microglial phenotype 
and DHA being withdrawn from the pretreatment group directly after injury.  In contrast, 
the post-injury DHA group likely benefited from the suppression of M1-related pro-
inflammatory cytokines (e.g. IL1β, TNFα, etc.; (Cao, Thomas et al. 2012; Cherry, 
Olschowka et al. 2014) by DHA or its docosanoid metabolites (Michael-Titus and 
Priestley 2014). 
 To better understand the lipidomic landscape following DHA administration and 
TBI, fatty acid analysis was conducted on brain, plasma, and red blood cells. Our 
findings confirm a recent report (Wu, Ying et al. 2014) that TBI significantly decreased 
brain DHA content. As such, the loss of brain DHA after brain injury is likely, regardless 
of the nature of the impact of TBI model. TBI was also shown to increase brain 
arachidonic acid content, a precursor of pro-inflammatory prostaglandins (Korbecki, 
Baranowska-Bosiacka et al. 2013). Dietary supplementation of DHA significantly 
influenced brain content of six other fatty acids. The finding that brain EPA content was 
not increased provides evidence to support the independent role of DHA in the current 
study. In the periphery, plasma and red blood cell fatty acid profiles were also 
significantly modified by dietary manipulation of DHA, but not TBI. 
 Potential reasons for the decrease of brain DHA content could include post-injury 
loss of DHA into the cerebrospinal fluid (Farias, Heidenreich et al. 2011), decreased 
brain DHA uptake as seen in models of Alzheimer‘s disease (Vandal, Alata et al. 2014), 
or higher rates of brain DHA utilization after TBI since damaged brain cells require more 
energy (Giza and Hovda 2001). Less conversion of its precursor, α-linolenic acid, to 
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DHA in the brain is also possible but unlikely given that the healthy brain only has a 
conversion efficiency of ≤1%, most α-linolenic acid is converted in the liver, and the 
brain rates are unchanged by omega-3 deficiency (Igarashi, DeMar et al. 2007). More 
data are needed to support these possible explanations, but they are consistent with the 
decreased expression of sirtuins, which are metabolic regulators, after TBI (Wu, Ying et 
al. 2011). More refined time courses would aid in understanding the interaction between 
brain injury and DHA availability.  
Recent reports suggest that the neuroprotective effects of omega-3 fatty acids may 
be in part due to interactions of specialized pro-resolving mediator (SPM) derivatives 
(Buckley, Gilroy et al. 2014), including the resolvins (Harrison, Rowe et al. 2015), 
lipoxins (Luo, Li et al. 2013), and protectins (Bazan, Eady et al. 2012), with specific 
cellular mechanisms to be identified. To this effect, our group tested the therapeutic 
efficacy of two omega-3 fatty acid-derived SPMs for experimental diffuse brain injury in 
the mouse. The DHA-derived SPM tested, aspirin-triggered resolvin D1, but not the 
EPA-derived SPM, resolvin E1, significantly preserved motor and cognitive function 
compared to vehicle (Harrison, Rowe et al. 2015). Similarly, another DHA-derived SPM, 
aspirin-triggered neuroprotectin D1, was sufficient to reduce neuroinflammation (Orr, 
Palumbo et al. 2013) and improve performance on a battery of tests of neurological 
function following experimental stroke in rats (Bazan, Eady et al. 2012). These data are 
consistent with our lipid profile findings that only brain DHA content increased with 
DHA supplementation even though both DHA and EPA increased in the plasma.  Our 
results are also consistent with the rapid metabolism and oxidation of EPA by the brain 
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(Chen and Bazinet 2015). Overall, these data add further support to the notion that DHA 
may play an important role as a precursor for bioactive lipid mediators in the context of 
acute neurological injury. 
 Findings of the current study could be taken into consideration for the design of 
future investigations. While both pre- and post-injury DHA supplementation resulted in 
attenuation of sensory hypersensitivity, only post-injury DHA supplementation 
effectively reduced inflammation measured by [
3
H]PK11195 binding density. Further 
studies are needed to examine other potential mechanisms through which pre-injury DHA 
supplementation contributes to and sustains therapeutic efficacy for weeks. Measurement 
of cytokine and chemokine levels could provide additional insight into specific pathways 
of action. The current study was focused on post-acute outcomes which coincide with 
late-onset morbidities. Extensions of this study could investigate the role of DHA 
supplementation in the acute window following TBI, however the current experimental 
model focuses on enduring neurological symptoms. 
3.6 CONCLUSIONS 
 
In conclusion, we found that dietary DHA supplementation showed efficacy at 
attenuating long-term sensory hypersensitivity and reducing inflammation, measured by 
[
3
H]PK-11195 binding density. Additionally, TBI resulted in significant changes across 
the fatty acid profile, notably including loss of brain DHA content. These results indicate 
that pre-injury supplementation of DHA may offer therapeutic efficacy against trauma-
induced deficits and post-injury supplementation may serve as an intervention to 
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replenish brain DHA content, both of which could lessen the permanent injury burden 
resulting from TBI. 
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CHAPTER 4 
4 RESOLVINS AT-D1 AND E1 DIFFERENTIALLY IMPACT FUNCTIONAL 
OUTCOME, POST-TRAUMATIC SLEEP, AND MICROGLIAL ACTIVATION 
FOLLOWING DIFFUSE BRAIN INJURY IN THE MOUSE 
Published in Brain, Behavior, and Immunity (Harrison et al. 2015) 
4.1 ABSTRACT 
 
Traumatic brain injury (TBI) is induced by mechanical forces which initiate a 
cascade of secondary injury processes, including inflammation. Therapies which resolve 
the inflammatory response may promote neural repair without exacerbating the primary 
injury. Specific derivatives of omega-3 fatty acids loosely grouped as specialized pro-
resolving lipid mediators (SPMs) and termed resolvins promote the active resolution of 
inflammation. In the current study, we investigate the effect of two resolvin molecules, 
RvE1 and AT-RvD1, on post-traumatic sleep and functional outcome following diffuse 
TBI through modulation of the inflammatory response.  
Adult, male C57BL/6 mice were injured using a midline fluid percussion injury 
(mFPI) model (6-10 min righting reflex time for brain-injured mice). Experimental 
groups included mFPI administered RvE1 (100ng daily), AT-RvD1 (100ng daily), or 
vehicle (sterile saline) and counterbalanced with uninjured sham mice. Resolvins or 
saline were administered daily for seven consecutive days beginning 3 days prior to TBI 
to evaluate proof-of-principle to improve outcome. Immediately following diffuse TBI, 
post-traumatic sleep was recorded for 24 hours post-injury. For days 1-7 post-injury, 
motor outcome was assessed by Rotarod. Cognitive function was measured at 6 days 
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post-injury using Novel Object Recognition (NOR). At 7 days post-injury, microglial 
activation was quantified using immunohistochemistry for Iba-1. 
In the diffuse brain-injured mouse, AT-RvD1 treatment, but not RvE1, mitigated 
motor and cognitive deficits. RvE1 treatment significantly increased post-traumatic sleep 
in brain-injured mice compared to all other groups. RvE1 treated mice displayed a higher 
proportion of ramified microglia and lower proportion of activated rod microglia in the 
cortex compared to saline or AT-RvD1 treated brain-injured mice. Thus, RvE1 treatment 
modulated post-traumatic sleep and the inflammatory response to TBI, albeit 
independently of improvement in motor and cognitive outcome as seen in AT-RvD1-
treated mice. This suggests AT-RvD1 may impart functional benefit through mechanisms 
other than resolution of inflammation alone. 
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4.2 INTRODUCTION 
 
Each year over 1.7 million people sustain traumatic brain injuries (TBI) in the 
United States alone (Faul, Xu et al. 2010). The consequences of TBI for the individual 
can include diminished quality of life manifested through a range of symptoms including 
acute and chronic pain (Tham, Palermo et al. 2013), loss of neurological function 
(Arciniegas, Topkoff et al. 2000), and impaired cognitive or emotional ability 
(Arciniegas, Topkoff et al. 2000; Albensi and Janigro 2003; Masel and DeWitt 2010). 
Few therapies are available to treat these debilitating morbidities and many promising 
therapeutic agents have failed to achieve efficacy in clinical trials (Margulies and Hicks 
2009). Animal models have been established to reproduce the complex pathophysiology 
of TBI and offer valuable means through which therapies can be tested on the resulting 
physiological, sensorimotor, and cognitive deficits. Pharmacological attempts to lessen 
the burden of TBI include a wide swath of treatment approaches, routinely using 
experimental compounds largely designed to target the cellular and molecular cascades 
which contribute to secondary injury in the hours to days following TBI (McIntosh, 
Juhler et al. 1998; Margulies and Hicks 2009). 
TBI is induced by mechanical forces which initiate a cascade of secondary injury 
processes, including inflammation (Werner and Engelhard 2007). To complicate our 
understanding of underlying processes, cerebral inflammation has been shown to 
contribute to both beneficial and detrimental effects on outcome (for review, see 
(Morganti-Kossmann, Rancan et al. 2002)). Following TBI, the brain is inundated with 
inflammation-mediating cytokines (Morganti-Kossmann, Rancan et al. 2001; Frugier, 
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Morganti-Kossmann et al. 2010; Semple, Bye et al. 2010) which prompt a spectrum of 
responses including cell differentiation, immune activation, and cell death (Allan and 
Rothwell 2001). While the role of early-onset inflammation in the pathophysiology of 
TBI is debatable, clinical and experimental data suggest that chronic over-production of 
inflammatory cytokines aggravate the primary injury (Schmidt, Heyde et al. 2005; Lloyd, 
Somera-Molina et al. 2008; Cao, Thomas et al. 2012), and thereby impact outcome. Our 
lab has previously reported that the cortical primary somatosensory barrel fields (S1BF) 
are a primary site of neuropathology following experimental diffuse traumatic brain 
injury (Hall and Lifshitz 2010; Lifshitz and Lisembee 2012), with pronounced microglial 
activation and the induction of a previously understudied rod morphology of activated 
microglia (Cao, Thomas et al. 2012; Ziebell, Taylor et al. 2012; Taylor, Morganti-
Kossmann et al. 2014). Rod microglia appear to constitute a phenotypically distinct class 
of activated microglia which present following acute neurological injury including 
diffuse TBI, infection and seizure (Wirenfeldt, Clare et al. 2009; Ziebell, Taylor et al. 
2012; Mukherjee, Zeitouni et al. 2013). The relative distribution of microglial 
morphologies can thereby serve as an indicator neuroinflammation and underlying 
pathological and reparative processes. The current study further assesses 
neuroinflammation after diffuse TBI using a semi-quantification method of microglial 
activation to determine proportions of ramified (unactivated) microglia in relation to 
morphological phenotypes activated in response to injury—activated and rod microglia. 
Cytokines are elevated and regulate inflammation following TBI (Semple, Bye et 
al. 2010; Ziebell and Morganti-Kossmann 2010). These cytokines, including pro-
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inflammatory interleukin-1 beta (IL-1β), can also serve dual roles as sleep regulatory 
substances (SRSs) which influence sleep-wake behavior through action on the sleep 
circuits within the brain (Krueger, Takahashi et al. 1995; Krueger, Obal et al. 2001; 
Krueger, Rector et al. 2007). The elevation of IL-1β following midline fluid percussion 
brain injury in the mouse has previously been documented to correspond temporally with 
an acute increase in post-traumatic sleep during the first six hours post-injury (Rowe, 
Striz et al. 2014). These data suggest a relationship between inflammation and SRSs such 
that post-traumatic sleep may serve as an indicator of SRS action. 
While inflammation is an essential component of the repair process, excessive or 
prolonged inflammation can aggravate injury-related damage (Bachstetter, Rowe et al. 
2013). Therapies which resolve the inflammatory response may promote neural recovery 
without exacerbating the primary injury. Certain derivatives of omega-3 fatty acids 
loosely grouped as specialized pro-resolving lipid mediators (SPMs) have been shown to 
promote the resolution of inflammation resulting from multiple induction pathways (for 
review, see (Recchiuti and Serhan 2012)). These lipid mediators of inflammation are 
described as eicosanoids or docsanoids depending on their derivation from either 
eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) respectively (Serhan, Hong 
et al. 2002) and encompass subclasses including resolvins, protectins, lipoxins, and 
maresins (Recchiuti and Serhan 2012). Dietary supplementation with precursors of 
SPMs, particularly DHA, has shown therapeutic potential by reducing lesion size and 
improving neurological function following a model of ischemic stroke (Belayev, 
Khoutorova et al. 2009) and TBI (Mills, Hadley et al. 2011; Wu, Ying et al. 2011) in rats 
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by decreasing axonal injury and preserving cognitive function. Further, DHA 
supplementation after experimental stroke led to increased brain levels of another 
docosanoid, neuroprotectin D1 (NPD1) (Belayev, Khoutorova et al. 2011), a lipid 
mediator of inflammation which was then shown to ameliorate the functional and 
histological consequences of experimental stroke on its own (Bazan, Eady et al. 2012). 
Therefore, pharmacotherapy targeting SPMs provides a pleiotropic approach to 
regulating inflammation resulting from TBI, rather than genetically or chemically 
targeting a single signaling pathway.  
Considering the similar inflammatory pathophysiologies of stroke and TBI, these 
data suggest that SPMs may regulate inflammation resulting from TBI.  In the current 
study, two lipid mediators of inflammation, resolvin E1 (RvE1) and aspirin-triggered 
resolvin D1 (AT-RvD1), are tested for their impact upon post-traumatic sleep, 
sensorimotor and cognitive outcome, and microglial activation after diffuse experimental 
brain injury in the mouse. These endogenous SPMs are proposed to bring the injury-
induced inflammatory response to conclusion as evidenced by a reduction in post-
traumatic sleep, shift in the microglial morphology profile, and thereby improvement in 
functional outcome. We hypothesize that RvE1 and AT-RvD1 will improve functional 
outcome from diffuse TBI through modulation of the inflammatory response. 
4.3 METHODS 
 
4.3.1 Animals 
 Male C57BL/6 mice (Harlan Laboratories, Inc., Indianapolis, IN) were used for 
all experiments (n=73). Mice were housed in a 12 h light/12h dark cycle at a constant 
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temperature (23°C ± 2° C) with food and water available ad libitum according to the 
Association for Assessment and Accreditation of Laboratory Animal Care International. 
All mice used in this study were singly housed. Mice were acclimated to their 
environment following shipment for at least three days prior to any experiments. After 
surgery, mice were evaluated daily during post-operative care by a physical examination 
and documentation of each animal‘s condition. Animal care was approved by the 
Institutional Animal Care and Use Committees at St. Joseph‘s Hospital and Medical 
Center (Phoenix, AZ). 
4.3.2 Midline Fluid Percussion Injury (mFPI) 
Mice (20-24g) were subjected to midline fluid percussion injury (mFPI) 
consistent with methods previously described (Lifshitz 2008; Harrison, Rowe et al. 2014; 
Rowe, Harrison et al. 2014; Rowe, Harrison et al. 2014; Rowe, Striz et al. 2014). Group 
sizes are indicated in the results section and figure legends for individual studies. Mice 
were anesthetized using 5% isoflurane in 100% oxygen for five minutes and the head of 
the mouse was placed in a stereotaxic frame with continuously delivered isoflurane at 
2.5% via nosecone. While anesthetized, body temperature was maintained using a 
Deltaphase
®
 isothermal heating pad (Braintree Scientific Inc., Braintree, MA). A midline 
incision was made exposing bregma and lambda, and fascia was removed from the 
surface of the skull. A trephine (3 mm outer diameter) was used for the craniotomy, 
centered on the sagittal suture between bregma and lambda without disruption of the 
dura. An injury cap prepared from the female portion of a Luer-Loc needle hub was fixed 
over the craniotomy using cyanoacrylate gel and methyl-methacrylate (Hygenic Corp., 
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Akron, OH). The incision was sutured at the anterior and posterior edges and topical 
Lidocaine ointment was applied. The injury hub was closed using a Luer-Loc cap and 
mice were placed in a heated recovery cage and monitored until ambulatory before being 
returned to their sleep cage. 
For injury induction 24 hours post-surgery, mice were re-anesthetized with 5% 
isoflurane delivered for five minutes. The cap was removed from the injury-hub assembly 
and the dura was visually inspected through the hub to make sure it was intact with no 
debris. The hub was then filled with normal saline and attached to an extension tube 
connected to the male end of the fluid percussion device (Custom Design and 
Fabrication, Virginia Commonwealth University, Richmond, VA). An injury of moderate 
severity for our injury model (1.4 atm) was administered by releasing the pendulum onto 
the fluid-filled cylinder. Sham-injured mice underwent the same procedure except the 
pendulum was not released. Mice were monitored for the presence of a forearm fencing 
response and righting reflex times were recorded for the injured mice as indicators of 
injury severity (Hosseini and Lifshitz 2009). The righting reflex time is the total time 
from the initial impact until the mouse spontaneously rights itself from a supine position. 
The fencing response is a tonic posturing characterized by extension and flexion of 
opposite arms that has been validated as an overt indicator of injury severity (Hosseini 
and Lifshitz 2009). The injury hub was removed and the brain was inspected for uniform 
herniation and integrity of the dura. The dura was intact in all mice; none were excluded 
as technical failures. The incision was cleaned using saline and closed using sutures. 
Moderate brain-injured mice had righting reflex recovery times greater than six minutes 
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and a positive fencing response. Sham injured mice recovered a righting reflex within 20 
seconds. After spontaneously righting, mice were placed in a heated recovery cage and 
monitored until ambulatory (approximately 5 to 15 minutes) before being returned to 
their piezoelectric sleep cage. Adequate measures were taken to minimize pain or 
discomfort.  
4.3.3 Pharmacological Treatment 
 Mice were treated with sterile saline (100µl, 0.9% NaCL), 100ng 17(R)-Resolvin 
D1 (AT-RvD1; Item # 13060, Cayman Chemical, Ann Arbor, MI), or 100ng Resolvin E1 
(RvE1; Item # 10007848, Cayman Chemical, Ann Arbor, MI). Resolvins were 
administered intraperitoneally in 100µl of sterile saline for seven consecutive days 
beginning three days before mFPI (see Fig. 1). The seven day dosing schedule was 
selected to evaluate proof-of-principle for resolvin efficacy by covering both prophylactic 
and treatment approaches. Dosing was selected with regard to published studies using 
protectins in cerebral ischemia in mice(Bazan, Eady et al. 2012). 
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Figure 4.1. Study Design. 
Mice were acclimated to their individual sleep cages before surgery and injury (blue). 
Mice were pre-treated with saline, AT-RvD1, or RvE1, for three days before surgery, and 
received post-injury injections for 4 consecutive days (orange). All mice received a 
midline craniectomy (red). One day post-surgery mice received either midline fluid 
percussion brain injury or sham injury (red). Immediately following injury, mice were 
placed back in their sleep cage and post-traumatic sleep was non-invasively recorded for 
24 hours (blue). Following injury, mice were assessed for sensorimotor function using the 
rotarod task (1, 3, 5, 7 days post-injury). Cognitive performance was assessed using novel 
object recognition (NOR) at 6 days post-injury. Following behavior tasks, tissue was 
collected at 7 days post-injury and prepared for neuroinflammation analysis using 
immunohistochemistry (IHC; purple). 
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4.3.4 Sleep Recordings  
The non-invasive sleep cage system (Signal Solutions, Lexington, KY) used in 
this study consisted of 16 separate units which simultaneously monitor sleep and wake 
states, as previously published (Donohue, Medonza et al. 2008; Mang, Nicod et al. 2014; 
Rowe, Harrison et al. 2014). Each cage unit housed a single mouse inside 18 x 18 
centimeter walled compartments with attached food and water structures(Donohue, 
Medonza et al. 2008). The cages had open bottoms resting on Polyvinylidine Difluoride 
(PVDF) sensors serving as the cage floor (Donohue, Medonza et al. 2008). The non-
invasive high-throughput PVDF sensors were coupled to an input differential amplifier 
and pressure signals were generated and classified by the classifier as motions consistent 
with either activity related to wake or inactivity and regular breathing movements 
associated with sleep (Donohue, Medonza et al. 2008; Rowe, Harrison et al. 2014). 
Briefly, sleep was characterized primarily by periodic (3 Hz) and regular amplitude 
signals recorded from the PVDF sensors, typical of respiration from a sleeping mouse. In 
contrast, signals characteristic of wake were both the absence of characteristic sleep 
signals and higher amplitude, irregular signals associated with volitional movements, 
even during quiet wake. The piezoelectric signals in two second epochs were classified 
by a linear discriminant classifier algorithm based on multiple signal variables to assign a 
binary label of ―sleep‖ or ―wake‖ (Donohue, Medonza et al. 2008). Mice sleep in a 
polycyclic manner (often more than 40 sleep episodes per hour if short arousals are 
recorded) (McShane, Galante et al. 2010) and therefore mouse sleep was quantified as the 
minutes spent sleeping per hour, presented as a percentage for each hour.  
   
 
84 
 
The current study was designed to avoid initial post-traumatic sleep recordings 
during a light transition period. As a result, sleep recordings began 6 hours into the light 
period, covered the light:dark transition, and continued for 6 hours into the dark period. 
Data collected from the cage system were binned over specified time periods (e.g. 1 hour) 
using the average of percent sleep, as well as binned by length of individual bouts of 
sleep and the median bout lengths were calculated. Where applicable, sleep metrics were 
compared between 6 hours of light and 6 hours of dark. 
4.3.5 Behavioral Testing 
Rotarod: Sensorimotor function was assessed using the Economex Rotarod 
system from Columbus Instruments (Columbus, OH). Mice were pre-trained for three 
consecutive days (60 sec at 4 RPM for 3 trials) prior to injury, following pre-injury drug 
treatment. For the test (1, 3, 5, 7 days post-injury), mice were placed on the rod with a 
starting speed of 4 RPM, and rod rotation speed was continuously increased over 5 
minutes up to a max speed of 28 RPM, as previously published (Bachstetter, Rowe et al. 
2013; Harrison, Rowe et al. 2014; Rowe, Harrison et al. 2014). The trial ended when the 
mouse fell from the rod or 5 minutes elapsed. Two trials were performed at each time 
point. Data are presented as latency to fall in seconds (average of two trials). 
Novel Object Recognition (NOR): Cognitive impairment was tested using the 
NOR test as previously published (Ennaceur and Aggleton 1997; Han, Tong et al. 2011; 
Rowe, Harrison et al. 2014). The test consisted of three phases: habituation, training, and 
testing. On day 6 post-injury, mice were placed in an open field (42 cm, 21 cm, 21 cm) 
for one hour of habituation. Mice were removed and two identical objects were placed in 
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opposing quadrants of the field for the training phase. Mice were placed in the center of 
the open field and given 5 minutes to explore the objects. Following training, mice were 
returned to their piezoelectric sleep cages. Testing began 4 hours after training. One 
familiar object was placed in an original location and one novel object was placed in the 
opposing quadrant of the open field. Mice were placed into the center and given 5 
minutes to explore. For testing, the times spent actively investigating the novel and 
familiar object were quantified. Investigation of an object included the mice sniffing, 
touching, or climbing onto an object while facing the object. If an animal climbed onto an 
object and sniffed into the air, this time was not calculated into the exploration of the 
novel object. Testing data are displayed as the percentage of total investigation time spent 
with each object and as a discrimination index (DI) in which DI = (Tnovel - Tfamiliar)/(Tnovel 
+ Tfamiliar). 
4.3.6 Analysis of Microglial Activation 
Tissue Preparation: At 7 days post-injury or sham operation, mice were given an 
overdose of sodium pentobarbital (i.p.) and transcardially perfused with 4% 
paraformaldehyde after a phosphate buffered saline (PBS) flush. Brains were removed 
and placed in 4% paraformaldehyde overnight. Brains were immersed in serial dilutions 
(15% and 30%) of sucrose for 24 hours each. The brains were removed from the 30% 
sucrose and frozen at -20° C. After freezing, brains were cryosectioned in the coronal 
plane at 20µm, mounted onto glass slides, and stored at -80° C.  
Iba-1 Immunofluorescence: Slides were removed from -80°C, placed in an oven 
at 60°C for approximately 4 hours and then rinsed three times for 5 minutes each in PBS. 
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Next, the slides were incubated in 4% goat serum blocking solution for 1 hour. Slides 
were incubated with the primary antibody (rabbit anti-ionized calcium binding adaptor 
molecule 1, IBA-1; 1:1000, Item # 0199-19741, Wako Chemicals, Richmond, VA) and 
stored at 4°C overnight. Slides were rinsed three times in PBS and the secondary 
antibody (biotinylated horse anti-rabbit; 1:250, Vector Laboratories, Burlingame, CA) 
was added and slides were incubated on a rocker at room temperature for 1 hour. Slides 
were washed in PBS three times for 5 minutes each and tertiary stain was applied 
(streptavidin Alexa© Fluor 594; 1:1000, Jackson Immunoresearch, Westgrove, PA) and 
slides were incubated for 1 hour at room temperature. Lastly, slides were rinsed three 
times in PBS and coverslipped with anti-fade medium (Fluoromount G; Southern 
Biotech, Birmingham, AL). Sections were examined for microglial activation in response 
to brain-injury using a Zeiss LSM 710 Confocal Laser Scanning Microscope with 
attached digital camera. 
Microglial Identification & Semi-Quantification: Stained sections (from 3-4 mice 
per group) were analyzed following Iba-1 staining to determine the proportion of 
microglial morphologies post-injury. The area of interest, the primary somatosensory 
barrel fields (S1BF), was chosen based on previous work demonstrating a multi-focal 
concentration of neuropathology and microglial activation in the S1BF following midline 
fluid percussion brain injury in the rat (Cao, Thomas et al. 2012; Lifshitz and Lisembee 
2012; Ziebell, Taylor et al. 2012). Sections were screened using a Zeiss (AXIO imager 
A2) microscope with attached digital camera (AxioCam MRc5). Images were captured 
with proprietary Zen software (Carl Zeiss, Germany) at 20X magnification. The area of 
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interest was examined in both hemispheres and in two different coronal planes: an 
anterior section (approximately Bregma -1.555mm) and a posterior section 
(approximately Bregma -2.255mm). A total of 4 photos per brain per area of interest were 
analyzed. Photomicrographs were analyzed in Image J software (National Institutes of 
Health, Bethesda, MD). On each photomicrograph, 250,000 pixel
2
 grid lines were placed 
and quantification was limited to 4 pre-defined boxes. Microglia within these boxes were 
classified as either having ramified (small soma, high defined processes), activated 
(hypertrophied soma, fewer processes), or rod (soma twice as long as width in one 
direction) morphologies. A minimum of 50 microglia were counted per section per 
region. Sham treatment groups were combined. 
4.3.7 Statistical Analysis 
Data are shown as mean ± SEM and analyzed using GraphPad Prism 6, with 
statistical significance assigned when p<0.05, unless otherwise indicated. For each test, 
shams receiving each treatment were statistically compared. No differences were detected 
between sham groups (treated and vehicle). To maintain comparable group sizes, a 
pooled sham group (n=12) was constructed using equal numbers of mice randomly 
selected from each treatment. Differences in righting reflex times were measured with a 
one-way analysis of variance (ANOVA). Differences in mortality were evaluated by chi-
square analysis between both resolvin and saline-treated brain-injured groups. Percent 
sleep was analyzed using a repeated measure two-way ANOVA. Cumulative sleep 
measured in minutes and cumulative bout lengths of sleep were analyzed with a one-way 
ANOVA. All significant sleep data were further analyzed using Tukey‘s multiple 
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comparisons test. Differences in rotarod performance at 24 hours post-injury were 
determined with a one-way ANOVA followed by Dunnett‘s multiple comparisons test. 
Differences in motor performance following TBI over the first week post-injury were 
determined with a repeated measure two-way ANOVA followed by Dunnett‘s multiple 
comparisons test. Differences in time spent exploring the novel versus familiar object 
were determined for each treatment group by paired t-test, using a modified p value of 
0.0125 to account for four separate tests. Proportional differences in rod microglial 
morphologies were subjected to chi-square analysis (Fisher‘s exact test) in which 
significance was defined by a modified p value of 0.0083 to correct for the 6 tests made 
within each morphological comparison. Statistical values are included in the figure 
legends. 
4.4 RESULTS 
4.4.1 Resolvin treatment did not influence the initial induction of diffuse TBI 
 We have previously reported suppression of the righting reflex response in mice 
following mFPI (Rowe, Harrison et al. 2014) as an injury-induced deficit and indicator of 
injury severity. Diffuse brain injury resulted in a significant suppression of the righting 
reflex in brain-injured mice, compared to anesthetized, uninjured shams, regardless of 
drug treatment (Fig 2). A one-way ANOVA comparing only brain-injured treatment 
groups showed no significant difference of righting reflex times, indicating that all brain-
injured mice received injuries of similar severities. Of the 73 mice in this study, 48 were 
brain-injured. As a result of injury, 19 mice died (40% mortality). Of the 18 mortalities, 5 
saline-treated mice died within 15 minutes of injury (33% mortality); 4 AT-RvD1-treated 
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mice died within 15 minutes of injury (27% mortality); 9 RvE1-treated animals died 
within 15 minutes of injury (50% mortality); all presumably from respiratory arrest. 
Differences in acute post-injury mortality were compared with chi-square analysis, 
revealing no significant treatment effects on mortality. 
4.4.2 RvE1 increased TBI-induced post-traumatic sleep 
As expected, we found that uninjured shams, regardless of drug treatment, slept 
similarly (data not shown). During the first 12 hours following injury, a repeated-measure 
two-way ANOVA revealed a significant main effect of both time and treatment group on 
percent sleep. Further, Tukey‘s multiple comparisons test revealed that RvE1-treated 
mice slept significantly more than all other groups during the first 12 hours following 
injury (Fig 3A). A more detailed analysis was performed by calculating the number of 
cumulative minutes spent sleeping during the first light and dark periods after brain 
injury. RvE1-treated brain-injured mice slept significantly more during the light period 
immediately following injury compared to saline-treated brain-injured mice (Fig 3B). 
During the following dark period, RvE1-treated brain-injured mice continued to sleep 
significantly more compared to uninjured sham and both other brain-injured groups (Fig 
3C). Overall, brain-injured mice treated with RvE1 slept significantly more than other 
brain-injured mice, since uninjured mice treated with RvE1 slept similar to the remaining 
uninjured mice, indicating a brain injury rather than a treatment effect. 
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Figure 4.2. TBI suppressed righting reflex regardless of drug treatment. 
Diffuse TBI resulted in a significant suppression of the righting reflex (mean ±SEM; 
F(3,34)=15.09, p<0.0001) compared to uninjured shams. Further, by excluding the 
uninjured shams, the one-way ANOVA revealed no significant differences between 
brain-injured mice, regardless of treatment (F(2,23)=0.06; p=0.9). (sham n=12, saline-
treated injury n=9, AT-RvD1-treated injury n=9, RvE1-treated injury n=8; #, p<0.05 
compared to sham). 
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Further, post-traumatic sleep showed a significant injury effect on number of sleep bouts 
during the first light period post-injury (Fig 3D). Post-hoc analysis indicated that 
regardless of treatment, all brain-injured groups slept significantly more sleep bouts 
compared to uninjured shams (Fig 3D). Overall, there was a group effect on the number 
of bouts in the dark period (Fig 3E). Tukey‘s multiple comparison test revealed RvE1-
treated brain-injured mice had significantly more bouts during the dark period compared 
to uninjured shams, saline-treated brain-injured mice, and AT-RvD1-treated brain-injured 
mice. These data show that RvE1 increased sleep through an increase in the number of 
sleep bouts, but not necessarily the length of the sleep bout. 
4.4.3 AT-RvD1 mitigated TBI-induced sensorimotor deficits on the rotarod task 
To assess motor function, the rotarod task was used as previously published 
(Bachstetter, Rowe et al. 2013; Harrison, Rowe et al. 2014; Rowe, Harrison et al. 2014).  
Motor function was tested as the latency to stay on the rotarod over 7 days post-injury, 
with significant effects on both time post-injury and between groups. Tukey‘s post-hoc 
analysis indicated that compared to uninjured shams, brain-injured mice treated with 
saline or RvE1 demonstrated significantly shorter latencies to fall from the rotarod. 
However, AT-RvD1-treated brain-injured mice did not show a significant deficit 
compared to uninjured shams and displayed significantly longer latencies than RvE1-
treated mice. Overall, diffuse brain injury reduced motor function measured on the 
rotarod task. AT-RvD1-treated brain-injured mice did not show injury-induced 
impairments measured by latency (Fig 4). While AT-RvD1-treated mice did not perform 
significantly better than saline-treated mice, they did not demonstrate a deficit in 
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comparison to sham. Together, these data suggest that AT-RvD1 improved or accelerated 
recovery from TBI, but perhaps not to an uninjured level. 
4.4.4 TBI-induced cognitive impairment was improved with AT-RvD1 treatment 
Cognitive function was measured using the novel object recognition task (Antunes and 
Biala 2012). Paired t-tests indicated significant differences between time spent exploring 
the novel and familiar objects for uninjured shams and AT-RvD1-treated brain- injured 
mice, indicating recall of the familiar object (Fig 5A).  However, saline-treated and 
RvE1-treated brain-injured mice spent equivalent times investigating both objects, 
indicating no recall of the familiar object (Fig 5A). Statistical comparisons between 
investigation times of the groups were not performed. A significant difference in 
investigation of novel and familiar was treated as the criterion for ‗recognition;‘ only 
sham and AT-RvD1-treated groups reached recognition criterion. To further analyze 
cognitive performance on the NOR task, the discrimination index was calculated as the 
time spent with the novel object minus the time spent with the familiar object divided by 
the total time spent exploring for each mouse. There was no significant difference in the 
discrimination index between groups (Fig 5B).  
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Figure 4.3. RvE1 increased post-traumatic sleep. 
During the first 12 hours following injury (A), a two-way ANOVA revealed a significant 
main effect of treatment group on sleep (F(3,31)=7.6, p<0.0006). Specifically, Tukey‘s 
multiple comparison test indicated that RvE1-treated mice slept significantly more than 
all other groups. RvE1-treated brain-injured mice slept more during the first light (B) and 
dark (C) period following injury. RvE1-treated brain-injured mice slept significantly 
more compared to saline-treated brain-injured mice in the light period (F(2,20)=5.0, 
p=0.02) and dark period (F(3,31)=9.1, p=0.0002) immediately following injury. Post-
traumatic sleep showed a significant injury effect on number of sleep bouts during the 
first light period (D) (F(3,31)=7.0, p=0.001) and dark period (E) (F(3,31)=16.3, 
p<0.0001). (saline-treated injury n=7, AT-RvD1-treated injury n=9, RvE1-treated injury 
n=7, sham n=12) (*, p<0.05 compared to sham; #, p<0.05 compared to vehicle; +, p<0.05 
compared to AT-RvD1) 
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Figure 4.4. AT-RvD1 prevented TBI-induced motor deficits measured by the 
rotarod task. 
There was a significant effect of time after injury on motor performance F(3,99)=32.0, 
p<0.0001). There was also a significant group effect on latency to stay on the rotarod 
(F(3,33)=4.6, p=0.008). Tukey‘s post-hoc analysis indicated that compared to uninjured 
shams, brain-injured mice treated with saline or RvE1 demonstrated significantly shorter 
latencies to fall from the rotarod. However, AT-RvD1-treated brain-injured mice 
performed comparably to uninjured shams and displayed significantly longer latencies 
than RvE1-treated mice. saline-treated injury n=11, AT-RvD1-treated injury n=6, RvE1-
treated n=8, sham n=12). (*, p<0.05 compared to sham; +, p<0.05 compared to AT-
RvD1) 
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4.4.5 RvE1 increased the proportion of ramified microglia and decreased the proportion 
of rod microglia in the sensory cortex  
Resolvin treatment did not alter the proportions of microglia phenotypes among saline 
and treated sham animals in somatosensory cortex (chi-square, p>0.05; data not shown). 
All brain-injured groups demonstrated a lower proportion of ramified microglia than 
uninjured sham mice at 7 days post-injury (chi-square, p<0.0001). RvE1-treated brain-
injured mice had a significantly higher proportion of ramified microglia compared to 
saline-treated (p=0.0001) and AT-RvD1 mice (p<0.0001). All brain-injured groups 
demonstrated a greater proportion of activated microglia than uninjured sham mice (chi-
square, p<0.0001). RvE1-treated brain-injured mice had a significantly lower proportion 
of activated microglia than AT-RvD1 treated mice (p=0.005). As expected, sham mice 
demonstrated no rod microglia. RvE1-treated brain-injured mice had a significantly lower 
proportion of rod microglia than saline-treated brain-injured mice (p=0.0002). These data 
show RvE1 significantly altered the inflammatory profile of microglia in somatosensory 
cortex, whereas microglial activation after AT-RvD1 treatment remained unchanged from 
the untreated condition. 
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Figure 4.5. AT-RvD1 prevented TBI-induced cognitive impairment measured by 
novel object recognition. 
Differences in time spent exploring the novel versus familiar object were determined for 
each treatment group by paired t-test, using a modified p value of 0.0125 to account for 
four separate tests. These tests revealed a significant differences between investigation 
time of novel and familiar objects among sham (t(11)=4.6, p=0.0008) and AT-RvD1 
treated brain-injured mice (t(8)=3.8, p=0.006) (A), indicating recall of the familiar object. 
However, saline-treated (t(7)=1.1, p=0.3) and RvE1-treated brain-injured mice (t(7)=1.7, 
p=0.1) spent similar times investigating both objects indicating no recall of the familiar 
object.The discrimination index (B) was calculated as the time spent with the novel 
object minus the time spent with the familiar object divided by the total time spent 
exploring. While sham and AT-RvD1 trended toward object recognition, there was no 
significant difference in discrimination indices between groups (F(3,33)=0.9, p=0.4). 
(saline-treated injury n=8, AT-RvD1-treated injury n=9, RvE1-treated injury n=8, shams 
n=12) (*, p<0.0125 between novel and familiar) 
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Figure 4.6. RvE1 increased the proportion of ramified microglia and decreased the 
proportion of rod microglia. 
Representative microscopic fields abundant with (A) ramified microglia (carets), (B) 
activated microglia (arrowheads), and (C) rod microglia (arrows) in the primary 
somatosensory barrel fields at 7 days post-injury. (D) Sham mice demonstrated a higher 
proportion of ramified microglia than all brain-injured groups (p<0.0001). RvE1-treated 
brain-injured mice had a significantly higher proportion of ramified microglia compared 
to saline-treated (p=0.0001) and AT-RvD1 mice (p<0.0001). (E) Sham mice 
demonstrated a lower proportion of activated microglia than all brain-injured groups 
(p<0.0001). RvE1-treated brain-injured mice had a significantly lower proportion of 
activated microglia than AT-RvD1 treated mice (p=0.005). (F) Sham mice demonstrated 
a lower proportion of rod microglia than all brain-injured groups (p<0.0001). RvE1-
treated brain-injured mice had a significantly lower proportion of rod microglia than 
saline-treated brain-injured mice (p=0.0002). (G) A combined representation of observed 
microglial morphological distributions. (*, p<0.05 compared to sham; #, p<0.05 
compared to vehicle; +, p<0.05 compared to AT-RvD1) 
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4.5 DISCUSSION 
The current study was designed with the proof-of-principle goals to:  1) test the 
administration of SPMs AT-RvD1 and RvE1 for therapeutic effect on translational 
outcomes of motor and cognitive function; 2) investigate a potential mechanism for SPM 
interactions in the injured brain by evaluating their effects upon microglial activation; 3) 
further probe the relationship between sleep and inflammation following diffuse brain 
injury in the mouse. One SPM, AT-RvD1, showed significant efficacy in mitigating the 
motor and cognitive deficits resulting from diffuse TBI. The other, RvE1, elicited a 
dramatic increase in post-traumatic sleep and tempered microglia activation without 
significantly influencing behavioral outcome compared to saline treatment. The 
divergence in histological (microglial activation) and physiological (sleep activity) 
outcomes from functional (motor and cognitive performance) outcomes suggests that 
microglial reactivity may contribute to post-traumatic sleep and that AT-RvD1 may 
achieve therapeutic efficacy through means other than inflammation resolution alone. 
Overall, SPMs demonstrate proof-of-principle as a therapeutic approach for diffuse brain 
injury, where additional studies are warranted, as described below.   
 Diffuse brain injury in humans results in long-term disabilities, including motor 
and cognitive impairments, which appreciably diminish quality of life (Arciniegas, 
Topkoff et al. 2000; Masel and DeWitt 2010). These injury-induced impairments can be 
modeled in rodents. The rotarod test has been used in the evaluation of motor function in 
rats (Hamm 2001) and mice (Fenn, Gensel et al. 2013; Harrison, Rowe et al. 2014; Rowe, 
Harrison et al. 2014), demonstrating impairments to remain on the accelerating rod 
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following diffuse TBI. In the current study, saline-treated brain-injured mice exhibited 
significant rotarod impairment compared to sham-injured mice. This impairment was also 
evident in RvE1-treated mice, but not in AT-RvD1-treated mice. Similar results were 
found in cognitive performance using the novel object recognition (NOR) test, where 
sham-injured and brain-injured AT-RvD1-treated mice investigated novel objects 
significantly more than familiar objects—indicating short term episodic recognition 
(Ennaceur and Delacour 1988)—but saline-treated and RvE1-treated brain-injured mice 
failed to recognize the familiar object.  Although no literature is available on the effects 
of SPMs on functional outcome following TBI, there are several studies which show that 
DHA and fish oil (containing both EPA and DHA) supplementation attenuate TBI-
induced motor (Desai, Kevala et al. 2014; Russell, Berman et al. 2014) and cognitive 
(Wu, Ying et al. 2011; Wu, Ying et al. 2013) deficits. The current set of studies were 
undertaken, because the neuroprotective effects of DHA and fish oil may be in part due to 
actions of their SPM derivatives, including the resolvins, lipoxins, and protectins. We 
selected two resolvins to evaluate in diffuse brain injury. To this effect, one study tested 
the therapeutic efficacy of aspirin-triggered neuroprotectin D1 (AT-NPD1), an SPM 
derived from DHA, in a rat model of experimental stroke. One i.v. dose of AT-NPD1 at 
three hours after onset of experimental stroke was sufficient to improve performance on a 
battery of tests of neurological function compared to rats treated with saline (Bazan, Eady 
et al. 2012). These data, in light of the functional improvements elicited by AT-RvD1 in 
the present manuscript, suggest that SPM derivatives may mediate the protective effects 
of omega-3 fatty acids. 
   
 
100 
 
 Clinical studies have provided evidence that TBI contributes to disorders in sleep 
regulation, including chronic sleep disturbance as well as excessive daytime sleepiness 
(Baumann, Werth et al. 2007; Castriotta, Wilde et al. 2007; Kempf, Werth et al. 2010; 
Baumann 2012). Chronic sleep issues in the rodent are unclear, with evidence both for 
(Lim, Elkind et al. 2013; Hazra, Macolino et al. 2014) and against (Rowe, Harrison et al. 
2014) sustained sleep issues. We have previously demonstrated that sleep is increased in 
the first 3-6 hours following diffuse TBI in the mouse (post-traumatic sleep) compared to 
sham, when injury was induced 3 hours after light onset (Rowe, Striz et al. 2014). In the 
present study, diffuse brain injury was delayed until 6 hours after the light onset and did 
not result in increased post-traumatic sleep among vehicle-treated mice. Therefore, the 
time of injury relative to the light:dark transition may influence post-traumatic sleep more 
than the time of day. Similarly, another study subjected mice to CCI and found that TBI 
resulted in acute decreases in wakefulness (Willie, Lim et al. 2012). It is unclear the 
cellular benefit or detriment of this acute post-traumatic sleep on recovery following TBI, 
however, we have previously shown immediate disruption of post-traumatic sleep does 
not worsen injury-induced motor or cognitive deficits (Rowe, Harrison et al. 2014) in the 
mouse. While the role of post-traumatic sleep in the pathophysiology of TBI remains 
unclear, data support a mechanistic link between inflammation and the induction of sleep 
(Krueger, Takahashi et al. 1995; Krueger, Obal et al. 2001; Krueger, Rector et al. 2007; 
Rowe, Striz et al. 2014). SPMs including RvE1 and AT-RvD1 may resolve inflammation 
resulting from TBI, as incorporated into the extended drug delivery design, and 
subsequently attenuate post-traumatic sleep disorders. 
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Presently, RvE1 treatment of TBI significantly increased post-traumatic sleep, 
without functional improvement, compared to saline-treated and AT-RvD1-treated brain-
injured mice. Further, microglial activation showed a lower proportion of rod microglia, 
with a higher proportion of ramified microglia, at 7 days post-injury when treated with 
RvE. The increase in sleep behavior and attenuation of the post-acute inflammatory 
response appear contradictory.  However, inflammation and, more recently, microglial 
activation have been implicated in sleep regulation (for review, see (Ingiosi, Opp et al. 
2013)). It has been proposed that some drugs, such as methamphetamine, exert sleep 
regulatory effects through actions on microglia (Wisor, Schmidt et al. 2011). For 
example, genetic depletion of microglia attenuated the wake-promoting effect of 
methamphetamine in mice, suggesting that the presence of microglia contributes to sleep 
regulation following cellular stress (Wisor, Schmidt et al. 2011). Clinically, intracellular 
monocyte pro-inflammatory cytokine production was correlated with sleep modulation 
(Thomas, Motivala et al. 2011). In the present study, post-traumatic sleep could increase 
in RvE1-treated mice with reduced post-acute microglial activation because of the delay 
between measurements, non-inflammatory sleep pressures, or unknown physiological 
mechanisms that also contributed to the higher mortality in RvE1 mice. Further, analysis 
of microglia morphology is only one indirect index of inflammation; direct measurement 
of inflammation-mediating cytokines would improve our understanding of the cellular 
processes involved. It remains likely that increased post-traumatic sleep of RvE1-treated 
mice, possibly a protective response, may promote resolution of inflammation as 
indicated by fewer activated rod microglia, albeit without functional benefit. Since sleep 
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disruption results in microglial activation (Hsu, Lee et al. 2003) without worsening 
functional outcome after diffuse TBI in mice (Rowe, Harrison et al. 2014), the effect of 
disrupting post-traumatic sleep in RvE1 treated mice would be intriguing. 
While electroencephalographic (EEG) recording offers insight into sleep quality 
and stage, the piezoelectric sleep monitoring system offers a non-invasive approach to 
only quantify wakefulness and sleep durations, concordant with EEG analysis (Mang, 
Nicod et al. 2014). It is unclear how TBI or resolvin treatment may independently alter 
respiratory rate and confound the algorithmic detection of sleep, but we have previously 
demonstrated that the piezoelectric sleep system detects discrete bouts of 3 Hz breathing 
classified as sleep following mFPI. Further, post-traumatic sleep was not continuous and 
was interleaved with periods classified as wake and movement(Rowe, Striz et al. 2014). 
Sham-injured mice treated with either RvE1 or AT-RvD1 did not show changes in sleep 
pattern compared to vehicle treated mice. 
 Of the SPMs investigated in the current study, RvE1 solely tempered microglial 
reactivity while AT-RvD1 solely reduced the functional consequences of diffuse brain 
injury. Because selective results were obtained, the mechanism through which SPMs 
imparts functional benefit may not be through resolution of inflammation alone. In 
various experimental paradigms, resolvins and protectins have been implicated in 
reducing the deleterious effects of oxidative stress (Wang, Yuan et al. 2014), a 
recognized component of TBI pathophysiology. Further research is warranted to 
determine the mechanism(s) through which AT-RvD1 improved functional outcome from 
TBI. Regardless, the omega-3 fatty acids and likely their derivatives can impart 
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functional recovery from TBI (Hasadsri, Wang et al. 2013), indicating that each 
derivative may target a specific pathophysiological process in a combination therapy 
manner. 
A systematic isobolographic approach could combine the two (or more) 
treatments in varying concentrations for different groups of animals to better study 
synergistic drug effects (Tallarida 2012). This method has been suggested as a valid 
method of detecting beneficial drug-drug interactions in the development of therapies for 
TBI (Shear and Tortella 2013). An isobolographic analysis of RvE1 and AT-RvD1 could 
potentially shed light on the interactions among post-traumatic sleep, inflammation, and 
functional outcome. Yet, this study may serve to caution against dissecting a pleotropic 
drug at the expense of separating specific effects and mechanisms. 
As the first study to specifically assess the effects of resolvins in experimental 
TBI, several factors should be taken into consideration in future studies. The current 
proof of principle design could be refined to optimize the resolvin dosing with respect to 
the time of injury. Additionally, no literature is available on the most effective or 
biologically applicable dosing of synthetic resolvins with respect to acute neurological 
injury. One study administered AT-RvD1 (i.v. 300ng/mouse) in a mouse model of 
fibromyalgia (Klein, Sperotto et al. 2014) while another study administered the 
comparable docosanoid neuroprotectin D1 (i.v. at 333 µg/kg) in a rat model of cerebral 
ischemia (Bazan, Eady et al. 2012). The current study falls between these wide margins 
of 12.5 µg/kg and 333 µg/kg respectively with a cumulative intraperitoneal dose of 
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~30µg/kg (700 ng/mouse). Further studies are warranted on the most appropriate 
administration and dosing schedules of lipid mediators. 
4.6 CONCLUSIONS 
In the diffuse brain-injured mouse, AT-RvD1 treatment, but not RvE1, mitigated 
motor and cognitive deficits. RvE1 treatment significantly increased post-traumatic sleep 
in comparison to all other groups. RvE1 treated mice displayed a higher proportion of 
ramified microglia and lower proportion of rod microglia in the cortex compared to saline 
or AT-RvD1 treated brain-injured mice. Increased post-traumatic sleep in the RvE1-
treated brain-injured mice may be associated with active resolution of acute 
inflammation. We demonstrate that modulation of post-traumatic sleep and the 
inflammatory response to TBI seen in RvE1-treated mice were accomplished 
independently of improvement in motor and cognitive outcome as seen in AT-RvD1-
treated mice. This suggests AT-RvD1 may impart neuroprotection through mechanisms 
other than inflammation resolution alone. 
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CHAPTER 5 
5 REMOTE ISCHEMIC CONDITIONING FOLLOWING DIFFUSE TBI IN THE 
MOUSE: ASSESSMENT OF FUNCTIONAL OUTCOME AND IDENTIFICATION OF 
PLASMA PROTEIN CORRELATES  
5.1 ABSTRACT 
 Millions of Americans sustain traumatic brain injuries (TBI) each year without 
seeking professional medical care. The secondary injury cascades of TBI begin 
immediately following injury and can persist for days to weeks. There is a need for 
practical therapies to prevent further secondary injury which can be applied while in 
transit to a medical facility or by an individual who would otherwise not seek medical 
care. Recent studies have shown remote ischemic conditioning (RIC) to have wide 
ranging protective effects in studies from stroke to cardiovascular infarct. This low-cost, 
universally-available, nontoxic therapy could be used to lessen the chronic consequences 
of TBI. RIC requires only a tourniquet or blood pressure cuff to transiently restrict blood 
flow to a limb in approximately four cycles of restriction and reperfusion. In the current 
study, we test RIC efficacy on functional outcome after fluid percussion brain injury in 
the mouse. Further, we use untargeted mass spectrometry proteomic analysis of plasma 
from RIC-treated mice to identify molecular correlates this therapeutic intervention. 
Diffuse brain injury in the mouse resulted in acute post-injury sensorimotor impairments 
regardless of RIC treatment. No TBI-induced cognitive or affective deficits were detected 
by 14 days post-injury. Proteomic analysis identified multiple proteins impacted by 
treatment group (TBI and RIC), including promising candidate proteins which appear 
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selectively responsive to RIC. These results represent a first-of-kind objective evaluation 
of potential RIC protein correlates and serve to inform future studies of the presently 
unclear mechanism underlying RIC efficacy. 
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5.2 INTRODUCTION 
In the United States alone, traumatic brain injury (TBI) affects approximately 1.7 
million individuals each year (Faul, Xu et al. 2010). No pharmacological or other 
treatments are available for individuals who suffer the lifelong neurological morbidities 
associated with TBI; clinical interventions have focused on prevention and symptom 
treatment rather than restoration of function after TBI. The lingering consequences of 
TBI include cognitive, motor, and emotional dysfunction. In this exploratory chapter, we 
assess a low-cost, universally-available, nontoxic therapy which could be used to lessen 
the chronic consequences of TBI – Remote Ischemic Conditioning (RIC). RIC requires 
only a tourniquet or blood pressure cuff to transiently restrict blood flow to a limb in 
approximately four cycles of restriction and reperfusion. From this simple intervention, 
we propose that restorative and regenerative bioactive molecules serve to reduce the 
secondary injury processes which would otherwise exacerbate the injury and worsen 
outcome. In addition to assessing RIC efficacy in a battery of behavioral tests following 
diffuse brain injury in the mouse, the current manuscript uses untargeted discovery 
proteomic analysis of plasma to elucidate circulating protein correlates of RIC. 
Minor ischemic injury in the brain protects from subsequent severe ischemic 
events (Shamloo, Rytter et al. 1999; Shamloo and Wieloch 1999; Shamloo and Wieloch 
1999; Tomasevic, Shamloo et al. 1999). In humans, though, even a transient ischemic 
attack can result in chronic cognitive impairment (van Rooij, Schaapsmeerders et al. 
2014). To translate a minor ischemic event into a safe therapy for various acute 
conditions, RIC is broadly defined as transiently occluding blood flow to an organ or 
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body part to impart protection in a distant organ or body part. Literature on RIC is varied 
in terms of the applied location, intended target of therapy, and timing of experimental 
RIC. RIC has been applied to the lower limb (Cheung, Kharbanda et al. 2006; Dave, Saul 
et al. 2006; Peng, Guo et al. 2012; Sun, Tong et al. 2012), upper limb (Gunaydin, Cakici 
et al. 2000; Kharbanda, Mortensen et al. 2002), kidney (Pell, Baxter et al. 1998), and liver 
(Peralta, Serafin et al. 2003), among others to protect the brain (Dave, Saul et al. 2006; 
Peng, Guo et al. 2012; Sun, Tong et al. 2012) and heart (Oxman, Arad et al. 1997; 
Cheung, Kharbanda et al. 2006), primarily. For cerebral ischemia, the timing of RIC has 
included a spectrum of pre-insult (Wang, Birch et al. 2010; Wang, Yu et al. 2013) and 
post-insult (Peng, Guo et al. 2012; Pignataro, Esposito et al. 2013) sequences to achieve 
efficacy. In a proof-of-principle clinical study that illustrated the feasibility of RIC as a 
pre-hospital therapy, 333 patients with suspected myocardial infarction were treated with 
RIC or no RIC while in transit to the hospital. Simply, a blood pressure cuff was placed 
on the arm and inflated through four 5 minute cycles interleaved with 5 minute 
reperfusion intervals. Patients treated with RIC had significantly greater cardiac salvage 
rates and did not experience any RIC-related adverse effects (Botker, Kharbanda et al. 
2010). These laboratory and clinical studies establish the need for investigation of RIC as 
an early intervention for TBI. 
It is likely that RIC has both long-lasting and fast-acting effects based on 
experimental studies demonstrating efficacy of both pre- and post-injury application. This 
first quality may make it ideal as a routine prophylactic conditioning regimen for 
individuals at high risk for TBI, including active-duty military personnel and athletes. 
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The second quality may make it ideal to implement for pre-hospital care at the scene of 
an injury or during transport. The current study includes translationally relevant measures 
of outcome, focusing on cognitive, motor, and affective dysfunction to detect both acute 
and chronic morbidities following diffuse TBI in the mouse. Additionally, we propose to 
explore the mechanisms of RIC action through discovery proteomics. Currently, the 
mechanism(s) through which RIC imparts protection is unclear (Tapuria, Kumar et al. 
2008). Conflicting reports suggest that RIC may work through nitric oxide (Kuntscher, 
Kastell et al. 2003), opioid receptors (Addison, Neligan et al. 2003), potassium ATP 
channels (Xia, Herijgers et al. 2003), inflammatory cytokines (Harkin, Barros D'Sa et al. 
2002), or free radicals (Chen, Wu et al. 2005). A vital first step in understanding RIC 
mechanism(s) is the unbiased identification of circulating plasma protein correlates of 
RIC. In an open-ended hypothesis-generating approach, here we use mass spectrometry 
to perform untargeted proteomic analysis of plasma from RIC-treated mice. Protein and 
pathway candidates identified as enriched by RIC will allow for follow-up hypotheses 
regarding the mechanistic underpinnings of the therapy. These hypotheses are anticipated 
to be testable using positive and/or negative genetic manipulation of identified proteins to 
understand their role in RIC efficacy. Ultimately, RIC could serve as a cost-effective and 
feasible therapy to restore function after TBI and other acute neurological conditions. 
5.3 METHODS 
5.3.1 Animals 
Male C57BL/6 mice (Harlan Laboratories, Inc., Indianapolis, IN) were used for 
behavioral and mass spectrometry experiments (n=47). Mice were housed in a 12 h 
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light/12h dark cycle at a constant temperature (23°C ± 2° C) with food and water 
available ad libitum according to the Association for Assessment and Accreditation of 
Laboratory Animal Care International. All mice used in this study were group housed. 
Mice were acclimated to their environment following shipment for at least three days 
prior to any experiments. After surgery, mice were evaluated daily during post-operative 
care by a physical examination and documentation of each animal‘s condition including 
weight. Animal care was approved by the University of Arizona Institutional Animal 
Care and Use Committee. 
5.3.2 Midline Fluid Percussion Injury 
Mice (20-24g) were subjected to midline fluid percussion injury (mFPI) 
consistent with methods previously described (Lifshitz 2008; Harrison, Rowe et al. 2014; 
Rowe, Harrison et al. 2014; Rowe, Harrison et al. 2014; Rowe, Striz et al. 2014). Group 
sizes are indicated in the results section and figure legends for individual studies. Mice 
were anesthetized using 5% isoflurane in 100% oxygen for five minutes and the head of 
the mouse was placed in a stereotaxic frame with continuously delivered isoflurane at 
2.5% via nosecone. While anesthetized, body temperature was maintained using a 
Deltaphase
®
 isothermal heating pad (Braintree Scientific Inc., Braintree, MA). A midline 
incision was made exposing bregma and lambda, and fascia was removed from the 
surface of the skull. A trephine (3 mm outer diameter) was used for the craniotomy, 
centered on the sagittal suture between bregma and lambda without disruption of the 
dura. An injury cap prepared from the female portion of a Luer-Loc needle hub was fixed 
over the craniotomy using cyanoacrylate gel and methyl-methacrylate (Hygenic Corp., 
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Akron, OH). The incision was sutured at the anterior and posterior edges and topical 
Lidocaine ointment was applied. The injury hub was closed using a Luer-Loc cap and 
mice were placed in a heated recovery cage and monitored until ambulatory before being 
returned to their home cage. 
For injury induction 24 hours post-surgery, mice were re-anesthetized with 5% 
isoflurane delivered for five minutes. The cap was removed from the injury-hub assembly 
and the dura was visually inspected through the hub to make sure it was intact with no 
debris. The hub was then filled with normal saline and attached to an extension tube 
connected to the male end of the fluid percussion device (Custom Design and 
Fabrication, Virginia Commonwealth University, Richmond, VA). An injury of moderate 
severity for our injury model (1.4 atm) was administered by releasing the pendulum onto 
the fluid-filled cylinder. Sham-injured mice underwent the same procedure except the 
pendulum was not released. Mice were monitored for the presence of a forearm fencing 
response and righting reflex times were recorded for the injured mice as indicators of 
injury severity (Hosseini and Lifshitz 2009). The righting reflex time is the total time 
from the initial impact until the mouse spontaneously rights itself from a supine position. 
The fencing response is a tonic posturing characterized by extension and flexion of 
opposite arms that has been validated as an overt indicator of injury severity (Hosseini 
and Lifshitz 2009). The injury hub was removed and the brain was inspected for uniform 
herniation and integrity of the dura. The dura was intact in all mice; none were excluded 
as technical failures. The incision was cleaned using saline and closed using sutures. 
Moderate brain-injured mice had righting reflex recovery times greater than six minutes 
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and a positive fencing response. Sham injured mice recovered a righting reflex within 20 
seconds. After spontaneously righting, mice were placed in a heated recovery cage and 
monitored until ambulatory (approximately 5 to 15 minutes) before being returned to 
their home cage. Adequate measures were taken to minimize pain or discomfort. 
5.3.3 Remote Ischemic Conditioning 
Remote ischemic conditioning was administered 15 to 30 minutes following 
recovery of righting reflex after mFPI. Anesthesia was induced using 5% isoflurane in 
100% oxygen for three minutes. Mice were placed in a supine position and light 
anesthesia was maintained throughout the RIC procedure using 1.5% isoflurane in 100% 
oxygen via nosecone. RIC was applied using a disposable plastic coated wire tie (100mm 
L x 2mm diameter). With the left mouse hindlimb extended at the knee, a wire tie was 
wrapped around the hindlimb as proximally to the hip as possible. Pressure was applied 
by twisting the wire tie approximately four times clockwise. RIC was administered in 
four cycles composed of 5 minutes RIC and 5 minutes reperfusion. Mice were monitored 
while recovering from anesthesia before being returned to their home cage. Non-RIC 
treated sham and TBI groups received equal anesthesia treatment without wire tie 
application. For additional information on the development and further refinement of 
non-invasive rodent RIC procedures, see Appendix B. 
5.3.4 Behavioral Testing 
 Mice were tested for sensorimotor function using the rotarod and neurological 
severity score at 1 and 7 days post-injury. Cognitive and affective function were assessed 
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using novel object recognition, open field test, elevated plus maze, and forced swim test 
at 14 days post-injury. 
Rotarod: Sensorimotor function was assessed using the Economex Rotarod 
system from Columbus Instruments (Columbus, OH). Mice were pre-trained for three 
consecutive days prior to injury: day one included habituation to a non-accelerating rod at 
5RPM while days two and three of training were conducted as normal test days with day 
3 scores used as baseline performance. For the test (1 and 7 days post-injury), mice were 
placed on the rod with a starting speed of 5 RPM, and rod rotation speed was 
continuously increased by 0.2 RPM per second. The trial concluded when the mouse fell 
from the rod. Three trials were performed at each time point. Data are presented as 
latency to fall in seconds (average of two highest latencies from a single time point). 
Neurological Severity Score (NSS): Post-traumatic neurological impairments 
were assessed using an 8-point NSS paradigm adapted from those previously used in 
experimental models of TBI (Chen, Constantini et al. 1996; Semple, Bye et al. 2010; 
Pleasant, Carlson et al. 2011; Ziebell, Bye et al. 2011). One point was given for failure on 
an individual task, and no points were given if a mouse completed a task successfully. 
Mice were observed for hind limb flexion, startle reflex, and seeking behavior (presence 
of these behaviors was considered successful task completion). Mice traversed in 
sequence, 3, 2, and 1 centimeter beams. The beams were elevated and mice were given 1 
minute to travel 30 centimeters on the beams. The task was scored as a success if the 
mouse traveled 30 centimeters with normal forelimb and hindlimb position 
(forelimb/hindlimb did not fall from the beam). Mice were also required to balance on a 
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0.5 centimeter beam and a 0.5 centimeter round rod for 3 seconds in a stationary position 
with front paws between hind paws. Non-parametric data are presented as a composite 
score ranging from 0 to 8 representing performance on all tasks combined. High final 
NSS scores were indicative of task failure and interpreted as neurological impairment. 
Novel Object Recognition (NOR): Cognitive impairment was tested using the 
NOR test as previously published (Ennaceur and Aggleton 1997; Han, Tong et al. 2011; 
Rowe, Harrison et al. 2014). The test consisted of three phases: habituation, training, and 
testing. On day 6 post-injury, mice were placed in an open field (40 cm x 40 cm x 30 cm, 
L x W x H) for fifteen minutes of habituation. Mice were removed and two identical 
objects were placed in opposing quadrants of the field for the training phase. Mice were 
returned to the center of the open field and given 5 minutes to explore the objects. 
Following training, mice were returned to their home cages. Testing began 4 hours after 
training. One familiar object was placed in an original location and one novel object was 
placed in the opposing quadrant of the open field. Mice were placed into the center and 
given 5 minutes to explore. Exploration behaviors were scored during testing using 
Noldus EthoVision XT (Noldus Information Technology Inc., Leesburg, VA). Custom 
zones approximately 2cm larger than each object were placed and exploration of an 
object was defined as the duration the mouse nose point was detected in this zone. 
Testing data are displayed as a discrimination index (DI) in which DI = (Tnovel - 
Tfamiliar)/(Tnovel + Tfamiliar). A positive DI indicates greater exploration time of the novel 
object compared to the familiar object. 
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Open field test: The open field task was used to assess anxiety-like behavior. At 
14 days after injury, mice were placed in the center of an open field (40cm x 40cm x 
30cm, L x W x H) and allowed to explore freely for 5 min. Their movement was tracked 
by an overhead camera and the distance traveled, time spent in the center of the arena (20 
× 20 cm), and number of entries into the center were calculated using EthoVision XT 
(Noldus Information Technology Inc., Leesburg, Va., USA). 
Forced swim test: Depression-like behavior was assessed using the forced swim 
task. Mice were placed into glass cylinders (20cm x 15cm, L x Diameter) filled with 
water (25°C) for 6 min. The first minute was excluded from analysis as an acclimation 
phase. Mice were recorded using an overhead camera. Videos were scored by an 
individual blinded to treatment groups for time spent mobile vs immobile. 
Elevated plus maze: Anxiety-like behavior was assessed using the elevated plus 
maze. Mice were placed into the center of a custom elevated plus maze comprised of two 
enclosed arms (25cm high walls) and two open arms of 8cm width meeting at a neutral 
zone (8cm x 8cm, L x W). Mice were recorded using an overhead camera while 
exploring the maze for 5 minutes. Noldus EthoVision XT (Noldus Information 
Technology Inc., Leesburg, Va., USA) was used to track the cumulative duration mice 
spent in closed and open arms. 
5.3.5 Untargeted Proteomic Analysis 
 Blood was collected from the same cohort of mice from behavioral studies via 
cheek bleed 24 hours following the administration of RIC (and TBI or sham). Blood was 
collected into EDTA-coated microcentrifuge tubes and immediately stored on ice. Plasma 
   
 
116 
 
was separated by centrifugation at 3,000 x g for 10 minutes and immediately stored at -
80C until use. High abundance proteins were removed from plasma samples using 
Seppro Mouse M7 spin columns (Sigma-Aldrich, St. Louis, Missouri) to increase 
resolution of low abundance proteins of interest. A buffer exchange was conducted to 
remove unwanted buffers from the Seppro column prior to digestion. Protein 
concentration was quantified using Pierce BCA (Thermo Fisher Scientific, Waltham, 
MA). Equal amounts of protein were brought into in-solution digestion, starting with urea 
to denature the proteins. Dithiothreitol (DTT) was added to reduce the proteins, followed 
by iodoacetemide to alkylate the proteins. Trypsin Gold was used to digest the proteins 
into peptides (Promega Corporation, Madison, WI). Samples were desalted to remove 
digestion agents and remaining salts. Protein concentration was quantified again by BCA 
and all injections were aligned to 1ug of peptides. 
LC-MS/MS data were acquired on a tribrid quadrupole-ion trap-Orbitrap 
instrument (Orbitrap Fusion Lumos, Thermo, San Jose, CA) interfaced with a 
nanoAcquity UPLC system (Waters, Millford-MA). Samples were first loaded on a 
trapping column (Acclaim PepMap 100 C18, 75 µm ID * 2 cm, 3 µm particle size, 100 Å 
pore size) and washed for 10 minutes with 99.5% Solvent A (0.1% formic acid in water) 
and 0.5% Solvent B (0.1% formic acid in acetonitrile) at a flow rate of 4 µl/min. The 
trapped peptides were transferred to an analytical column (PepMap RSLC C18, 50 µm ID 
* 15 cm, 2 µm particle size, 100 Å pore size) and eluted at a flow rate of 300 nl/min 
using the following gradient: 3% to 7% B in 1 minute, 7% to 25% B in 72 minutes, 25% 
B to 45% B in 10 minutes, 45% to 90% B in 0.5 minutes, 90% B for 1 minute, 3% B in 
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0.5 minute and re-equilibration for 10 minutes. Data-dependent acquisition was 
performed in Top Speed mode with a duty cycle of 3 seconds and following parameters: 
spray voltage of 2100V, ion transfer tube temperature of 275 °C, survey scan in the 
Orbitrap at a resolution of 120K at 200 m/z, scan range of 400-1500 m/z, AGC target of 
2E5 and maximum ion injection time of 50 ms. Every parent scan was followed by a 
daughter scan using High Energy Collision (HCD) dissociation of top abundant peaks 
and detection in the iontrap with the following settings: quadrupole isolation mode, 
isolation window at 1.4 m/z, AGC target of 5E3 with maximum ion injection time of 35 
ms and HCD collision energy of 35%. Dynamic exclusion was set to 60 seconds. Twelve 
standard controls of E. coli proteome analysis were conducted in which no anomalous 
variation was detected (data not shown). Peptide spectrum peaks were used to calculate 
area under the curve for relative abundance comparisons. Protein identification and 
relative quantification was conducted with Proteome Discoverer v2.1 (Thermo Fisher 
Scientific, Waltham, MA) and Mascot v2.3 (Matrix Science, Boston, MA) using the 
Mouse SwissProt 2015 database. 
5.3.5 Statistical Analysis 
 Data shown were analyzed using GraphPad Prism 6, with statistical significance 
assigned when p<0.05, unless otherwise indicated. For each behavioral test, shams 
receiving each treatment were statistically compared. No differences were detected 
between sham groups (RIC and no-RIC). To maintain comparable group sizes for these 
studies, a pooled sham group was constructed by combining all mice from each group. 
Differences in open field, elevated plus maze, and novel object recognition were 
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determined with a one-way ANOVA followed by Dunnett‘s multiple comparisons test. 
Differences in rotarod performance following TBI over the first week post-injury were 
determined with a repeated measure two-way ANOVA followed by Dunnett‘s multiple 
comparisons test. Differences in neurological severity scores were determined at each 
testing time point by Kruskal-Wallis test. Differences in relative abundance (area under 
the curve) of proteins identified by mass spectrometry were determined between groups 
by Mann-Whitney U test. 
5.4 RESULTS 
5.4.1 Diffuse TBI resulted in acute sensorimotor impairment regardless of RIC treatment 
 Sensorimotor function was assessed at days 1 and 7 post-injury using the 
Neurological Severity Score (NSS) and rotarod tests (Figure 5.1). At 1 day post-injury, 
there was a significant main effect of treatment on the NSS (KW(3,39)=13.91, p=0.001) 
with post-hoc analysis indicating significantly higher NSS scores among TBI and 
TBI+RIC groups when compared to sham (p<0.05). While the main effect of treatment 
remained significant at 7 days post-injury in the NSS (KW(3,39)=8.477), post-hoc 
analysis indicated that neither TBI nor TBI+RIC were individually significantly higher 
than sham (p>0.05). Similarly, the rotarod test showed an overall effect of treatment 
group on latency (F(2,35)=3.314, p=0.0481) with specific effects indicating latencies 
from both TBI and TBI+RIC groups were lower than sham at 1 day post-injury (p<0.05). 
These specific effects dissipated by 7 days post-injury when both groups returned to 
sham level (p<0.05). 
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5.4.2 Diffuse TBI did not result in cognitive or affective impairments at 14 days post-
injury 
 To test for potential therapeutic effects of RIC, mice were subjected to a battery 
of cognitive and affective behavioral tests at 14 days post-injury (Figure 5.2). All groups 
spent more time exploring novel rather than familiar objects with no effect of TBI or RIC 
treatment (F(2,35)=0.7944, p=0.460). No anxiety-like behaviors were detected among 
brain-injured groups compared to sham as measured by time in the center of the open 
field test (F(2,35)=0.4097, p=0.667) or open arms of the elevated plus maze 
(F(2,35)=0.9961, p=0.905). Demonstrating no TBI-induced depression-like behaviors, all 
groups performed similarly in time spent immobile during the forced swim test 
(F(2,35)=0.1634, p=0.850). 
5.4.3 Mass spectrometry identified candidate protein correlates of RIC in plasma 
 Untargeted proteomic analysis was performed by mass spectrometry of plasma 
collected 24 hours following RIC administration. 565 unique proteins were identified 
among all samples with an average of 227 unique proteins identified per sample. Four 
analyses were conducted to identify proteins which were most increased or decreased in 
response to RIC among sham and brain-injured mice. For each of these comparisons, the 
ten proteins with the greatest absolute value fold-change were identified along with 
proteins identified exclusively in one comparison group. For sham mice, these data are 
presented for proteins which were increased (Table 5.1) and decreased (Table 5.2) among 
RIC treated mice. For brain-injured mice, these data are presented for proteins which 
were increased (Table 5.3) and decreased (Table 5.4) among RIC treated mice. 
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Figure 5.1. Diffuse TBI resulted in acute sensorimotor deficits regardless of RIC 
treatment. 
The Neurological Severity Score (NSS) indicated sensorimotor impairment among both 
TBI and TBI+RIC groups compared to sham at 1 day post-injury which resolved by 7 
days post-injury (A). Similarly, the rotarod detected acute motor deficits among TBI and 
TBI+RIC groups which resolved by 7 days post-injury regardless of treatment (B). (Sham 
n=14, TBI n=12, TBI+RIC n=12) 
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Figure 5.2. Diffuse TBI did not result in cognitive or affective impairment at 14 
days-post injury. 
All groups of mice investigated novel objects more than familiar objects presented in the 
novel object recognition (NOR) task, indicating no cognitive impairment (A). No TBI- or 
RIC-induced changes in anxiety-like behavior were detected in the open field test (B) or 
elevated plus maze (C). No TBI- or RIC-induced changes in depression-like behaviors 
were indicated by the forced swim test (D). (Sham n=14, TBI n=12, TBI+RIC n=12) 
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A Mann-Whitney U test indicated that RIC resulted in increased selenium-binding 
protein 1 (Fold-change=10.7, U=13.50, p=0.0256) and regenerating islet-derived protein 
3-gamma (Fold-change=3.5, U=12.00, p=0.0348) among sham mice. Keratin, type II 
cytoskeletal 5, was identified as significantly decreased following RIC among sham mice 
(Fold-change=-63.8, U=9.00, p=0.0070). In the context of TBI, mice treated with RIC 
demonstrated significantly higher levels of selenium-binding protein 1 (fold-
change=90.2, U=27.50, p=0.0072), adipocyte fatty acid binding protein (Fold-
change=60.1, U=27.50, p=0.0072), and bisphosphoglycerate mutase (Fold-change=26.1, 
U=38.50, p=0.0363). 
 Two proteins were identified as being particularly responsive to RIC regardless of 
TBI. Selenium-binding protein 1 and adipocyte fatty acid-binding protein were each 
identified in more than 50% of RIC plasma samples (Figure 5.3). Fatty acid-binding 
protein was identified in 71.4% of total RIC samples (Sham+RIC and TBI+RIC) and 
only 21.7% of non-RIC samples (Naïve, Sham, and TBI). Similarly, selenium-binding 
protein 1 was identified in 61.9% of total RIC samples but only 13.0% of non-RIC 
samples. Significant overall group effects were detected among selenium-binding protein 
1 (KW(5,44)=19.44, p=0.0007) and fatty-acid binding protein (KW(5,44)=12.06, 
p=0.0025). 
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Table 5.1. Proteins increased in Sham+RIC vs Sham groups. 
Protein Fold Change p-value 
Uteroglobin 12.8 0.1406 
Hyaluronan-binding protein 2 12.7 0.7128 
Selenium-binding protein 1 10.7 0.0256 
Ig gamma-2B chain C region 10.7 0.7128 
Fructose-1,6-bisphosphatase 1 6.4 0.4667 
Phosphoglycerate mutase 1 5.4 0.7128 
Sorbitol dehydrogenase 4.8 > 0.9999 
BPI fold-containing family A member 2 4.7 0.5692 
Proteasome subunit beta type-1 4.7 0.0350 
Regenerating islet-derived protein 3-gamma 3.5 0.0348 
Identified only in Sham+RIC % Samples  
Afamin 100.0%  
Proteoglycan 4 50.0%  
Neuroplastin 37.5%  
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA 37.5%  
 
The top ten proteins most increased in relative abundance among Sham+RIC treated mice 
in comparison to Sham mice are displayed with respective fold increases. Four proteins 
were identified in Sham+RIC mice but not Sham mice. Resulting statistical p-values from 
the Mann-Whitney U test are presented. 
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Table 5.2. Proteins decreased in Sham+RIC vs Sham groups. 
Protein Fold Change p-value 
Keratin, type II cytoskeletal 5 -63.8 0.0070 
Cathepsin Z -59.1 0.0256 
Dynein heavy chain 12, axonemal -13.7 0.7333 
Proteasome subunit alpha type-2 -13.2 0.4667 
Keratin, type II cytoskeletal 2 oral -4.8 0.4517 
Keratin, type II cytoskeletal 79 -4.1 0.3538 
Neuropilin-1 -3.5 0.2000 
Ig heavy chain V region M167 -3.4 0.4126 
Insulin-like growth factor-binding protein 4 -3.3 0.1515 
Protein S100-A8 -3.1 0.3231 
Identified only in Sham (no RIC) % Samples  
Isoform 3 of Afamin 100.0%  
Isoform C of Proteoglycan 4 75.0%  
Platelet-activating factor acetylhydrolase 50.0%  
Cytoskeleton-associated protein 2  50.0%  
Ig gamma-1 chain C region, membrane-bound form 50.0%  
RUN domain-containing protein 3A 37.5%  
Transcription factor IIIB 50 kDa subunit 50.0%  
Thrombospondin-1 37.5%  
Vigilin 37.5%  
Corepressor interacting with RBPJ 1 37.5%  
Myosin-1 37.5%  
Adhesion G protein-coupled receptor F5 37.5%  
 
The top ten proteins most decreased in relative abundance among Sham+RIC treated 
mice in comparison to Sham mice are displayed with respective fold decreases. Twelve 
proteins were identified in Sham mice but not Sham+RIC mice. Resulting statistical p-
values from the Mann-Whitney U test are presented. 
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Table 5.3. Proteins increased in TBI+RIC vs TBI groups. 
Protein Fold Change p-value 
Selenium-binding protein 1 90.2 0.0072 
Cofilin-1  77.2 0.1694 
Alpha-enolase  69.7 0.0728 
Fatty acid-binding protein, adipocyte 60.1 0.0072 
Phosphoglycerate kinase 1  41.7 0.7064 
Alpha-synuclein  31.7 0.3614 
Proteasome subunit beta type-3  29.0 0.7064 
S-formylglutathione hydrolase 29.0 0.3614 
Bisphosphoglycerate mutase 26.1 0.0363 
Peroxiredoxin-1 15.2 0.6730 
Identified only in TBI+RIC % Samples  
Isoform 2 of Ig mu chain C region 100.0%  
Isoform C of Proteoglycan 4 84.6%  
Actin, alpha cardiac muscle 1 76.9%  
Protein S100-A8 38.5%  
Neuroplastin 30.8%  
Peroxiredoxin-6  30.8%  
Coagulation factor XI  30.8%  
Protein CDV3 30.8%  
Parvalbumin alpha 30.8%  
Osteopontin 23.1%  
Transcobalamin-2 23.1%  
Acyl-CoA-binding protein 23.1%  
Phosphoglycerate mutase 1 23.1%  
Napsin-A 23.1%  
Beta-enolase 23.1%  
Isoform 2 of Adenylosuccinate synthetase isozyme 1 23.1%  
Stress-induced-phosphoprotein 1 23.1%  
Thymosin beta-4 23.1%  
Chitinase-like protein 3 23.1%  
Vasopressin-neurophysin 2-copeptin 23.1%  
Vasorin 23.1%  
 
The top ten proteins most increased in relative abundance among TBI+RIC treated mice 
in comparison to TBI mice are displayed with respective fold increases. Twenty one 
proteins were identified in TBI+RIC mice but not TBI mice. Resulting statistical p-values 
from the Mann-Whitney U test are presented. 
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Table 5.4. Proteins decreased in TBI+RIC vs TBI groups. 
Protein Fold Change p-value 
Keratin, type II cytoskeletal 5 -321.1 0.0005 
Ig heavy chain V region M167 -38.6 0.0715 
Platelet-activating factor acetylhydrolase -26.2 0.1925 
Keratin, type II cytoskeletal 2 oral -21.0 0.0715 
Serine protease inhibitor Kazal-type 3 -18.2 > 0.9999 
Vitamin K-dependent protein Z -11.3 0.2103 
BPI fold-containing family A member 2  -10.1 0.9618 
Flavin reductase (NADPH) -8.7 0.4495 
Hyaluronan-binding protein 2 -8.4 0.9108 
Complement C1q subcomponent subunit A -8.2 0.0407 
Identified only in TBI (no RIC) % Samples  
Ig mu chain C region  100.0%  
Proteoglycan 4 90.0%  
Actin, alpha skeletal muscle  80.0%  
Corepressor interacting with RBPJ 1 60.0%  
Transcription factor IIIB 50 kDa subunit 60.0%  
 
The top ten proteins most decreased in relative abundance among TBI+RIC treated mice 
in comparison to TBI mice are displayed with respective fold decreases. Five proteins 
were identified in TBI mice but not TBI+RIC mice. Resulting statistical p-values from 
the Mann-Whitney U test are presented. 
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Figure 5.3. Selenium-binding protein 1 and fatty-acid binding protein are selectively 
responsive to RIC. 
Relative abundance of selenium-binding protein 1 (A) and fatty-acid binding protein (B) 
are indicated for all samples. Percentage of samples in which the protein of interest was 
identified is displayed with those of RIC-treated groups shown in red. (Naïve n=5, Sham 
n=8, Sham+RIC n=8, TBI n=10, TBI+RIC n=13) 
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5.5 DISCUSSION 
 The current study was designed with two aims: (1) assess the therapeutic potential 
of RIC in a mouse model of diffuse TBI and (2) identify molecular correlates of RIC. 
RIC did not prevent very acute sensorimotor impairments resulting from diffuse TBI. The 
lack of TBI-induced cognitive or affective deficits at the selected time points precluded 
assessment of RIC efficacy in these domains. Despite the lack of positive proof of RIC 
efficacy in improving behavioral outcome in this model of TBI, the body of literature 
supporting RIC efficacy in multiple domains warranted further study of RIC mechanism. 
Untargeted proteomic analysis identified multiple proteins differentially impacted by TBI 
and/or RIC, including promising candidate proteins which responded selectively to RIC 
regardless of TBI. Overall, these findings lay a vital groundwork for advancing 
understandings of RIC mechanism by starting with an objective and hypothesis-
generating analytical chemistry approach. 
 The findings of acute sensorimotor dysfunction from the current study reflect 
previous findings from our group (Harrison, Rowe et al. 2014; Harrison, Rowe et al. 
2015). Though previous findings from our group have demonstrated cognitive 
impairment resulting from diffuse TBI in the mouse (Harrison, Rowe et al. 2015), these 
studies were conducted at earlier time points within one week of injury as opposed to two 
weeks in the current study. The later time point was selected for the current study to 
assess more translationally relevant long-term outcome. Few studies have addressed the 
effect of RIC on functional outcome from brain injury. A recent study of closed head 
injury in mice indicated that RIC prevented acute motor deficits in the rotarod and acute 
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cognitive deficits in the NOR test (Sandweiss, Azim et al. 2017). One important 
limitation of this study was the exclusion of any non-brain-injured controls for 
comparison. Differences in findings from the current study could also be due to 
differences in the time course of cognitive impairment assessment, with the 
aforementioned study testing only within the first week post-injury. A study using the 
bilateral common carotid artery occlusion (BCCAO) model of cerebral 
ischemia/reperfusion injury indicated no effect of RIC on spontaneous motor activity but 
a protective effect of RIC on associative learning (Wang, Zhang et al. 2017). Differences 
in injury models, time of behavioral testing, and timing and method of RIC application 
make comparisons among the few functional studies of RIC after brain injury difficult 
and warrants additional study. 
 Selenium-binding protein 1 was identified as significantly increased among RIC-
treated mice regardless of TBI. Selenium-binding protein 1 has not previously been 
studied specifically in the context of either RIC or TBI. There are numerous studies 
demonstrating increased levels of selenium-binding protein 1 among patients with 
schizophrenia (Kanazawa, Chana et al. 2008; Udawela, Money et al. 2015) which could 
indicate either its involvement in brain disease or potential for use as a neuropsychiatric 
biomarker. Selenium-binding protein 1 knockout mice have shown no gross phenotypic 
changes but levels of tumor-related genes, including Notch1, were increased in its 
absence (Tsujimoto, Ishida et al. 2013). A recent study demonstrated that notch pathway 
activation may be neuroprotective following TBI (Wang, Zhang et al. 2015), a finding 
which would suggest that a RIC-induced increase selenium-binding protein 1 may not be 
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a major neuroprotective mechanism. Dietary supplementation with elemental selenium 
has shown to attenuate impairments in functional outcome and mitochondrial damage 
following controlled cortical impact TBI in rats (Crowdus Meyer 2015). Further 
investigation is warranted to elucidate whether RIC-induced increase in selenium-binding 
protein 1 could act synergistically with dietary selenium supplementation after TBI. 
 Adipocyte fatty acid binding protein (fatty acid binding protein 4, fabp4), 
currently shown as selectively increased by RIC in the context of TBI, has not been 
studied in either RIC or TBI. Other members of the fatty acid binding protein family, 
particularly fatty acid binding protein 5, have been demonstrated to mediate the blood-
brain-barrier transport of DHA (Pan, Scanlon et al. 2015; Figueroa, Serrano-Illan et al. 
2016). Further, administration of small interfering RNA to silence fatty acid binding 
protein 5 was shown to suppress the neuroprotective effect of DHA on outcome from 
experimental spinal cord injury in rats (Figueroa, Serrano-Illan et al. 2016). It is plausible 
that RIC could play a role in elevating fatty acid binding proteins which would facilitate 
DHA uptake in the brain and further improve the efficacy of omega-3 fatty acid 
supplementation demonstrated in Chapter 3. 
 The current study includes the first untargeted proteomic analysis of RIC plasma 
to date. While there have been many investigations of potential RIC mechanisms, they 
have largely focused on targeted analysis of molecules of interest using traditional 
molecular biology approaches (for review, see (Tapuria, Kumar et al. 2008)). These 
approaches can provide valuable insight and have resulted in a wide array of proposed 
mechanistic pathways, but are subject to experimenter bias in the determination of targets 
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of interest. Untargeted proteomic analysis is not subject to this bias and allows for 
objective identification of RIC-driven changes in the plasma proteome. It is plausible that 
RIC efficacy is not entirely dependent upon the proteome, though, and accordingly a 
recent untargeted metabolomic study identified α-hydroxybutyrate as a potential 
cardioprotective factor resulting from RIC (Laursen, Hansen et al. 2017). A general 
cellular pathway and secondary injury mechanism currently identified as impacted by 
RIC and TBI is inflammation. Studies of RIC in models of sepsis (Turner, Brabb et al. 
2011; Calder 2017) have similarly indicated potential anti-inflammatory effects. Studies, 
including those from our group, have also indicated beneficial effects of reducing 
neuroinflammation following TBI (Harrison, Rowe et al. 2015). Future confirmation of 
candidate protein correlates of RIC including selenium-binding protein 1 and fatty acid-
binding protein by traditional molecular biology approaches will lay the groundwork for 
this new avenue of RIC mechanism exploration. 
5.6 CONCLUSIONS 
 Despite inconclusive findings on the neuroprotective effects of RIC in the 
currently tested model of diffuse TBI, we were able to identify preliminary molecular 
correlates of RIC in the context of TBI. As the first study of its kind to objectively assess 
RIC-driven changes in the plasma proteome, the current study provides a broad 
framework within which potential mechanisms of RIC efficacy can begin to be placed. 
With top matches of proteins impacted by RIC being associated with previously proposed 
pathways of inflammation and oxidative stress responses, these findings do not stand 
alone but rather complement our cumulative understanding of this therapeutic approach. 
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It is unlikely that any one protein or molecule drives the neuro-, cardio-, and otherwise 
protective effects of RIC. Ongoing analyses on the currently presented data set will be 
aimed at narrowing down pathways of cellular processes which promote these protective 
effects. At the culmination of this hypothesis-generating approach, fatty acid binding 
proteins appear to be a promising avenue of RIC mechanism which could facilitate the 
transport of vital fatty acids across the blood-brain-barrier following TBI. A preliminary 
study is warranted to test whether RIC increases brain DHA content after acute DHA 
supplementation. Parallel studies could be conducted in available fatty acid binding 
protein knockout mice (Furuhashi and Hotamisligil 2008) to detect whether these 
molecules are required for RIC facilitation of DHA uptake. Finally, the role of fatty acid 
binding proteins in RIC efficacy could be determined by conducting a RIC+TBI study in 
fatty acid binding protein knockout mice. If this family of molecules is necessary for RIC 
efficacy, any neuroprotective effects or positive influence on functional outcome would 
be nullified in the transgenic mice.  
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CHAPTER 6 
6 CONCLUSIONS 
Practical therapies are needed for the millions of TBI sufferers who would not 
otherwise seek treatment. These at-home or on-the-field interventions require special 
consideration for convenience and safety such that an individual unsure of whether to 
seek medical attention would feel comfortable self-administering a practical therapy as a 
safeguard. These therapeutic approaches do not replace professional medical care, but 
hopefully can be used in conjunction with clinical recommendations to improve public 
health. A score card for evaluation of practical therapies at a glance has been developed 
and applied to the treatments from each chapter of this dissertation (Table 6.1). 
The current body of work assessed four classes of potential practical therapies for 
diffuse TBI. The first of these, OTC analgesics, showed little difference in outcome from 
TBI in mice (Table 6.2). This negative result, however, was complemented by the finding 
that acute administration of ibuprofen and acetaminophen did not adversely affect 
outcome. This is an important result since these pain relievers are largely taken to treat 
the acute symptoms of diffuse TBI, such as headache. While OTC analgesics did not 
show much promise as a practical therapy, results suggest that these common 
medications do not exacerbate ongoing secondary injury processes when taken acutely 
for pain relief. 
The present study of omega-3 fatty acids detailed in Chapter 3 is the first of its kind to 
assess a comprehensive timeline of supplementation prior to and following experimental 
TBI (Table 6.3). Results showed that dietary supplementation with DHA either prior to or 
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following diffuse TBI decreased post-acute inflammatory responses and decreased 
injury-induced sensory sensitivity. The unique study design also indicated that DHA 
administered in the weeks immediately following TBI provided more potent anti-
inflammatory effects than that taken prior to injury. This was an unexpected result 
considering the relatively long time required for DHA to incorporate into cell 
membranes, but it indicated further promise of DHA as a practical therapy since the 
window for effective treatment relative to injury appears to encompass both pre-injury 
and post-injury supplementation. 
Treatment with omega-3 derived resolvins E1 (RvE1) and AT-D1 (AT-RvD1) 
were assessed for their potential to circumvent the lengthy cellular uptake phase required 
by fatty acid supplementation (Table 6.4). Each resolvin tested demonstrated quite 
different effects on outcome. RvE1 increased post-injury sleep and attenuated microglial 
activation in response to diffuse TBI. RvD1 did not affect these two outcome measures, 
but significantly reduced TBI-induced motor and cognitive impairments. These results 
indicate that RvD1 may be a candidate practical therapy with the caveat of very limited 
availability to the public. Though RvE1 did not improve functional outcome, findings 
suggest that it did attenuate the inflammatory response; further studies are warranted to 
understand how the impact of RvE1 on secondary injury may be harnessed to a 
therapeutic effect. 
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Table 6.1. Practical Therapy Score Card Template 
Practical Therapy Score Card 
Safety  
Availability  
Ease of administration  
Cost effectiveness  
Currently tested efficacy 
e.g. Motor function  
e.g. Affective function  
Symbol Description 
~ Inconclusive or unknown 
- Negative effect or quality 
0 No effect 
+ Positive effect or quality 
++ Very positive effect or quality 
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Treatment with RIC demonstrated little effect on functional outcome from diffuse TBI in 
mice (Table 6.5). Despite this finding in the current model of TBI, RIC has shown great 
promise of neuroprotection in models of stroke and focal TBI. For this reason, mass 
spectrometric analysis of plasma samples from RIC-treated mice was used to identify 
candidate molecular correlates of RIC. Identification of these candidates represents a vital 
first step in understanding the neuroprotective mechanisms underlying RIC. 
Practical therapies examined in this dissertation were administered in differing 
protocols: OTC pain relievers once (i.p.) after injury, DHA orally either before or after 
injury, resolvins (i.p.) both before and after injury, and RIC after injury. While these 
differing approaches make it difficult to draw one-to-one comparisons between 
treatments, they also mirror the diversity of treatment regimens in the clinical case. 
Routes and timing of administration were determined based both on previous literature 
available and translational considerations for when and how these therapies would be 
most likely used in the clinical case. Conclusions of efficacy are based on the currently 
utilized administration regimens and it is plausible that changing route of administration 
or timing could alter outcomes in any tested approach. When oral administration was 
indicated in humans but not feasible in rodents, intraperitoneal injection was chosen for 
its consistency, slower uptake, and liver metabolism similar to oral administration 
(Turner, Brabb et al. 2011).  
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Table 6.2. Practical Therapy Score Card: OTC analgesics 
Practical Therapy Score Card: OTC analgesics 
Safety + 
Availability ++ 
Ease of administration ++ 
Cost effectiveness ++ 
Currently tested efficacy 
Motor function 0 
Inflammatory cytokines 0 
 
Table 6.3. Practical Therapy Score Card: Dietary DHA 
Practical Therapy Score Card: Dietary DHA 
Safety ++ 
Availability ++ 
Ease of administration + 
Cost effectiveness + 
Currently tested efficacy 
Spatial learning 0 
Sensory sensitivity + 
Microglial activation ++ 
 
Table 6.4. Practical Therapy Score Card: Resolvins 
Practical Therapy Score Card: Resolvins 
Safety ~ 
Availability - 
Ease of administration ~ 
Cost effectiveness - 
Currently tested efficacy 
Motor function ++ 
Cognitive function ++ 
Microglial activation 0 
 
Table 6.5. Practical Therapy Score Card: RIC 
Practical Therapy Score Card: RIC 
Safety ++ 
Availability ++ 
Ease of administration ++ 
Cost effectiveness ++ 
Currently tested efficacy 
Motor function 0 
Affective function ~ 
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Greater understanding of the pharmacokinetic and pharmacodynamic properties 
of each of these treatments would allow for fine tuning of optimal treatment dosage and 
timing. Pharmacokinetic preliminary studies of how practical treatments are processed by 
the body would test how long administered molecules or biomarkers of treatment are 
present in the plasma and brain. Knowing how quickly these targets dissipate or are 
metabolized provides insight into timing of administration. Practical therapies such as 
RIC present unique challenges to pharmacokinetic strategies since there are no definitive 
biomarkers of the treatment to date (though preliminary candidate proteins have been 
identified in Chapter 5). Studies of pharmacodynamics are warranted where there is 
evidence of efficacy in at least one outcome measure. Dose-response studies would be 
ideal for identifying optimal concentration or dosages of practical therapies which 
maximize beneficial effect on a predetermined outcome measure and minimize potential 
risk of harm from excessive dosing. While studies of pharmacokinetics would be difficult 
with a practical therapy such as RIC, studies of pharmacodynamics are plausible and 
warranted. In the case of RIC, understanding the optimal duration and number of cycles 
could be elucidated by their differential effects on biomarkers of TBI or rodent 
performance on behavioral tests. These approaches, coupled with confirmation of 
administered compound levels in the brain and plasma provide context to better evaluate 
efficacy, but also are resource intensive beyond conventional molecular biology 
techniques.  
Similarly to routes of administration, not all chapters of this dissertation use the 
same outcome measures to evaluate efficacy. There is, however, common ground in that 
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they all incorporate tests of functional outcome. There is much value in identifying 
underlying mechanism of treatment efficacy. In some cases, the identification of 
mechanism could lead to approaches which augment a practical therapy (e.g. dietary 
supplementation with DHA before RIC administration). Ultimately, though, practical 
therapies must lessen the consequences of TBI. For this, behavioral testing of functional 
outcome in multiple domains which mirror the human condition remains paramount in 
the evaluation of practical therapies. 
There currently exists no regulatory body in the U.S. to oversee the advancement 
and implementation of practical therapies. Nutritional supplements and physiological 
interventions such as RIC face challenges in implementation—particularly outside of 
direct clinical advisement. How information about these practical therapies (including 
what to use them for and when to use them) could be effectively disseminated remains 
unclear. While physicians may recommend at-home application of practical therapies, 
this still excludes the large population of individuals never seeking medical attention for 
diffuse TBI. One potential answer is in a public awareness campaign for thoroughly 
tested, evidence-based practical therapies for TBI, but this also comes with the risk of 
inadvertently advocating self-treatment over professional medical attention. It will likely 
require a coordinated effort of new governmental oversight, public education, and clinical 
advisement for practical therapies to manifest as improved public health. 
Practical therapies do not by definition stand alone and may benefit patients by 
their addition to other treatments, including other practical therapies. Chapter 5 used mass 
spectrometry to identify fatty acid binding proteins as a potential protein increased in 
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plasma by RIC. Research from other groups demonstrating that fatty acid binding 
proteins can facilitate the transport of DHA across the blood-brain barrier indicate that 
RIC as described in Chapter 5 may act synergistically with DHA supplementation as 
described in Chapter 3. One of the practical drawbacks of DHA supplementation is the 
relatively long period required for DHA cellular uptake and RIC could plausibly shorten 
this time by allowing greater DHA availability in the brain. The combining of practical 
therapies detracts from the practicality of the treatment by decreasing the ease of 
administration but may be warranted for increases in efficacy. Combining therapies 
introduces further complication in the timeline of therapy application where further 
research would be warranted to maximize any synergistic effect with regard to timing.  
Overall, the findings of this dissertation suggest that practical therapies may serve 
to fill a gap in contemporary public health by treating otherwise untreated sufferers of 
diffuse TBI. Omega-3 fatty acid supplementation, SPM administration, and RIC all 
exhibited at least some positive effect on outcome from TBI in the mouse without any 
observed negative effects. Advancing the field of practical therapies requires additional 
rigorous study of treatments from home remedies to cutting edge techniques requiring 
only resources available to the average person. 
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10 APPENDIX A 
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APPENDIX B 
REMOTE ISCHEMIC CONDITIONING METHOD DEVELOPMENT 
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 Many rodent studies of RIC have used transient femoral artery clamping to induce 
RIC (Ren, Yan et al. 2009; Peng, Guo et al. 2012; Sandweiss, Azim et al. 2017). It is 
understandable that many RIC studies to date have been undertaken as proof of principle 
endeavors, but surgically opening the hind limb decreased the practicality of the 
treatment and failed to reflect the human RIC paradigm achieved with a blood pressure 
cuff. With respect to practical treatments for diffuse TBI and testing acute behavioral 
outcome, we deemed femoral artery clamping too invasive for the studies presented in 
Chapter 5. Several methodological approaches were pilot tested and have since been 
refined beyond the approach used in Chapter 5. Here these will be briefly described. 
 Common twine was chosen as a pilot material for RIC induction for its tensile 
strength and relatively thick diameter over which the RIC forces could be exerted. 
Isoflurane anesthesia was achieved and maintained as described in Chapter 5. A short 
length of twine (~10cm) was tied to a wooden applicator stick (Puritan Medical Products, 
Guilford, ME) cut to length (~5cm). The loose end of twine was wrapped around the left 
mouse hind limb and tied to the applicator stick. The applicator stick was twisted 
approximately two turns clockwise to apply pressure and was secured to the underlying 
bench with laboratory tape. After 5 minutes of RIC, the twine was cut to allow for 
reperfusion. This method was simplified by the use of plastic coated wire ties as 
described in Chapter 5. 
 Since the conduct of the studies described in Chapter 5, a further refined non-
invasive RIC approach was developed by our lab using orthodontic rubber bands. This 
approach was adapted from a previously reported model of murine hind limb ischemia 
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used in the study of peripheral artery disease (Crawford, Hashmi et al. 2007). Anesthesia 
was induced using 5% isoflurane in 100% oxygen for 3 minutes. The mouse was 
removed from the anesthesia induction chamber and a McGivney hemorrhoidal ligator 
(MedixPlus Quality Instruments) was used to apply a 1/8‖ 4.5oz heavy force orthodontic 
rubber band as proximally to the hip as possible. The mouse was moved to a recovery 
cage for 5 minutes and the orthodontic rubber band was then clipped to allow for 
reperfusion. 4.5 minutes following reperfusion, the mouse was reintroduced to 5% 
isoflurane in 100% oxygen for 30 seconds. A new orthodontic rubber band was applied to 
begin the second of 4 RIC cycles. 
 This non-invasive approach to rodent RIC induction is more comparable to 
human RIC than femoral artery clamping and applies a more consistent force than 
previous twine and wire tie approaches. Further, the ease of application of the orthodontic 
rubber bands allows for greatly reduced isoflurane exposure time during the RIC 
procedure (4.5 minutes total vs 43 minutes total in previous approaches). This is of 
particular concern in studies of RIC efficacy in neurological injury due to the potentially 
confounding effects of anesthesia on outcome (Rowe, Harrison et al. 2013). Mice are 
allowed to wake intermittently during the RIC procedure and show no overt pain or 
discomfort due to the orthodontic rubber band. Future RIC studies from this group will 
incorporate this refined non-invasive approach. 
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11 APPENDIX C 
TABLE OF PRE-CLINICAL EFFICACY OF RIC IN NEUROLOGICAL DISEASE 
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Table C1. Pre-clinical efficacy of RIC in neurological disease 
Citation Model 
Conditioning 
Location 
Protection 
Target 
Type Protocol Primary Result 
(Sandweiss, 
Azim et al. 
2017) 
TBI, mouse 
(closed skull) 
Hindlimb Brain Post 
6x4min, 
2hrs post-
injury 
Improved 
cognitive & 
motor outcome 
(Ren, Wang 
et al. 2015) 
Stroke, rat Hindlimb Brain Per 
3x10min 
during 
MCAO 
Decreased lesion 
volume 
(Ren, Wang 
et al. 2015) 
Stroke, rat Hindlimb Brain Per+Post 
3x10min 
daily, 14d 
Decreased lesion 
volume (more 
than Per alone) 
(Qi, Dong 
et al. 2015) 
Stroke, rat Hindlimb Brain Per+Post Unclear 
Decreased 
mitochondrial 
damage 
(Khan, 
Hoda et al. 
2015) 
Vascular 
cognitive 
impairment, 
mouse 
Hindlimb Brain Post 
4x5min, 
bilateral, 
7-21d 
post-
injury 
Improved 
cognitive 
function, 
decreased cell 
death 
(Hoda, 
Bhatia et al. 
2014) 
Stroke 
(embolic), 
mouse 
Hindlimb Brain Per 
4x10min 
(2hrs 
after 
induction) 
Prevented 
mortality 
(Shan, Li et 
al. 2013) 
Stroke, rat Hindlimb Brain Per 3x5min 
Increased 
platelet-derived 
microparticles 
(Hasseldam, 
Hansen-
Schwartz et 
al. 2013) 
Stroke, rat Hindlimb Brain Post 3x15min 
Decreased 
marker of 
ischemia 
(pimonidazole) 
(Yuan, Zhu 
et al. 2012) 
Stroke, rat Hindlimb Brain Post 
3x5min 
daily, 3d 
Decreased lesion 
and behavioral 
deficits 
(Hoda, 
Siddiqui et 
al. 2012) 
Stroke 
(embolic), 
mice 
Hindlimb Brain Per 
5x5min 
(2hrs 
after 
induction) 
Improved 
neurological 
function 
(Hahn, 
Manlhiot et 
al. 2011) 
Stroke, rat Hindlimb Brain Pre 
4x5min 
before 
induction 
Decreased lesion 
volume 
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